OLIGOSSACARÍDEO DO LEITE DE MAMÍFEROS (MMO) FUCOSILADO E MMO FUCOSILADO PARA USO

Fucosylated MMO stimulates immune response in farm animals to combat shipping fever pathogens, effectively preventing and treating pneumonia, addressing the economic and health impacts of this disease.

BR112025023978A2Pending Publication Date: 2026-11-10INBIOSE NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025023978
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-14
Filing Date
2024-05-03
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Farm animals experience shipping fever, a lung disease with multifactorial etiology, leading to pneumonia and significant economic losses due to medical costs and poor performance, and existing therapies are inadequate.

Method used

The use of fucosylated mammalian milk oligosaccharides (MMO) to stimulate the immune response in animals, particularly through T lymphocyte activation, providing indirect protection against pathogens associated with shipping fever.

Benefits of technology

Fucosylated MMO effectively prevents and treats shipping fever by enhancing immune response, reducing the incidence and severity of pneumonia and associated symptoms without adverse effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and / or treating shipping fever in an animal, more specifically in a farmed animal or a domesticated animal. More specifically, the invention relates to a fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and / or treating shipping fever pneumonia and / or shipping fever diarrhea in an animal, more specifically in a farmed animal or a domesticated animal.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 128 “FUCOSYLATED MAMMALIAN MILK OLIGOSACCHARIDE (MMO) AND FUCOSYLATED MMO FOR USE” Field of Invention

[001] The present invention relates to a fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and / or treating shipping fever in an animal, more specifically in a farmed or domesticated animal. More specifically, the present invention relates to a fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and / or treating pneumonia associated with shipping fever in an animal, more specifically in a farmed or domesticated animal. Background of the Invention

[002] The health status of a farm animal, that is, an animal that is raised in an agricultural environment with the aim of producing various products, such as food, fur or wool, has a huge impact on the economic resilience of farms due to medical costs, animal losses and long-term effects on performance.

[003] Farm animals are commonly transported to farm facilities. This transport not only brings animals closer together (sometimes from different farms), but it is also well known that this stressful transport has negative effects on immunity, response to infections, and inflammatory responses. Animals transported over long distances can develop shipping fever, a lung disease with a multifactorial etiology involving infectious agents (viral and / or bacterial; usually a primary viral infection followed by a secondary bacterial superinfection), environmental stressors, and host factors (Earley et al, 2017, Animal 11(3): p. 486-492; Gaudino, et al, 2022, Vet. Res. 53(1); Maeda and Oikawa, 2019, Front. Vet. Sci. 6(27)). Shipping fever Petition 870250100655, dated 03 / 11 / 2025, page 93 / 226 2 / 128 can lead to pneumonia, as well documented, for example, in cattle and horses (Earley et al., 2017, Animal 11(3): p. 486-492; Vivek Joshi et al., 2016, J. Immunol. and Immunopath. 18(2)). Pneumonia is, unfortunately, the most common cause of death and poor performance in farm animals (Poulsen and McGuirk, 2009, Vet. Clin. North. Am. Food anim. Pract. 25(1): p. 121-137; Arné et al, 2011, Int J. Microbiol., article 746356).

[004] The development of an effective therapy to prevent and / or treat shipping fever, especially shipping fever-associated pneumonia, is a medical and economic imperative. Brief Description of the Invention

[005] Surprisingly, a fucosylated MMO, according to the invention, has been found to be an effective agent in the prevention and / or treatment of shipping fever in animals. The said fucosylated MMO is not associated with adverse effects and is safe for use in animals.

[006] In a first aspect, the invention provides a fucosylated MMO for use in a method for preventing and / or treating shipping fever in an animal, wherein, preferably, said animal is a farm animal or a domesticated animal.

[007] In a second aspect, the invention provides a method for preventing and / or treating shipping fever in an animal, preferably a farm animal or a domesticated animal, wherein a fucosylated MMO according to the first aspect is administered to said animal.

[008] In a third aspect, the invention provides the use of a fucosylated MMO according to the first aspect for the manufacture of a medicament to prevent and / or treat shipping fever in an animal, preferably a farm animal or a domesticated animal. Petition 870250100655, dated 03 / 11 / 2025, p. 94 / 226 3 / 128 Detailed Description of the Invention: Fucosylated MMO for Use in the Prevention / Treatment of Shipping Fever

[009] In a first aspect, the invention provides fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and / or treating shipping fever in an animal, preferably wherein said animal is a farm animal or a domesticated animal, more preferably wherein said animal is a farm animal.

[010] Preferably, the invention provides a composition comprising a fucosylated MMO, wherein said composition is for use in a method for preventing and / or treating shipping fever in an animal, preferably wherein said animal is a farm animal or a domestic animal, more preferably wherein said animal is a farm animal. Throughout the present application and claims, the term “a fucosylated MMO” is preferably replaced by “a composition comprising a fucosylated MMO”, more preferably replaced by “a composition consisting essentially of a fucosylated MMO”, even more preferably replaced by “a composition consisting of a fucosylated MMO”. Transportation Fever

[011] In an example of carrying out the first aspect of the invention, fucosylated MMO is for use in a method for preventing and / or treating shipping fever in an animal, wherein, preferably, said animal is a farm animal or a domesticated animal, and more preferably said animal is a farm animal.

[012] In a preferred embodiment, the method is used to prevent and / or treat pneumonia associated with shipping fever. The 'fever' Petition 870250100655, dated 03 / 11 / 2025, p. 95 / 226 'Shipping fever' is a well-described lung disease that occurs in animals transported over long distances. Shipping fever has a multifactorial etiology involving infectious agents (viral and / or bacterial; usually a primary viral infection followed by a secondary bacterial superinfection), environmental stress factors, and host factors (Earley et al, 2017, Animal 11(3): p. 486-492; Gaudino, et al, 2022, Vet. Res. 53(1); Maeda and Oikawa, 2019, Front. Vet. Sci. 6(27)).

[013] In the context of the invention, the animal in question is preferably a horse or cattle, more preferably cattle. When the animal in question is bovine, “shipping fever” is also referred to as “bovine respiratory disease (BRD)” or “bovine respiratory disease complex” (Vivek Joshi et al., 2016, J. Immunol. and Immunopath. 18(2); Earley et al., 2017, Animal 11(3): p. 486-492). Therefore, when the animal in question is bovine, the terms “shipping fever”, “bovine respiratory disease”, “BRD” and “bovine respiratory disease complex” may be used interchangeably in the context of the present invention.

[014] In a more preferred embodiment, the aforementioned pneumonia is acute pneumonia. As understood by the skilled technician in the subject, acute pneumonia involves inflammation of the alveoli and interstitial tissues of the lungs, resulting in acute respiratory symptoms and signs, including cough, shortness of breath, chest pain, and sputum production (Torres et al., 2021, Nature Reviews Disease primers 7(25); Ames, 2016, Vet. Clin. North Am. Food Anim. Pract.. 13(3): p. 379-391). The alveoli are filled with pus and fluid (in contrast to a healthy subject, where the alveoli are filled with air when breathing), which makes breathing painful and limits oxygen uptake. Chronic pneumonia is pneumonia that lasts at least 6 weeks; a chest radiograph usually shows diffuse or focal shadows.

[015] In an example of additional and / or alternative embodiment Petition 870250100655, dated 03 / 11 / 2025, page 96 / 226 5 / 128 preferred, the aforementioned method is for preventing and / or treating diarrhea associated with shipping fever.

[016] The inventors have surprisingly discovered that a fucosylated mammalian milk oligosaccharide (MMO) according to the invention increases the immune response in the treated subject, preferably increases T lymphocyte-mediated immunity in the treated subject, more preferably increases T lymphocyte activation in the treated subject.

[017] The technical effect of treating a subject with a fucosylated MMO according to the invention, therefore, encompasses an indirect mechanism of protection, stimulating the immune response in the treated subject, as described in the present invention, to protect against and / or combat pathogens, rather than a direct mechanism where the fucosylated MMO would act directly on the pathogen and / or block its entry by binding to a receptor essential for the pathogen. This is particularly beneficial in the context of shipping fever, where animals are more prone to infection and generally exhibit weakened immunity due to transport-induced stress. Furthermore, said indirect mechanism provides protection against a broad spectrum of pathogens, rather than acting against a specific pathogen.

[018] This technical effect can be evaluated in a subject by a qualified professional using routinely available techniques in the field. A particularly useful and preferred method is flow cytometry (preferably fluorescence-activated cell screening, i.e., FACS) to assess T cell activation in a subject. In this case, peripheral blood mononuclear cells can be isolated from a subject's blood sample using standard techniques such as density gradient centrifugation. To identify activated T lymphocytes, a panel of appropriate activated T cell markers can be used during flow cytometry analysis (preferably FACS). This includes the Petition 870250100655, dated 03 / 11 / 2025, page 97 / 226 6 / 128 classic T-cell markers, such as CD3, CD4, and CD8, combined with one or more known activation markers, such as CD69, CD25, and HLADR. An alternative method for evaluating the aforementioned technical effect is illustrated in the Examples below (analysis of differential expression of the complete transcriptome). Subject

[019] In an example of carrying out the first aspect of the invention, said fucosylated MMO is for use in a method for preventing and / or treating shipping fever in an animal, preferably where the animal is a farm animal or a domesticated animal, more preferably a farm animal.

[020] As understood by the expert in the field, a “farm animal” refers to an animal raised in an agricultural environment to produce various goods, such as food (meat, organs, eggs, dairy products) and / or fur or wool. A farm animal is preferably selected from the list consisting of cattle, swine, sheep, goats, horses, donkeys, mules, hinnies, camelids (preferably llamas or alpacas), rabbits and poultry: more preferably selected from the list consisting of cattle, swine, sheep, goats, horses, camelids (preferably llamas or alpacas), rabbits and poultry; even more preferably selected from the list consisting of cattle, swine, sheep, goats, horses, camelids (preferably llamas or alpacas) and poultry; even more preferably selected from a list consisting of cattle, pigs, sheep, goats, camelids (preferably llamas or alpacas) and poultry;even more preferably selected from the list consisting of cattle, pigs, sheep, goats, camelids (preferably llamas or alpacas) and poultry; even more preferably selected from the list consisting of cattle, pigs, sheep and goats; even more preferably selected from the list consisting of cattle, sheep and goats; most preferably the said livestock animal is a bovine animal. Petition 870250100655, dated 03 / 11 / 2025, page 98 / 226 7 / 128

[021] Alternatively, a farm animal is preferably selected from the list consisting of cattle and pigs, with cattle being more preferably chosen.

[022] As understood by a person skilled in the art, a “domesticated animal” refers to an animal that has been selectively bred and adapted over generations to live with humans. A domesticated animal, in the context of the present invention, is preferably a companion animal, a horse, a donkey, a mule or a hinny; more preferably, said domesticated animal is selected from the list consisting of a dog, a cat, a horse, a donkey, a mule and a hinny; even more preferably, said domesticated animal is selected from the list consisting of a dog, a cat and a horse; most preferably, said domesticated animal is a horse.

[023] In the context of this invention, the term “birds” refers to birds raised by humans for eggs, meat and / or feathers. Throughout this application and claims, the bird is preferably a chicken, a quail, a turkey, a duck, a pigeon and a goose, more preferably a chicken, a quail or a turkey, more preferably a chicken or a quail, and even more preferably a chicken. Throughout this application and claims, the terms “chicken” / “hen” are preferably replaced by “broiler chicken”.

[024] In a preferred embodiment of the invention, said farm animal or domesticated animal is selected from the list consisting of bovine, swine, ovine, caprine, horse, donkey, mule, hinny, camelid (preferably llama or alpaca), dog, cat, rabbit and birds; more preferably selected from the list consisting of bovine, swine, ovine, caprine, horse, donkey, mule, hinny, camelid (preferably llama or alpaca) and birds; even more preferably selected from the list consisting Petition 870250100655, dated 03 / 11 / 2025, page 99 / 226 8 / 128 in cattle, sheep, goats, horses, donkeys, mules, hinnies, camelids (preferably llamas or alpacas) and poultry; even more preferably selected from the list consisting of cattle, horses, donkeys, mules, hinnies and poultry; even more preferably selected from the list consisting of cattle, horses, donkeys, mules and hinnies; even more preferably selected from the list consisting of cattle and horses; most preferably the animal in question is cattle.

[025] In a preferred additional and / or alternative embodiment, the animal in question is a multigastric animal, preferably a ruminant or camelid, more preferably a ruminant.

[026] Preferably, the camelid in question is a llama or an alpaca, more preferably the camelid in question is an alpaca.

[027] Preferably, the ruminant in question is selected from the list consisting of cattle, sheep and goats, more preferably the ruminant in question is cattle.

[028] In a preferred alternative embodiment, the animal in question is a monogastric animal, preferably selected from the list consisting of pig, horse, donkey, mule, hinny, rabbit and birds, more preferably selected from the list consisting of pig, horse, donkey, mule, hinny and birds, even more preferably selected from the list consisting of pig, horse, donkey, mule and hinny, even more preferably pig or horse, most preferably pig.

[029] Throughout the description and claims, unless specifically indicated otherwise, the terms “subject” and “animal” may preferably be replaced by “subject with such need” and “animal with such need”, respectively.

[030] In a more preferred embodiment, the animal said, according to the invention, is a non-adult animal. In an example of Petition 870250100655, dated 03 / 11 / 2025, pp. 100 / 226 9 / 128 In a more preferred and / or alternative embodiment, the animal described in the invention is a young animal. Throughout this application and claims, unless specifically indicated otherwise, a “non-adult animal” may preferably be replaced by “juvenile animal” or “young animal”.

[031] As understood by the expert in the matter: - A young bovine is a calf; - A young pig is a piglet; - A young sheep is a lamb; - a young goat is a kid; - A young horse is a foal; - A young llama is a baby; - A young alpaca is a baby; A young dog is a puppy; A young cat is a kitten; - A young rabbit is a baby (baby rabbit); - A young bird / chicken is a chick.

[032] In a more preferred further and / or alternative embodiment, the animal said according to the invention is a pre-weaned animal.

[033] In a more preferred further and / or alternative embodiment, the animal said according to the invention is an animal that is weaned.

[034] As understood by the expert in the subject, weaning refers to the process of removing a young animal's access to milk and gradually accustoming it to the adult diet.

[035] Throughout this request and claims, each example of accomplishment disclosed in the context in which the subject is a horse. Petition 870250100655, dated 03 / 11 / 2025, pp. 101 / 226 10 / 128 is also used to describe someone who is a donkey, a mule, or a hinny. Method for Preventing and / or Treating Shipping Fever

[036] In an example of carrying out the first aspect of the invention, said fucosylated MMO is for use in a method for preventing and / or treating shipping fever in an animal, preferably where the animal is a farm animal or a domesticated animal, more preferably a farm animal.

[037] The animal in question is as described in the “Subject” section.

[038] In the context of the present invention, the term “prevent” shipping fever, as described in this invention, preferably means to avoid the occurrence of said shipping fever and / or to reduce the incidence of said shipping fever. In other words, “prevent” preferably refers to mitigating the risk of suffering from said shipping fever. The terms “prevention” and “prophylaxis” are used interchangeably in the context of the present invention. The term “treat” shipping fever, as described in this document, preferably means to inhibit said shipping fever, for example, to stop the development of said shipping fever; to alleviate said shipping fever, for example, to cause the regression of said shipping fever; and / or to alleviate a condition caused by or resulting from said shipping fever, for example, to alleviate, prevent or treat the symptoms of said shipping fever.In other words, "treating" preferably refers to reducing the duration (number of days / weeks / months) that the subject will suffer from said shipping fever, the risks, complications and / or severity of said shipping fever; this also includes relieving the symptoms caused by said shipping fever.

[039] In a preferred embodiment, the method of Petition 870250100655, dated 03 / 11 / 2025, p. 102 / 226 11 / 128 according to the invention comprises administering an effective amount of said fucosylated MMO (referred to in the “Oligosaccharide” section), according to the invention, to said animal (referred to in the “Subject” section). As understood by those skilled in the art, an “effective amount” is the amount of said oligosaccharide required to confer a therapeutic effect on the animal, as described in this application. Effective amounts vary, as recognized by those skilled in the art, depending on the subject, the route of administration, the use of excipients, and other known factors.

[040] In a preferred additional and / or alternative embodiment, said fucosylated MMO is administered to the animal at least once, preferably at least twice, between birth (0 weeks) and 5 weeks of age, preferably between birth and 4 weeks of age, more preferably between birth and 3 weeks of age.

[041] It is particularly preferable in the context of this invention that the said fucosylated MMO be administered at least once to the said animal, preferably at least twice, more preferably daily: - in the three weeks, preferably two weeks, more preferably one week, prior to the day of transport of the animal in question; and / or - on the day of transport of the animal in question; and / or - within three weeks, preferably two weeks, more preferably one week, after the day the animal was transported.

[042] More preferably, the aforementioned fucosylated MMO is administered to the said animal at least once, preferably at least twice, more preferably daily: Petition 870250100655, dated 03 / 11 / 2025, p. 103 / 226 12 / 128 (i) - in the three weeks, preferably two weeks, more preferably one week, prior to the day of transport of the animal in question; and / or - on the day of the animal's transport; or (ii) - on the day of transport of the animal in question; and / or - within three weeks, preferably two weeks, more preferably one week, after the day the animal was transported.

[043] In a more preferred embodiment, said fucosylated MMO is administered at a daily dose of 0.0001 to 15.0 grams (g), preferably 0.0001 to 10.0 g, more preferably 0.0001 to 5.0 g, even more preferably 0.0001 to 2.0 g, even more preferably 0.0001 to 1.0 g, even more preferably 0.0005 to 1.0 g, most preferably 0.0010 to 1.0 g. More preferably, the aforementioned fucosylated MMO is administered at a daily dose of 0.001-15.0 g, preferably from 0.001 to 10.0 g, more preferably from 0.001 to 5.0 g, even more preferably from 0.001 to 2.0 g, even more preferably from 0.001 to 1.0 g, even more preferably from 0.005 to 1.0 g, most preferably from 0.010 to 1.0 g.Even more preferably, the aforementioned fucosylated MMO is administered at a daily dose of 0.01 to 15.0 g, preferably 0.01 to 10.0 g, more preferably 0.01 to 5.0 g, even more preferably 0.01 to 2.0 g, even more preferably 0.01 to 1.0 g, even more preferably 0.015 to 1.0 g, most preferably 0.02 to 1.0 g. In the context of the present invention, an amount of an oligosaccharide, according to the invention, expressed in grams or milligrams per daily dose, as used herein. Petition 870250100655, dated 03 / 11 / 2025, p. 104 / 226 13 / 128 invention, means that the quantity of the oligosaccharide is such that, when administering the daily dose to a subject, the subject will receive the number of grams or milligrams of the oligosaccharide. In other words, if the daily dose is, for example, 50 mg, the subject will receive a total of 50 mg per day. This can be done in one or more portions. Therefore, if the daily dose is 50 mg divided into 2 portions, a single portion consists of 25 mg and a daily portion consists of 2 of these individual portions.

[044] In a more preferred additional and / or alternative embodiment, said fucosylated MMO is administered at a daily dose of 0.01 to 150.0 milligrams (mg), preferably 0.01 to 125.0 mg, more preferably 0.01 to 100.0 mg, even more preferably 0.05 to 100.0 mg, even more preferably 0.1 to 100.0 mg, most preferably 0.1 to 80.0 mg, per kg of body weight of said animal.

[045] In a further preferred embodiment, said fucosylated MMO is administered at a daily dose of 0.01 to 1.0 g, preferably 0.01 to 0.75 g, more preferably 0.01 to 0.65 g, even more preferably 0.01 to 0.60 g, even more preferably 0.01 to 0.50 g, even more preferably 0.015 to 0.50 g, even more preferably 0.015 to 0.40 g, even more preferably 0.015 to 0.30 g, even more preferably 0.015 to 0.20 g, most preferably 0.015 to 0.10 g. This embodiment is, for example, particularly preferred if the animal is cattle or a horse, more preferably if the animal is a calf or a foal, and even more preferably if the animal is a heifer.

[046] In a further and / or alternative embodiment, the fucosylated MMO is administered at a daily dose of 0.1 to 50.0 mg, preferably 0.1 to 30.0 mg, more preferably 0.1 to 25.0 mg, even more preferably 0.1 to Petition 870250100655, dated 03 / 11 / 2025, pp. 105 / 226 14 / 128 20.0 mg, even more preferably from 0.1 to 15.0 mg, even more preferably from 0.1 to 10.0 mg, even more preferably from 0.25 to 10.0 mg, most preferably from 0.5 to 10.0 mg, per kg of body weight of said animal. This embodiment is, for example, particularly preferred if the animal is cattle or a horse, more preferably if the animal is a calf or a foal, and even more preferably if the animal is a heifer.

[047] In an even more preferred alternative embodiment, the said fucosylated MMO is administered at a daily dose of 0.01 to 5.0 g, preferably 0.1 to 2.5 g, more preferably 0.1 to 1.5 g, even more preferably 0.1 to 1.2 g, even more preferably 0.2 to 1.2 g, even more preferably 0.3 to 1.2 g, even more preferably 0.4 to 1.2 g, more preferably 0.5 to 1.2 g. This embodiment is, for example, particularly preferred if the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), more preferably if the animal is a piglet, a lamb, a kid or a young animal, even more preferably if the animal is a piglet, a lamb or a kid, more preferably if the animal is a piglet.

[048] In a further and / or alternative embodiment, the fucosylated MMO is administered at a daily dose of 0.1 to 150.0 mg, preferably 0.1 to 125.0 mg, more preferably 1.0 to 125.0 mg, even more preferably 5.0 to 125.0 mg, even more preferably 5.0 to 100.0 mg, even more preferably 5.0 to 80.0 mg, most preferably 10.0 to 80.0 mg, per kg of body weight of the animal. This embodiment is, for example, particularly preferred if the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), more Petition 870250100655, dated 03 / 11 / 2025, pp. 106 / 226 15 / 128 preferably if the animal is a piglet, lamb, goat or kid, even more preferably if the animal is a piglet, lamb or goat, most preferably if the animal is a piglet.

[049] In a further preferred embodiment, said fucosylated MMO is administered to the animal for at least 1 week, preferably for at least 2 weeks, more preferably for at least 3 weeks, even more preferably for at least 4 weeks, most preferably for at least 6 weeks.

[050] In an even more preferred additional and / or alternative embodiment, said fucosylated MMO is administered to the animal for < 32 weeks, preferably for < 28 weeks, more preferably for < 24 weeks, even more preferably for < 20 weeks, even more preferably for < 16 weeks, even more preferably for < 12 weeks, most preferably for < 6 weeks.

[051] In a further preferred embodiment, said fucosylated MMO is administered to the animal for a period of 1 to 36, preferably 1 to 30, even more preferably 1 to 28, even more preferably 1 to 24, even more preferably 1 to 18, even more preferably 1 to 12, even more preferably 1 to 8, even more preferably 1 to 6, even more preferably 1 to 4, most preferably 2 to 4 consecutive weeks.

[052] In a further preferred embodiment, the said fucosylated MMO is administered to the said animal: - if the subject is bovine: for a period of 1 to 36, preferably from 1 to 32, more preferably from 1 to 30, even more preferably from 1 to 28, even more preferably from 1 to 24, even more preferably from 1 to 18, even more preferably from 1 to 12, even more preferably from 2 to 12, most preferably from 3 to 12, Petition 870250100655, dated 03 / 11 / 2025, p. 107 / 226 16 / 128 consecutive weeks; - if the subject is a pig: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a sheep: for a period of 1 to 36, preferably 1 to 32, more preferably 1 to 30, even more preferably 1 to 28, even more preferably 1 to 24, even more preferably 1 to 18, even more preferably 1 to 12, even more preferably 1 to 8, even more preferably 1 to 6, even more preferably 1 to 4, most preferably 2 to 4 consecutive weeks; - if the subject is a goat: for a period of 1 to 36, preferably from 1 to 32, more preferably from 1 to 30, even more preferably from 1 to 28, even more preferably from 1 to 24, even more preferably from 1 to 18, even more preferably from 1 to 12, even more preferably from 1 to 8, even more preferably from 1 to 6, even more preferably from 1 to 4, most preferably from 2 to 4 consecutive weeks; - if the subject is a horse: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a camelid: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a rabbit: for a period of 1 to 12, Petition 870250100655, dated 03 / 11 / 2025, pp. 108 / 226 17 / 128 preferably from 1 to 8, more preferably from 1 to 6, even more preferably from 1 to 4, most preferably from 2 to 4 consecutive weeks; - if the subject is a puppy: for a period of 1 to 12 weeks, preferably 1 to 8 weeks, more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a cat: for a period of 1 to 12 weeks, preferably 1 to 8 weeks, more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - If the subject is a bird: for a period of 1 to 8 weeks, preferably 1 to 6 weeks, more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks.

[053] Preferably, the said fucosylated MMO according to the invention is administered at least once a week (i.e., at least one daily dose is administered in a week), more preferably at least once every 3 days, even more preferably at least once every 2 days, most preferably it is administered at least once a day (i.e., one daily dose is administered every day).

[054] The inventors have surprisingly discovered that a fucosylated MMO, according to the invention, is sufficient to obtain an effective medicine for preventing and / or treating shipping fever, as described herein. The administration of other (oligo)saccharides is not necessary to obtain the said therapeutic effect.

[055] In this context of the invention, the invention provides a fucosylated MMO and a sialylated MMO, preferably a fucosylated MMO and two Petition 870250100655, dated 03 / 11 / 2025, pp. 109 / 226 18 / 128 or more sialylated MMOs (i.e., a first sialylated MMO and a second sialylated MMO, optionally, other sialylated MMOs are administered), more preferably one fucosylated MMO and two sialylated MMOs (i.e., a first sialylated MMO and a second sialylated MMO), for use in a method to prevent and / or treat shipping fever in an animal, preferably wherein said animal is a farm animal or a domesticated animal, and more preferably said animal is a farm animal. For clarity, the expression “more preferably two sialylated MMOs” in this context of the invention means that no additional sialylated MMOs are administered to the subject.In other words, the method for preventing and / or treating shipping fever in an animal, as described in the present invention, comprises administering a fucosylated MMO, as described in the present invention, and a sialylated MMO, preferably a fucosylated MMO and two or more sialylated MMOs (i.e., a first sialylated MMO and a second sialylated MMO, and optionally, other sialylated MMOs are administered), more preferably a fucosylated MMO and two sialylated MMOs (i.e., a first sialylated MMO and a second sialylated MMO).

[056] It is preferable that the administered MMOs be administered as a mixture, more preferably as part of a composition, even more preferably as part of a composition according to the “Composition” section. The said fucosylated MMO is as described in the present invention (see the “Oligosaccharide” section). In a preferred embodiment, the said sialylated MMO comprises a sialic acid, preferably a Neu5Ac, which is linked to a monosaccharide in an alpha-2,3, alpha-2,6 or alpha-2,8 linkage, preferably an alpha-2,3 or alpha-2,6 linkage, and wherein said monosaccharide is preferably selected from galactose, N Petition 870250100655, dated 03 / 11 / 2025, pp. 110 / 226 19 / 128 acetylglucosamine and Neu5Ac, more preferably said monosaccharide is galactose or N-acetylglucosamine, and even more preferably said monosaccharide is galactose. Those skilled in the art will understand that the expression “sialic acid is linked to a monosaccharide” refers to the situation where sialic acid is linked to a monosaccharide by means of a glycosidic linkage and where said sialic acid and the monosaccharide are part of the oligosaccharide of the invention (which may comprise additional monosaccharide(s) besides said sialic acid and said monosaccharide). In a further and / or alternative preferred embodiment, said sialylated MMO consists of 3 to 8, more preferably 3 to 7, even more preferably 3 to 6, most preferably 3 to 5 monosaccharides.In a further and / or alternative preferred embodiment, said sialylated MMO comprises lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, preferably said sialylated MMO comprises lactose or LacNAc at its reducing end, more preferably said sialylated MMO comprises lactose at its reducing end.

[057] A sialylated MMO comprising lactose at its reducing end is preferably selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c and LST d; more preferably selected from the list consisting of 3'SL, 6'SL, 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, LST a, LST b, LST c and LST d; Even more preferably selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c and LST d; most preferably wherein said sialylated MMO is 3'-sialyl-lactose (3'SL) or 6'-sialyl-lactose (6'SL). A sialylated MMO comprising lacto-NBiose (LNB) at its reducing end is preferably selected from Petition 870250100655, dated 03 / 11 / 2025, p. 111 / 226 20 / 128 list consisting of 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB) and monofucosylmonosialyl-lacto-N-octaose (sialyl Lewis a); more preferably, said sialylated MMO is 3'SLNB or 6'SLNB. A sialylated MMO comprising N-acetyl-lactosamine (LacNAc) at its reducing end is preferably selected from the list consisting of 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialyl-lactosamine (6'SLacNAc) and sialyl Lewis x; more preferably, said sialylated MMO is 3'SLacNAc or 6'SLacNAc.In a more preferred embodiment, the sialyl MMO according to the invention is selected from a list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialillactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB), sialyl Lewis a, 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialyl-lactosamine (6'SLacNAc) and sialyl Lewis x. More preferably, the said sialylated MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x. More preferably, the said sialylated MMO is 3'-sialyl-lactose (3'SL) or 6'-sialillactose (6'SL).In a more preferred, additional and / or alternative embodiment, the first sialylated MMO according to the invention is selected from a list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB), sialyl Lewis a, 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialyl-lactosamine (6'SLacNAc), and sialyl Lewis x. Even more preferably, the first sialyl-based MMO is selected from the list consisting of 3'SL, 6'SL, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc, and sialyl Lewis x. Even more preferably, the first sialyl-based MMO is selected from the list. Petition 870250100655, dated 03 / 11 / 2025, p. 112 / 226 21 / 128 consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x. Even more preferably, the first sialylated MMO is selected from the list consisting of 3'SL, 6'SL, 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc. Even more preferably, the first sialylated MMO is 3'-sialyl-lactose (3'SL) or 6'-sialillactose (6'SL), the first sialylated MMO being, even more preferably, 3'SL. In a more preferred, additional and / or alternative embodiment, the second sialylated MMO according to the invention is selected from a list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyllactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialillacto-N-biose (6'SLNB), monofucosylmonosialyl-lacto-N-octaose (sialyl Lewis a), 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialyl-lactosamine (6'SLacNAc) and sialyl Lewis x. Even more preferably, the second sialylated MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x. Even more preferably, the second sialylated MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x. Even more preferably, the second sialylated MMO is selected from the list consisting of 3'SL, 6'SL, 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc. Even more preferably, the second sialylated MMO is 6'-sialyl-lactose (6'SL) or 3'sialyl-lactose (3'SL), most preferably, the second sialylated MMO is 6'SL.

[058] When a fucosylated MMO and a first sialylated MMO are administered to the animal in question, the fucosylated MMO and the first sialylated MMO are preferably administered on the same day, more preferably administered simultaneously. Furthermore, it is an example of a preferred embodiment that the amount of the first sialylated MMO is Petition 870250100655, dated 03 / 11 / 2025, p. 113 / 226 22 / 128 administered to the aforementioned animal should be from 0.1 to 30.0, preferably from 0.1 to 25.0, more preferably from 0.1 to 20.0, even more preferably from 0.1 to 15.0, even more preferably from 0.2 to 15.0, even more preferably from 0.3 to 15.0, even more preferably from 0.4 to 15.0, even more preferably from 0.5 to 15.0 times the quantity of the aforementioned fucosylated MMO administered to the aforementioned animal. Furthermore, a more preferred embodiment is that the amount of said fucosylated MMO administered to said animal is less than the amount of said first sialylated MMO, and preferably that said amount of said fucosylated MMO is 1.1 to 10.0 times less, preferably 1.5 to 7.5 times less, more preferably 2.5 to 7.5 times less, most preferably 4.0 to 7.0 times less than the amount of said first sialylated MMO.

[059] When a fucosylated MMO, a first sialylated MMO and a second sialylated MMO, according to the invention, are administered to said animal, said fucosylated MMO, said first sialylated MMO and said second sialylated MMO are preferably administered on the same day, more preferably administered simultaneously. Furthermore, it is a preferred embodiment that the ratio between the amount of said first sialylated MMO administered to said animal and the amount of said second sialylated MMO administered to said animal is similar to that found in the maternal milk of the same species (preferably as described in the “Composition” section).More preferably, the amount of the first sialylated MMO administered to the animal is greater than the amount of the second sialylated MMO; preferably, the amount of the first sialylated MMO is 1.1 to 40.0 times greater, more preferably 1.1 to 35.0 times greater, and most preferably 1.5 to 35.0 times greater than the amount of the second sialylated MMO. Even more preferably, the amount of the first sialylated MMO administered to the animal... Petition 870250100655, dated 03 / 11 / 2025, pp. 114 / 226 23 / 128 animal is greater than the amount of the second sialylated MMO, preferably, the amount of the first sialylated MMO is 1.1 to 6.0, more preferably 1.1 to 5.0, even more preferably 1.25 to 4.0, even more preferably 1.25 to 3.0, even more preferably 1.5 to 3.0, most preferably 1.5 to 2.5 times greater than the amount of the second sialylated MMO. An example of a preferred additional and / or alternative embodiment is that the quantity of said first sialylated MMO administered to the animal is 0.1 to 30.0, preferably 0.1 to 25.0, more preferably 0.1 to 20.0, even more preferably 0.1 to 15.0, even more preferably 0.2 to 15.0, even more preferably 0.3 to 15.0, even more preferably 0.4 to 15.0, most preferably 0.5 to 15.0 times the quantity of said first fucosylated MMO administered to said animal.Preferably, the amount of said first fucosylated MMO administered to the animal is less than the amount of said first sialylated MMO, preferably the amount of said first fucosylated MMO is 1.1 to 10.0, preferably 1.5 to 7.5, more preferably 2.5 to 7.5, and most preferably 4.0 to 7.0 times less than the amount of said first sialylated MMO. An example of a further and / or preferred alternative embodiment is that the amount of said second sialylated MMO administered to the animal is 0.1 to 30.0, preferably 0.1 to 25.0, more preferably 0.1 to 20.0, even more preferably 0.1 to 15.0, even more preferably 0.2 to 15.0, even more preferably 0.3 to 15.0, even more preferably 0.4 to 15.0, most preferably 0.5 to 15.0 times the amount of said fucosylated MMO administered to the animal.Preferably, the amount of fucosylated MMO administered to the animal is less than the amount of the second sialylated MMO, preferably 1.1 to 10.0 times less, preferably 1.5 to 7.5 times less, more preferably 1.5 to 5.0 times less. Petition 870250100655, dated 03 / 11 / 2025, pp. 115 / 226 24 / 128 preferably 2.5 to 5.0 times smaller than the amount of the second sialylated MMO.

[060] It is a more preferred embodiment that the total amount of the first sialylated MMO and the second sialylated MMO be from 0.1 to 30.0, preferably from 0.1 to 25.0, more preferably from 0.1 to 20.0, even more preferably from 0.1 to 15.0, even more preferably from 0.2 to 15.0, even more preferably from 0.3 to 15.0, even more preferably from 0.4 to 15.0, most preferably from 0.5 to 15.0 times the amount of said fucosylated MMO administered to said animal.Preferably, the amount of said fucosylated MMO administered to said animal is less than the total amount of the first sialylated MMO and the second sialylated MMO, preferably the amount of said fucosylated MMO is 1.1 to 15.0 times less, preferably 1.5 to 15.0, more preferably 2.5 to 15.0, even more preferably 5.0 to 15.0, even more preferably 5.0 to 12.5, most preferably 5.0 to 10.0 times less than the total amount of the first sialylated MMO and the second sialylated MMO.It is an example of a further, more preferred embodiment that the amount of all sialylated MMOs administered to said animal is from 0.1 to 30.0, preferably from 0.1 to 25.0, more preferably from 0.1 to 20.0, even more preferably from 0.1 to 15.0, even more preferably from 0.2 to 15.0, even more preferably from 0.3 to 15.0, even more preferably from 0.4 to 15.0, most preferably from 0.5 to 15.0 times the amount of said fucosylate administered to said animal. Preferably, the amount of said fucosylated MMO administered to said animal is smaller, preferably 1.1 to 15.0 times smaller, more preferably 1.5 to 15.0 times smaller, even more preferably 2.5 to 15.0 times smaller, even more preferably 5.0 to 15.0 times smaller, even more preferably 5.0 to 12.5 times smaller. Petition 870250100655, dated 03 / 11 / 2025, pp. 116 / 226 25 / 128 smaller, more preferably 5.0 to 10.0 times smaller than the amount of all sialylated MMOs administered to the animal in question.

[061] In this context of the invention, the silylated MMO / first silylated MMO / second silylated MMO is administered in a daily dose of 0.0001 to 15.0 g, preferably 0.0001 to 10.0 g, more preferably 0.0001 to 5.0 g, even more preferably 0.0001 to 2.0 g, even more preferably 0.0001 to 1.0 g, even more preferably 0.0005 to 1.0 g, more preferably 0.0010 to 1.0 g. More preferably, the silylated MMO / first silylated MMO / second silylated MMO is administered at a daily dose of 0.001 to 15.0 g, preferably 0.001 to 10.0 g, more preferably 0.001 to 5.0 g, even more preferably 0.001 to 2.0 g, even more preferably 0.001 to 1.0 g, even more preferably 0.005 to 1.0 g, more preferably 0.010 to 1.0 g.Even more preferably, the silylated MMO / first silylated MMO / second silylated MMO is administered at a daily dose of 0.01 to 15.0 g, preferably 0.01 to 10.0 g, more preferably 0.01 to 5.0 g, even more preferably 0.01 to 2.0 g, even more preferably 0.01 to 1.0 g, even more preferably 0.015 to 1.0 g, more preferably 0.02 to 1.0 g.

[062] In a more preferred additional and / or alternative embodiment, the sialylated MMO / first sialylated MMO / second sialylated MMO is administered at a daily dose of 0.01 to 150.0 mg, preferably 0.01 to 125.0 mg, more preferably 0.01 to 100.0 mg, even more preferably 0.05 to 100.0 mg, even more preferably 0.1 to 100.0 mg, most preferably 0.1 to 80.0 mg, per kg of body weight of said animal.

[063] In an even more preferred embodiment, the aforementioned sialylated MMO / first sialylated MMO is administered in a dose Petition 870250100655, dated 03 / 11 / 2025, pp. 117 / 226 26 / 128 daily 0.01 to 1.0 g, preferably 0.01 to 0.75 g, more preferably 0.025 to 0.75 g, even more preferably 0.05 to 0.75 g, most preferably 0.05 to 0.50 g. This embodiment is, for example, particularly preferred if the animal is cattle or a horse, more preferably if the animal is a calf or a foal, and even more preferably if the animal is a calf. In a further and / or even more preferred alternative embodiment, said silylated MMO / first silylated MMO is administered at a daily dose of 0.1 to 100.0 mg, preferably 0.1 to 75.0 mg, more preferably 0.5 to 75.0 mg, even more preferably 1.0 to 75.0 mg, even more preferably 2.5 to 75.0 mg, most preferably 2.5 to 50.0 mg, per kg of body weight of said animal.This embodiment is, for example, particularly preferred if the animal is cattle or a horse, more preferably if the animal is a calf or a foal, and even more preferably if the animal is a heifer.

[064] In an even more preferred alternative embodiment, the silylated MMO / first silylated MMO is administered at a daily dose of 0.01 to 5.0 g, preferably 0.1 to 2.5 g, more preferably 0.1 to 2.0 g, even more preferably 0.1 to 1.5 g, even more preferably 0.2 to 1.5 g, even more preferably 0.3 to 1.5 g, even more preferably 0.4 to 1.5 g, more preferably 0.5 to 1.5 g. This embodiment is, for example, particularly preferred if the animal is a pig, a sheep, a goat, or a camelid (preferably a llama or alpaca), more preferably if the animal is a piglet, a lamb, a kid, or a young animal, even more preferably if the animal is a piglet, a lamb, or a kid, most preferably if the animal is a piglet. In an even more preferred additional and / or alternative embodiment, the aforementioned sialylated MMO / first sialylated MM is Petition 870250100655, dated 03 / 11 / 2025, pp. 118 / 226 27 / 128 administered at a daily dose of 0.1 to 150.0 mg, preferably 0.5 to 150.0 mg, more preferably 1.0 to 150.0 mg, even more preferably 1.0 to 125.0 mg, even more preferably 2.5 to 125.0 mg, even more preferably 5.0 to 125.0 mg, even more preferably 10.0 to 125.0 mg, even more preferably 25.0 to 125.0 mg, even more preferably 50.0 to 125.0 mg, most preferably 75.0 to 125.0 mg per kg of body weight of the animal in question. This embodiment is, for example, particularly preferred if the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), more preferably if the animal is a piglet, a lamb, a kid or a young animal, even more preferably if the animal is a piglet, a lamb or a kid, most preferably if the animal is a piglet.

[065] In a further and / or alternative embodiment, the second sialylated MMO is administered at a daily dose of 0.01 to 1.0 g, preferably 0.01 to 0.75 g, more preferably 0.025 to 0.75 g, even more preferably 0.025 to 0.50 g, most preferably 0.025 to 0.25 g. This embodiment is, for example, particularly preferred if the animal is cattle or a horse, more preferably if the animal is a calf or a foal, and even more preferably if the animal is a calf.In a further and / or alternative embodiment, the aforementioned second sialylated MMO is administered at a daily dose of 0.1 to 100.0 mg, preferably 0.1 to 75.0 mg, more preferably 0.25 to 75.0 mg, even more preferably 0.5 to 75.0 mg, even more preferably 1.0 to 75.0 mg, even more preferably 1.0 to 50.0 mg, most preferably 1.0 to 25.0 mg per kg of body weight of the animal. This embodiment is, for example, particularly preferred if the... Petition 870250100655, dated 03 / 11 / 2025, pp. 119 / 226 28 / 128 If the animal is a bovine or a horse, more preferably if the animal is a calf or a foal, and even more preferably if the animal is a calf.

[066] In an even more preferred alternative embodiment, the second sialylated MMO is administered at a daily dose of 0.01 to 5.0 g, preferably 0.1 to 2.5 g, more preferably 0.1 to 2.0 g, even more preferably 0.1 to 1.5 g, even more preferably 0.1 to 1.2 g, even more preferably 0.15 to 1.2 g, even more preferably 0.2 to 1.2 g, most preferably 0.25 to 1.2 g. This embodiment is, for example, particularly preferred if the animal is a pig, a sheep or a goat, more preferably if the animal is a piglet, a lamb or a kid, and even more preferably if the animal is a piglet.In a further and / or alternative embodiment, the second sialylated MMO is administered at a daily dose of 0.1 to 150.0 mg, preferably 1.0 to 150.0 mg, more preferably 1.0 to 125.0 mg, even more preferably 2.5 to 125.0 mg, even more preferably 5.0 to 125.0 mg, even more preferably 10.0 to 125.0 mg, even more preferably 25.0 to 125.0 mg, even more preferably 25.0 to 100.0 mg, most preferably 25.0 to 80.0 mg per kg of body weight of said animal. This embodiment is, for example, particularly preferred if the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), more preferably if the animal is a piglet, a lamb, a kid or a young animal, even more preferably if the animal is a piglet, a lamb or a kid, most preferably if the animal is a piglet.

[067] Although additional (oligo)saccharides may be administered according to the invention, the present invention relates to the fact that Petition 870250100655, dated 03 / 11 / 2025, pages 120 / 226 29 / 128 that only the fucosylated MMO according to the invention is required to achieve an efficient therapeutic effect, as described herein.

[068] Therefore, it is particularly preferable that the aforementioned method for preventing and / or treating shipping fever in an animal, as described herein, does not comprise the administration of lacto-N-tetraose (LNT). In a further and / or alternative preferred embodiment, the aforementioned method for preventing and / or treating shipping fever in an animal, as described herein, does not comprise the administration of lacto-N-neotetraose (LNnT). In a further and / or alternative preferred embodiment, the aforementioned method for preventing and / or treating shipping fever in an animal, as described herein, does not comprise the administration of N-acetyl-lactosamine.

[069] In a further example of a preferred alternative embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, does not comprise the administration of an oligosaccharide containing N-acetyl-lactosamine, preferably does not comprise a saccharide containing N-acetyl-lactosamine. In a further example of a preferred alternative embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, does not comprise the administration of 3'sialyl-lactose. In a further example of a preferred alternative embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, does not comprise the administration of 6'sialyl-lactose.More preferably, the method for preventing and / or treating shipping fever in an animal, as described in this document, does not involve the administration of a sialylated mammalian milk oligosaccharide, even more preferably does not involve the administration of a sialylated oligosaccharide, even more preferably. Petition 870250100655, dated 03 / 11 / 2025, pages 121 / 226 30 / 128 does not involve the administration of a sialylated saccharide. In a further and / or alternative preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, does not involve the administration of a fructo-oligosaccharide (FOS). In a further and / or alternative preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, does not involve the administration of a galacto-oligosaccharide (GOS). In a further and / or alternative preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, does not involve the administration of an isomalto-oligosaccharide.

[070] In a further preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, does not comprise the administration of a neutral non-fucosylated MMO. In a further preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, comprises the administration of a fucosylated MMO according to the invention and no additional MMO (preferably, no additional oligosaccharide, more preferably, no additional saccharide). In a further preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described herein, comprises only the administration of the fucosylated MMO, as described herein.

[071] In another example of a preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described in the present invention, further comprises administering a microbial strain that does not use, or preferably is not capable of using, the Petition 870250100655, dated 03 / 11 / 2025, pp. 122 / 226 31 / 128 referred to as fucosylated MMO as a carbon source. In an alternative preferred embodiment, the method for preventing and / or treating shipping fever in an animal, as described in the present invention, does not comprise the administration of a microbial strain. Oligosaccharide

[072] A fucosylated mammalian milk oligosaccharide (MMO) according to the invention is an MMO comprising a fucose.

[073] As understood by those skilled in the subject, mammalian milk oligosaccharides (MMOs) comprise milk oligosaccharides found in milk at any stage during lactation, including human colostrum (i.e., human milk oligosaccharides or HMOs) and mammals including, but not limited to, cows (Bos taurus), sheep (Ovis aries), goats (Capra aegagrus hircus), Bactrian camels (Camelus bactrianus), horses (Equus ferus caballus), pigs (Sus scropha), dogs (Canis lupus familiaris), ezo brown bears (Ursus arctos yesoensis), polar bears (Ursus maritimus), Japanese black bears (Ursus thibetanus japonicus), striped skunks (Mephitis mephitis), and crested seals. (Cystophora cristata), Asian elephants (Elephas maximus), African elephant (Loxodonta africana), giant anteater (Myrmecophaga tridactyla),Common bottlenose dolphins (Tursiops truncates), northern minke whales (Balaenoptera acutorostrata), tammar kangaroos (Macropus eugenii), red kangaroos (Macropus rufus), common possum (Trichosurus vulpecula), koalas (Phascolarctos cinereus), eastern quoll (Dasyurus viverrinus), platypus (Ornithorhynchus anatinus) (Urashima T. et al., 2011, Milk Oligosaccharides, Nova Biomedical Books, New York ISBN 978-1-61122-831-1; Coppa et al, 2013, Ital. J. Pediatr. 2013, 39 (2)). An abundant number of milk saccharide structures have been elucidated so far. Most of them, Petition 870250100655, dated 03 / 11 / 2025, pp. 123 / 226 32 / 128 milk oligosaccharides found in animals such as mammals and humans comprise lactose at the reducing end (Urashima et al, 2011). Other milk oligosaccharides comprise N-acetyl-lactosamine (Gal-31,4 GlcNAc) or lacto-N-biose (Gal-p1,3-GlcNAc) at the reducing end (Urashima et al, 2011; Wrigglesworth et al, 2020, PLoS ONE 15(12); Urashima et al, 2013, Biosci. Biotechnol. Biochem 77(3): p. 455-466; Wei et al, 2018, Sci. Rep. 8:4688). Examples of this are 3-FLN (Gal-p1,4-(Fuc-α1,3-)GlcNAc; also known as Lewis x antigen), 3'-SLN (Neu5Ac-α2,3-Gal-β1,4GlcNAc), 6'-SLN (Neu5Ac-α2,6-Gal-β1,4-GlcNAc) (Urashima et al, 2011; (Wrigglesworth et al, 2020; Wei et al, 2018). Furthermore, milk saccharides comprise milk glycosaminoglycans (GAGs; Coppa et al, 2013; Rai et al, 2021, Int. J. Biol. Macromolecules, 193(A): p. 137-144). Human ABO blood group system antigens, such as the A determinant (GalNAcalfa1,3 (Fuc-alpha1,2)-Gal), the B determinant (Gal-alpha1,3(Fuc-alpha1,2)-Gal), and the H determinant (Fuc-alpha1,2-Gal), have been shown to be present in mammalian milk saccharides (e.g., tetrasaccharide A in a lion and leopard; Wrigglesworth et al, 2020).

[074] Throughout the present application and claims, a “mammalian milk oligosaccharide (MMO)” is preferably a “human milk oligosaccharide (HMO)”.

[075] In the context of the present invention, the term “oligosaccharide” preferably refers to a saccharide containing from 2 to 20 monosaccharides, i.e., with a degree of polymerization (DP) of 2 to 20; more preferably, to a saccharide containing from 3 to 20 monosaccharides, i.e., with a degree of polymerization (DP) of 3 to 20. In other words, the term “oligosaccharide” preferably refers to a saccharide consisting of 2 to 20, more preferably 3 to 20, monosaccharide units that Petition 870250100655, dated 03 / 11 / 2025, pp. 124 / 226 33 / 128 are linked together by means of glycosidic bonds in a linear or branched structure. The linkage (i.e., glycosidic bond) between two sugar units, i.e., two monosaccharides, can be expressed, for example, as 1,4, 1->4 or (1-4), which are used interchangeably in the present invention.

[076] More preferably, an oligosaccharide, as described in the present invention, consists of 3-8, even more preferably 3 to 7, even more preferably 3 to 6, and even more preferably 3 to 5 monosaccharides. For clarity, the expression “xy” or “of xay” refers to a range of, and including, x, and including y. For example, 3-5 monosaccharides means that 3, 4 or 5 monosaccharides are present.

[077] Preferably, the fucosylated MMO according to the invention contains only one fucose, i.e., the MMO consists of two or more monosaccharides and only one of the monosaccharides is a fucose.

[078] In a preferred embodiment of the invention, said fucosylated MMO is a neutral oligosaccharide. A “neutral” oligosaccharide, as used in the present invention and as generally understood in the state of the art, is an oligosaccharide without a negative charge originating from a carboxylic acid group.

[079] In a further and / or preferred alternative embodiment, said fucosylated MMO comprises a fucose that is linked to a monosaccharide via an alpha-1,2, alpha-1,3 or alpha-1,4 linkage, preferably an alpha-1,2 or alpha-1,3 linkage, more preferably an alpha-1,2 linkage, and wherein said monosaccharide is preferably selected from glucose, N-acetylglucosamine and galactose, more preferably said monosaccharide is glucose or galactose, and even more preferably said monosaccharide is galactose. Those skilled in the art will understand that the expression “the fucose is linked to a Petition 870250100655, dated 03 / 11 / 2025, pp. 125 / 226 34 / 128 monosaccharide” refers to the situation where fucose is linked to a monosaccharide by means of a glycosidic linkage and where said fucose and the monosaccharide form part of the oligosaccharide of the invention (which may comprise additional monosaccharide(s) besides said fucose and said monosaccharide).

[080] In a further and / or alternative preferred embodiment, the fucosylated mammalian milk oligosaccharide comprises lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, preferably the fucosylated oligosaccharide comprises lactose or LacNAc at its reducing end, more preferably the fucosylated oligosaccharide comprises lactose at its reducing end.

[081] A fucosylated oligosaccharide comprising lactose at its reducing end is preferably selected from the list consisting of 2'-fucosyllactose (2'FL), 3-fucosyllactose (3-FL), difucosyllactose (diFL), lacto-N-fucopentaose I (LNFP I), blood group A antigen type 1 hexaose (GalNAc-LNFP I), blood group B antigen type 1 hexaose (Gal-LNFP I), lacto-N-fucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose V (LNFP V), lacto-N-difucohexaose I (LNDFH I), lacto-N-difucohexaose II (LNDFH II), Lewis b-Lewis x, monofucosyl-lacto-N-hexaose III (MFLNH III), difucosyl-lacto-N-hexaose (a) (DFLNH (a)), difucosillacto-N-hexaose (DFLNH), trifucosyl-lacto-N-hexaose (TFLNH), lacto-N-neofucopentaose I (LNnFP I), lacto-N-neofucopentaose V (LNnFP V, LNFP VI) and lacto-N-neodifucohexaose (LNnDFH), more preferably selected from the list consisting of 2'FL, diFL, LNFP I, GalNAc-LNFP I, Gal-LNFP I, LNDFH I, lewis b-lewis x, DFLNH (a),TFLNH and LNnFP I, even more preferably selected from the list consisting of 2'FL, diFL, LNFP I and LNnFP I, and even more preferably the milk oligosaccharide of, Petition 870250100655, dated 03 / 11 / 2025, pages 126 / 226 35 / 128 mammalian fucosylated is 2'FL or diFL, and more preferably, mammalian milk oligosaccharide fucosylated is 2'FL.

[082] A fucosylated oligosaccharide comprising lacto-N-biose (LNB) at its reducing end is preferably selected from the list consisting of 2'-fucosyl-lacto-N-biose (2'FLNB), 4-fucosyl-lacto-N-biose (4FLNB) and difucosyl-lacto-N-biose (diFLNB), more preferably wherein said fucosylated mammalian milk oligosaccharide is 2'FLNB or diFLNB, more preferably wherein said fucosylated mammalian milk oligosaccharide is 2'FLNB.

[083] A fucosylated oligosaccharide comprising N-acetylactosamine (LacNAc) at its reducing end is preferably selected from the list consisting of 2'-fucosyl-N-acetyl-lactosamine (2'FlacNAc), difucosyl-N-acetyl-lactosamine (diFLacNAc) and 3-fucosyl-N-acetyllactosamine (3FlacNAc), wherein, more preferably, said fucosylated mammalian milk oligosaccharide is 2'FlacNAc or diFLacNAc, wherein, more preferably, said fucosylated mammalian milk oligosaccharide is 2'FlacNAc.

[084] In a more preferred embodiment, the fucosylated MMO according to the invention is selected from a list consisting of 2'-fucosyllactose (2'FL), 3-fucosyllactose (3-FL), difucosyllactose (diFL), 2'-fucosyl-N-acetyllactosamine (2'FlacNAc), difucosyl-N-acetyllactosamine (diFLacNAc), 3-fucosyl-N-acetyllactosamine (3FlacNAc), 2'-fucosyllacto-N-biose (2'FLNB), 4-fucosyl-lacto-N-biose (4FLNB), difucosyl-lacto-N-biose (diFLNB), lacto-N-fucopentaose I (LNFP I), blood group A antigen type 1 hexaose (GalNAc-LNFP I), blood group B antigen type 1 hexaose (Gal-LNFP I) Petition 870250100655, dated 03 / 11 / 2025, pp. 127 / 226 36 / 128 x, monofucosilacto-N-hexaose III (MFLNH III), difucosilacto-N-hexaose (a) (DFLNH (a)), difucosilacto-N-hexaose (DFLNH), trifucosilacto-N-hexaose (TFLNH), lacto-N-neofucopentaose I (LNnFP I), lacto-N-neofucopentaose V (LNnFP V, LNFP VI) e lacto-N-neodifucohexaose (LNnDFH).More preferably, the fucosylated MMO according to the invention is selected from the list consisting of 2'FL, diFL, LNFP I, GalNAc-LNFP I, Gal-LNFP I, LNDFH I, Lewis B-Lewis X, DFLNH (a), TFLNH, LNnFP I, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc, even more preferably selected from the list consisting of 2'FL, diFL, LNFP I, LNnFP I, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc, even more preferably selected from the list consisting of 2'FL, diFL, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc, even more preferably selected from the list consisting of 2'FL, 2'FLNB and 2'FlacNAc, wherein, even more Preferably, the fucosylated mammalian milk oligosaccharide is 2'FL or diFL, more preferably the fucosylated mammalian milk oligosaccharide is 2'FL.

[085] The fucosylated mammalian milk oligosaccharides mentioned above are commercially available and / or the production / purification of these oligosaccharides has been described and therefore enables the technician to produce / obtain any of the aforementioned fucosylated oligosaccharides appropriately. For example (each reference is incorporated by reference): - 2'FL: Zhou et al, 2021, ACS Synth. Biol. 10(3): p. 447-458; Lu et al, 2021, ACS Synth. Biol. 10(5): p. 923-938; document WO2022 / 034073; Carbosynth (OF06739); - 3-FL: Zhou et al, 2021; ACS Synth. Biol. 10(3): p. 447-458, Lu et al, 2021, ACS Synth. Biol. 10(5): p. 923-938; document WO2022 / 034073; Carbosynth (OF05673); - diFL: document WO2022 / 034073; Petition 870250100655, dated 03 / 11 / 2025, pp. 128 / 226 37 / 128 - 2'FlacNAc: document WO 2022 / 034075; - 3FlacNAc: document WO 2022 / 034075; - diFLacNAc: document WO 2022 / 034075; - 2'FLNB: document WO 2022 / 034075; - 4FLNB: document WO 2022 / 034075; - diFLNB: document WO 2022 / 034075; - LNFP I: Derya et al, 2020, J. biotech. 319: p. 31-38; Carbosynth (OL05676); - GalNAc-LNFP I: document WO 2022 / 034077; - Gal-LNFP I: document WO 2022 / 034077; - LNFP II: Zeuner et al, 2018, ACS Synth. Biol. 10(3): p. 447-458; - LNFP III: Zeuner et al, 2018, ACS Synth. Biol. 10(3): p. 447-458; Carbosynth (OL04212); - LNFP V: document WO2020 / 115671; Carbosynth (OL06817); - LNDFH I: Huang et al, 2021, ACS Catal. 11(5): p. 2631-2643; Carbosynth (OL01664); - LNDFH II: Yu et al, 2017, chem. Comm. 53(80): p. 11012-11015; Huang et al, 2021, ACS Catal. 11(5): p. 2631-2643; Carbosynth (OL06826); - MFLNH III: Carbosynth (OM05898); - DFLNH (a): Carbosynth (OD05375); - DFLNH: Carbosynth (OD06532); - TFLNH: Isosep (57 / 18-0010); - LNnFP I: Elicityl (GLY033-2-90%); - LNnFP V: Dumon et al, 2001, Glyconj. J. 18(6): p. 465-474; - LNnDFH: Dumon et al, 2001, Glyconj. J. 18(6): p. 465-474. [ 086] In a more preferred further and / or alternative embodiment, the aforementioned fucosylated MMO according to the invention (and optionally any, preferably all, of the other oligosaccharides Petition 870250100655, dated 03 / 11 / 2025, pp. 129 / 226 38 / 128 of mammalian milk, if also administered to said animal (also referred to in the "Composition" section)) was isolated from a microbial culture or fermentation, cell culture, enzymatic reaction, or chemical reaction. Alternatively, said fucosylated MMO of the invention (and optionally any, preferably all, other mammalian milk oligosaccharides, if also administered to said animal (also referred to in the "Composition" section)) was isolated from a natural source, such as human or animal milk, preferably animal milk, by, for example, chromatography or filtration technology. The isolation of said fucosylated MMO typically results in a solution containing said oligosaccharide. Such a solution can, for example, be obtained by a method comprising the steps of: (a) cultivate at least one cell as defined in the present invention, preferably a single cell, capable of producing said fucosylated MMO, in a suitable culture medium to form a culture broth, preferably in which said cell is metabolically modified for the production of said fucosylated MMO, and (b) purify said fucosylated MMO from the culture broth by: (i) clarifying the culture broth, and (ii) removing salts and / or components from the clarified culture broth medium and / or, (iii) concentrating said fucosylated oligosaccharide in said clarified culture broth, thus providing a solution comprising a purified oligosaccharide.

[087] In the context of the invention, “clarification of the culture broth” refers to the removal of suspended particles and contaminants, particularly cells, cell components, insoluble metabolites and Petition 870250100655, dated 03 / 11 / 2025, pp. 130 / 226 39 / 128 debris produced by cell culture according to the invention. Clarification is preferably one or more of the following processes: centrifugation, flocculation, decantation and / or filtration.

[088] In the context of the invention, “removal of salts and / or components from the clarified culture broth medium” refers to the removal of substantially all proteins, as well as peptides, amino acids, RNA and DNA and any endotoxins and glycolipids from the clarified culture broth, preferably after its clarification. In this step, the proteins and related impurities can be removed from the saccharide in a conventional manner. Preferably, proteins, salts, by-products, dyes, endotoxins and other related impurities are removed from said oligosaccharide by ultrafiltration, nanofiltration, biphasic partitioning, reverse osmosis, microfiltration, activated carbon or charcoal treatment, non-ionic surfactant treatment, enzymatic digestion, high-performance tangential flow filtration, tangential flow ultrafiltration, electrophoresis (e.g., using polyacrylamide gel electrophoresis on plates or sodium dodecyl sulfate-polyacrylamide (PAGE)).Affinity chromatography (using affinity ligands, including, for example, DEAE-Sepharose, poly-Llysine and polymyxin-B, selective endotoxin adsorbent matrices), ion-exchange chromatography (such as, but not limited to, cation exchange, anion exchange, mixed-bed ion exchange, inside-out ligand binding), hydrophobic interaction chromatography and / or gel filtration (i.e., size exclusion chromatography), particularly by chromatography, more particularly by ion-exchange chromatography or hydrophobic interaction chromatography or ligand exchange chromatography. With the exception of size exclusion chromatography, proteins and related impurities are retained by a selected chromatographic medium or membrane, wherein the oligosaccharide remains in the clarified culture broth. Petition 870250100655, dated 03 / 11 / 2025, pp. 131 / 226 40 / 128 containing the aforementioned oligosaccharide.

[089] Further purification of said oligosaccharide may be carried out, for example, by the use of (activated) charcoal or carbon, nanofiltration, ultrafiltration, electrophoresis, enzymatic treatment or ion exchange to remove any remaining DNA, protein, LPS, endotoxins or other impurities. Alcohols, such as ethanol, and aqueous mixtures of alcohols may also be used. Another purification step is carried out by crystallization, evaporation or precipitation of the product.

[090] Several drying techniques are known to those skilled in the art and can be used to obtain powder from a solution containing said oligosaccharide. The powder is preferably obtained by spray drying, freeze drying, freeze drying with spray drying, crystallization, lyophilization, strip drying, drum or roll drying and / or agitated thin film drying, preferably by spray drying, drum or roll drying, or agitated thin film drying, more preferably by spray drying or agitated thin film drying, and, most preferably, by spray drying, from a solution containing said saccharide. Preferably, said oligosaccharide, according to the invention, constitutes > 70.0%, preferably > 75.0%, more preferably > 80.0% (w / w) of said powder.Preferably, the said powder contains < 15% by weight, preferably < 10% by weight, more preferably < 9% by weight, more preferably < 8% by weight, more preferably < 7% by weight, even more preferably < 5% by weight, even more preferably < 4% by weight of liquid, even more preferably < 3% by weight of liquid, even more preferably < 2% by weight of liquid, more preferably < 1% by weight, wherein, preferably, the liquid is water.

[091] In an example of additional and / or alternative embodiment Petition 870250100655, dated 03 / 11 / 2025, pp. 132 / 226 41 / 128 more preferably, the said fucosylated MMO according to the invention (and optionally any, preferably all, other mammalian milk oligosaccharides, if also administered to said animal (also referred to in the “Composition” section)) is / are provided as a powder according to the invention. Preferably, said powder is as defined above in this section.

[092] In a further and / or more preferred alternative embodiment, said fucosylated MMO according to the invention (and optionally any, preferably all, other mammalian milk oligosaccharides, if also administered to said animal (also referred to in the “Composition” section)) was produced, preferably in vitro and / or ex vivo, by a cell, preferably a single cell, wherein said cell is preferably chosen from the list consisting of a microorganism, a plant cell, an animal cell and a protozoan cell. In other words, said saccharide of the invention was produced by a cell culture in vitro and / or ex vivo, wherein said cells are preferably chosen from the list consisting of a microorganism, a plant cell, an animal cell or a protozoan cell.

[093] Preferably, said cell is a microorganism. Preferably, said microorganism is selected from a list consisting of a bacterium, a yeast, and a fungus. Furthermore, it is preferable that said cell is genetically modified for the production of said fucosylated MMO according to the invention. Throughout the description and claims, the terms “was isolated” and “is obtained” are used interchangeably unless specifically indicated otherwise.

[094] The last bacterium belongs preferentially to the phylum Proteobacteria or to the phylum Firmicutes or to the phylum Cyanobacteria or to the phylum Petition 870250100655, dated 03 / 11 / 2025, pp. 133 / 226 42 / 128 Deinococcus-Thermus, and the bacterium preferentially belongs to the phylum Proteobacteria. The last bacterium belonging to the phylum Proteobacteria preferentially belongs to the family Enterobacteriaceae, preferentially to the species Escherichia coli. The last bacterium refers preferentially to any strain belonging to the species Escherichia coli, such as, but not limited to, Escherichia coli B, Escherichia coli C, Escherichia coli W, Escherichia coli K12, Escherichia coli Nissle. More specifically, the last term refers to cultured strains of Escherichia coli - designated as E. coli K12 strains - that are well adapted to the laboratory environment and, unlike wild-type strains, have lost the ability to thrive in the intestine. Well-known examples of E. coli K12 strains are K12 Wild type, W3110, MG1655, M182, MC1000, MC1060, MC1061, MC4100, JM101, NZN111, and AA200.Therefore, preferably, the present invention relates specifically to a mutated and / or transformed strain of Escherichia coli, as indicated above, wherein said E. coli strain is a K12 strain. More specifically, the present invention relates to a mutated and / or transformed strain of Escherichia coli, as indicated above, wherein said K12 strain is E. coli MG1655. The cited bacterium belonging to the phylum Firmicutes preferably belongs to the Bacilli, preferably of the species Bacillus, such as Bacillus subtilis or B. amyloliquefaciens. The cited bacterium belonging to the phylum Actinobacteria preferably belongs to the family Corynebacteriaceae, with members Corynebacterium glutamicum or C. afermentans, or belongs to the family Streptomycetaceae with members Streptomyces griseus or S. fradiae. The yeast mentioned belongs preferentially to the phylum Ascomycota or to the phylum Basidiomycota or to the phylum Deuteromycota or to the phylum Zygomycetes.The yeast mentioned belongs preferentially to the genus Saccharomyces (with members such as, for example, Saccharomyces cerevisiae, S. bayanus, S. boulardii), Pichia (with. Petition 870250100655, dated 03 / 11 / 2025, pp. 134 / 226 43 / 128 members such as, for example, Pichia pastoris, P. anomala, P. kluyveri), Komagataella, Hansunella, Kluyveromyces (with members such as, for example, Kluyveromyces lactis, K. marxianus, K. thermotolerans), Yarrowia (such as, for example, Yarrowia lipolytica), Eremothecium, Zygosaccharomyces, Starmerella (such as, for example, Starmerella bombicola) or Debaromyces. This last yeast is preferentially selected from Pichia pastoris, Yarrowia lipolytica, Saccharomyces cerevisiae and Kluyveromyces lactis. The fungus mentioned preferentially belongs to the genera Rhizopus, Dictyostelium, Penicillium, Mucor or Aspergillus. "Plant cells" include cells from plants with and without flowers, as well as algal cells, for example, Chlamydomonas, Chlorella, etc. Preferably, the plant cell in question is a cell from tobacco, alfalfa, rice, cotton, rapeseed, tomato, corn, maize, or soybeans.The animal cell mentioned is preferably derived from non-human mammals (e.g., cattle, buffalo, pig, sheep, mouse, rat), birds (e.g., chicken, duck, ostrich, turkey, pheasant), fish (e.g., swordfish, salmon, tuna, sea bass, trout, catfish), invertebrates (e.g., lobster, crab, shrimp, clams, oyster, mussel, sea urchin), reptiles (e.g., snake, alligator, turtle), amphibians (e.g., frogs) or insects (e.g., fly, nematode) or is a genetically modified cell line derived from human cells, excluding embryonic stem cells.Both human and non-human mammalian cells are preferably chosen from the list comprising an epithelial cell such as, for example, a mammary epithelial cell, a mammary myoepithelial cell, a mammary progenitor cell, an embryonic renal cell (e.g., HEK293 or HEK 293T cell), a fibroblast cell, a COS cell, a Chinese hamster ovary (CHO) cell, a murine myeloma cell such as, for example, an N20, SP2 / 0 or YB2 / 0 cell, an NIH3T3 cell, a non-mammary adult stem cell or its derivatives, as described. Petition 870250100655, dated 03 / 11 / 2025, pages 135 / 226 44 / 128 in document WO21067641, preferably a mesenchymal stem cell or its derivatives, as described in document WO21067641. The insect cell mentioned is preferably derived from Spodoptera frugiperda, such as Sf9 or Sf21 cells, Bombyx mori, Mamestra brassicae, Trichoplusia ni, such as BTI-TN-5B1-4 cells, or Drosophila melanogaster, such as Drosophila S2 cells. The protozoan cell mentioned is preferably a Leishmania tarentolae cell.

[095] In a more preferred, further and / or alternative embodiment, said fucosylated MMO of the invention was produced, preferably in vitro and / or ex vivo, by a mammary epithelial cell, mammary myoepithelial cell and / or mammary progenitor cell, preferably wherein said cell is generated from non-mammary adult stem cells, more preferably wherein said cell is generated from mesenchymal stem cells. Such cells are well known to those skilled in the art, being, in this respect, referred to, for example, in documents WO2021 / 067641 and WO2021 / 242866 (mammary epithelial cells derived from non-mammary adult stem cells, preferably from mesenchymal stem cells) and in document WO2021 / 142241 (mammary epithelial cells, mammary myoepithelial cells, mammary progenitor cells).

[096] In a further preferred embodiment, the fucosylated MMO of the invention (and optionally any, preferably all, other mammalian milk oligosaccharides, if also administered to the animal (also referred to in the “Composition” section)) was produced, preferably in vitro and / or ex vivo, by a microorganism cell, preferably the microorganism is a bacterium, a yeast or a fungus, more preferably the microorganism is a bacterium or a yeast, even more preferably the microorganism is a Petition 870250100655, dated 03 / 11 / 2025, pp. 136 / 226 45 / 128 bacteria, most preferably the microorganism is Escherichia coli.

[097] In the context of the invention, it is also within the scope of the present invention that two or more different cells (preferably as defined in the present invention) produce the fucosylated MMO according to the invention. However, it is preferable that a single cell produces said oligosaccharide, i.e., a single culture of said cell produces the oligosaccharide of the invention.

[098] In a further and / or alternative embodiment, said fucosylated MMO according to the invention (and optionally any, preferably all, other mammalian milk oligosaccharides, if also administered to said animal (also referred to in the “Composition” section)) is preferably chemically linked to a vehicle / carrier for administration of said MMO. Preferably, said vehicle is a ceramide-based vehicle or a polypeptide-based vehicle, more preferably said vehicle is a ceramide-based vehicle. Preferably, said polypeptide-based vehicle is epsilon-polylysine, alpha-polylysine, (poly)aspartic acid, polyglutamic acid or polyornithine. These vehicles are commercially available (e.g., Sigma-Aldrich, Carbosynth). The aforementioned ceramide-based vehicle is preferably selected from a list consisting of d18:1 / 16:0, t18:0 / 16:0, t18:0-h16:0, t18:0-h22:0 and t18:0-h24:0.These ceramide vehicles are commercially available and well known to those skilled in the art, being described, for example, in document WO2010 / 037785, which is incorporated herein by reference. d18:1 / 16:0 is also known as C16 ceramide and N-palmitoylsphingosine and is therefore interchangeable for use in the present invention. d18:0 / -16:0 is also known as C16 ceramide and N-palmitoylsphingosine and is therefore interchangeable for use in the present invention. t18:0-h16:0, t18:0-h22:0 and t18:0-h24:0 are. Petition 870250100655, dated 03 / 11 / 2025, pp. 137 / 226 46 / 128 glycosylinositolphosphoceramides (GIPCs). According to expert knowledge, “d” and “t” refer to the hydroxylation state of the entire ceramide or the long-chain base fraction (d is 2 groups, t is 3 groups), while “h” denotes a hydroxylation of the fatty acyl group.

[099] The aforementioned fucosylated mammalian milk oligosaccharide and, optionally, any other mammalian milk oligosaccharides, preferably all of them, if also administered to the said animal, are preferably encapsulated (i.e., forming an encapsulate). This is particularly advantageous for protecting the said oligosaccharide(s) from conditions related to the manufacture or storage of a composition according to the invention, especially when said composition is a nutritional composition (see the “Composition” section). Such conditions typically involve high pressure (e.g., a pressure above 10 bar during extrusion), high temperature (e.g., a temperature above 100 °C during extrusion and cooking), pH below 5, pH above 8 and / or high moisture content (e.g., wet extrusion).Furthermore, other molecules within a composition, especially a nutritional composition such as proteins, may chemically interact with said fucosylated MMO (and any other additional MMO, if present), particularly under the adverse conditions during the manufacture of a nutritional composition. Therefore, throughout this application and claims, said “fucosylated MMO” is preferably replaced by “encapsulated fucosylated MMO”. If any other MMO is present (also referred to in the “Composition” section), it is preferable that all MMOs be encapsulated, preferably all MMOs be co-encapsulated.

[100] The said encapsulation is particularly advantageous when the composition according to the invention is a nutritional composition (referred to in the “Composition” section) that is manufactured by extrusion (dry or Petition 870250100655, dated 03 / 11 / 2025, pp. 138 / 226 47 / 128 moist, preferably moist).

[101] It is preferable that the encapsulated material be of the core-shell type, i.e., the support material forms a shell around the active agent (i.e., the MMO(s) according to the invention), preferably wherein the core has an average diameter (D(v,0.5)) of 125 to 250 micrometers (µm), preferably 150-250 µm, more preferably 165-250 µm, more preferably 165-225 µm, and wherein the encapsulated material has an average diameter (D(v,0.5)) that is 20 to 100 µm, preferably 20-75 µm, more preferably 35-75 µm, larger than the average diameter of the core.

[102] The vehicle preferably comprises a hot-melt material, more preferably an oil and / or a wax, even more preferably a hydrogenated oil and / or a wax, optionally also comprising starch, wherein the starch preferably constitutes less than 15% (w / w) of the carrier material, more preferably the starch constitutes less than 10% (w / w) of the carrier material.

[103] The said oil is preferably selected from the list consisting of palm oil, sunflower oil, soybean oil, rapeseed oil, coconut oil, babassu oil, palm kernel oil, corn oil, sesame oil and cottonseed oil; more preferably, the said oil is selected from the list consisting of palm oil, sunflower oil, soybean oil and rapeseed oil; even more preferably, the said oil is palm oil, most preferably, the said oil is hydrogenated palm oil.

[104] The said wax is preferably selected from the list consisting of candelilla wax, carnauba wax, beeswax, rice bran wax, paraffin wax, jojoba wax, microcrystalline wax and Japan wax; more preferably, the said wax is candelilla wax or carnauba wax; more preferably, the said wax is candelilla wax. Petition 870250100655, dated 03 / 11 / 2025, pp. 139 / 226 48 / 128

[105] It is preferable that the fucosylated MMO or all MMOs present in the encapsulate constitute 5 to 50% (w / w), preferably 10 to 40% (w / w), more preferably 20 to 40% (w / w), even more preferably 20 to 35% (w / w), in relation to the total weight of the encapsulate.

[106] Throughout the present application and claims, it is particularly preferable that said fucosylated MMO according to the invention and optionally any, preferably all, other mammalian milk oligosaccharides, if also administered to said animal, form part of a composition, preferably a composition according to the “Composition” section. Composition

[107] In a preferred embodiment of the first aspect, the invention provides a composition comprising a fucosylated mammalian milk oligosaccharide (MMO), wherein said composition is for use in a method for preventing and / or treating shipping fever in an animal, preferably a farm animal or domestic animal, more preferably a farm animal.

[108] The aforementioned fucosylated MMO is as described in the “oligosaccharide” section. The aforementioned shipping fever is as described in the “Shipping Fever” section. The aforementioned method of prevention and / or treatment is as described in the “Method for preventing and / or treating” section. The aforementioned animal is as described in the “Subject” section.

[109] In a preferred embodiment, said fucosylated mammalian milk oligosaccharide (MMO) is present from 0.001 to 1.000% by weight, preferably from 0.001 to 0.750% by weight, more preferably from 0.001 to 0.500% by weight, even more preferably from 0.001 to 0.400% by weight, even more preferably from 0.005 to 0.400% Petition 870250100655, dated 03 / 11 / 2025, pp. 140 / 226 49 / 128 by weight, even more preferably from 0.005 to 0.300% by weight, even more preferably from 0.005 to 0.250% by weight, most preferably from 0.005 to 0.100% by weight, relative to the total weight of the composition. Throughout this application and the claims, unless specifically indicated otherwise, the term “% by weight” means weight by weight (i.e., w / w). If the composition is, for example, a solid composition, then 1.0% by weight means 1.0 g of fucosylated MMO per 100.0 grams of the solid composition. If the composition is, for example, a liquid composition, then 1.0% by weight means 1.0 g of fucosylated MMO per 100.0 grams of the liquid composition.

[110] Throughout this application and claims, if the composition in question is a milk substitute (for example, a milk substitute for calves), the % by weight, as cited throughout this application and claims, refers to the % by dry weight. If the aforementioned composition is a milk substitute (for calves), then, for example, the paragraph mentioned above should be read as: “In a preferred embodiment, said fucosylated mammalian milk oligosaccharide (MMO) is present in a concentration of 0.001 to 1.000% by dry weight, preferably 0.001 to 0.750% by dry weight, more preferably 0.001 to 0.500% by dry weight, even more preferably 0.001 to 0.400% by dry weight, even more preferably 0.005 to 0.400% by dry weight, even more preferably 0.005 to 0.300% by dry weight, even more preferably 0.005 to 0.250% by dry weight, most preferably 0.005 to 0.100% by dry weight”.

[111] Furthermore, a milk replacer (e.g., milk replacer for calves) is often given to a calf, for example, in liquid form. Therefore, in this context, it is preferable that a liquid milk replacer contain 10.0 to 30.0% (w / v), more Petition 870250100655, dated 03 / 11 / 2025, pp. 141 / 226 50 / 128 preferably from 12.0 to 28.0% (w / v) of powdered milk substitute. Herein, it is preferable that the milk substitute powder be dissolved in water to obtain said liquid milk substitute. Throughout this application and claims, the term “% w / v” refers to the weight of the dissolved substance in grams (e.g., powdered milk substitute) per 100 milliliters of the final solution (e.g., liquid milk substitute). If the milk replacer is a milk replacer for calves, it is particularly preferable that the liquid calf milk replacer contain 10.0 to 20.0% (w / v), more preferably 12.0 to 20.0% (w / v), even more preferably 12.0 to 18.0% (w / v), even more preferably 14.0 to 18.0% (w / v), and even more preferably 15.0% (w / v) of powdered calf milk replacer. It is preferable that the powdered calf milk replacer be diluted in water to obtain the calf milk replacer.If the milk substitute in question is a milk substitute for a piglet, it is particularly preferable that a liquid milk substitute contain 10.0 to 30.0% (w / v), more preferably 15.0 to 30.0% (w / v), even more preferably 20.0 to 30.0% (w / v), even more preferably 22.0 to 28.0% (w / v), even more preferably 25.0% (w / v) of powdered milk substitute. It is preferable that the powdered milk substitute be made with water to obtain the said liquid milk substitute.

[112] In a more preferred embodiment, said fucosylated MMO is present in a concentration of 0.001 to 0.250% by weight, preferably 0.001 to 0.200% by weight, more preferably 0.001 to 0.100% by weight, even more preferably 0.001 to 0.020% by weight, even more preferably 0.001 to 0.010% by weight, even more preferably 0.002 to 0.010% by weight, even more preferably 0.003 to 0.010% by weight, even more preferably 0.003 to 0.0075% by weight, most preferably 0.003 to 0.006% by weight Petition 870250100655, dated 03 / 11 / 2025, pp. 142 / 226 51 / 128 weight in relation to the total weight of the composition. This embodiment is, for example, particularly preferred if the animal is cattle or a horse, more preferably if the animal is a calf or a foal, and even more preferably if the animal is a heifer.

[113] In a more preferred alternative embodiment, said fucosylated MMO is present in a concentration of 0.010 to 1.000% by weight, preferably 0.010 to 0.750% by weight, more preferably 0.010 to 0.500% by weight, even more preferably 0.010 to 0.400% by weight, even more preferably 0.050 to 0.400% by weight, even more preferably 0.100 to 0.400% by weight, more preferably 0.100 to 0.300% by weight, relative to the total weight of the composition. This embodiment is, for example, particularly preferred if the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), more preferably if the animal is a piglet, a lamb, a kid or a young animal, even more preferably if the animal is a piglet, a lamb or a kid, most preferably if the animal is a piglet.

[114] In a preferred embodiment of the invention, said composition further comprises a second mammalian milk oligosaccharide (MMO), preferably wherein said second mammalian milk oligosaccharide is a silylated MMO, more preferably wherein said second mammalian milk oligosaccharide is a silylated MMO comprising lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, even more preferably said silylated MMO comprises lactose or LacNAc at its reducing end, most preferably said silylated MMO comprises lactose at its reducing end.

[115] Preferably, the second MMO consists of 3 to 8, more Petition 870250100655, dated 03 / 11 / 2025, pp. 143 / 226 52 / 128 preferably 3 to 7, even more preferably 3 to 6, most preferably 3 to 5, monosaccharides.

[116] A sialylated MMO comprising lactose at its reducing end is preferably selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c and LST d; more preferably selected from the list consisting of 3'SL, 6'SL, 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, LST a, LST b, LST c and LST d; even more preferably selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c and LST d; more preferably wherein the said sialylated MMO is 3'-sialyl-lactose (3'SL) or 6'-sialyl-lactose (6'SL).

[117] A sialylated MMO comprising lacto-N-biose (LNB) at its reducing end is preferably selected from the list consisting of 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB) and monofucosylmonosialyl-lacto-N-octaose (sialyl Lewis a); more preferably, said sialylated MMO is 3'SLNB or 6'SLNB.

[118] A sialylated MMO comprising N-acetyl-lactosamine (LacNAc) at its reducing end is preferably selected from the list consisting of 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialillactosamine (6'SLacNAc) and sialyl Lewis x; more preferably, said sialylated MMO is 3'SLacNAc or 6'SLacNAc.

[119] When a second MMO, preferably a sialylated MMO, is present in said composition, then it is a preferred embodiment that the quantity of said second MMO in said composition is from 0.1 to 30.0, preferably from 0.1 to 25.0, more preferably from 0.1 to 20.0, even more preferably from 0.1 to 15.0, even more preferably from 0.2 to 15.0, even more preferably from Petition 870250100655, dated 03 / 11 / 2025, pp. 144 / 226 53 / 128 0.3 to 15.0, even more preferably from 0.4 to 15.0, most preferably from 0.5 to 15.0 times the quantity of said fucosylated MMO in said composition. A more preferred embodiment is that the quantity of said fucosylated MMO in said composition is less than the quantity of said second MMO, preferably said quantity of said fucosylated MMO is from 1.1 to 15.0, more preferably from 1.5 to 15.0, even more preferably from 2.5 to 15.0, even more preferably from 5.0 to 15.0, even more preferably from 5.0 to 12.5, most preferably from 5.0 to 10.0 times less than the quantity of said second MMO in said composition.It is an even more preferred embodiment that, when the second MMO is a sialylated MMO, the amount of fucosylated MMO in the composition is less than the amount of the second MMO, preferably the amount of fucosylated MMO is 1.1 to 10.0, preferably 1.5 to 7.5, more preferably 2.5 to 7.5, most preferably 4.0 to 7.0 times less than the amount of the second MMO in the composition.

[120] In a further preferred embodiment, said composition further comprises a third mammalian milk oligosaccharide (MMO), preferably wherein said third mammalian milk oligosaccharide is a sialylated MMO, more preferably wherein said third mammalian milk oligosaccharide is a sialylated MMO comprising lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, even more preferably said sialylated MMO comprises lactose or LacNAc at its reducing end, most preferably said sialylated MMO comprises lactose at its reducing end.

[121] Preferably, the second MMO consists of 3 to 8, more preferably 3 to 7, even more preferably 3 to 6, more Petition 870250100655, dated 03 / 11 / 2025, pp. 145 / 226 54 / 128 preferably 3 to 5 monosaccharides.

[122] A sialylated MMO comprising lactose at its reducing end is preferably selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c and LST d; more preferably selected from the list consisting of 3'SL, 6'SL, 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, LST a, LST b, LST c and LST d; even more preferably selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c and LST d; more preferably wherein the said sialylated MMO is 6'-sialyl-lactose (6'SL) or 3'-sialyl-lactose (3'SL).

[123] A sialylated MMO comprising lacto-N-biose (LNB) at its reducing end is preferably selected from the list consisting of 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB) and monofucosylmonosialyl-lacto-N-octaose (sialyl Lewis a); more preferably, said sialylated MMO is 3'SLNB or 6'SLNB.

[124] A sialylated MMO comprising N-acetyl-lactosamine (LacNAc) at its reducing end is preferably selected from the list consisting of 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialillactosamine (6'SLacNAc) and sialyl Lewis x; more preferably, said sialylated MMO is 3'SLacNAc or 6'SLacNAc.

[125] When a third MMO, preferably a sialylated MMO, is present in said composition, then it is an example of a preferred embodiment that the quantity of said third MMO in said composition is from 0.1 to 30.0, preferably from 0.1 to 25.0, more preferably from 0.1 to 20.0, even more preferably from 0.1 to 15.0, even more preferably from 0.2 to 15.0, even more preferably from 0.3 to 15.0, even more preferably from 0.4 to 15.0, more preferably Petition 870250100655, dated 03 / 11 / 2025, pp. 146 / 226 55 / 128 from 0.5 to 15.0 times the quantity of said fucosylated MMO in said composition. A more preferred embodiment is that the quantity of said fucosylated MMO in said composition is less than the quantity of said third MMO, preferably said quantity of said fucosylated MMO is from 1.1 to 15.0, more preferably from 1.5 to 15.0, even more preferably from 2.5 to 15.0, even more preferably from 5.0 to 15.0, even more preferably from 5.0 to 12.5, most preferably from 5.0 to 10.0 times less than the quantity of said third MMO in said composition.It is a further preferred embodiment that, when the third MMO is a sialylated MMO, the amount of fucosylated MMO in the composition is less than the amount of the third MMO, preferably the amount of fucosylated MMO is 1.1 to 10.0, preferably 1.5 to 7.5, more preferably 1.5 to 5.0, most preferably 2.5 to 5.0 times less than the amount of said third MMO in said composition.

[126] When a second MMO (preferably a silylated MMO, i.e., a first silylated MMO) and a third MMO (preferably a silylated MMO, i.e., a second silylated MMO) are present in said composition, it is an example of a preferred embodiment that the ratio between the amount of said second MMO and the amount of said third MMO in said composition is similar to that found in the breast milk of the same species. Throughout this application and the claims, unless specifically indicated otherwise, a “similar” ratio preferably refers to a ratio that is identical to, or within the range of ±20% of, said ratio, preferably ±10% of said ratio. When the animal is a bovine, the second MMO is a silylated MMO and the third MMO is a silylated MMO, said ratio is preferably from 1.1 to 6.0, more preferably from 1.1 to 5.0, still Petition 870250100655, dated 03 / 11 / 2025, pp. 147 / 226 56 / 128 more preferably from 1.25 to 4.0, even more preferably from 1.25 to 3.0, even more preferably from 1.5 to 3.0, most preferably from 1.5 to 2.5. When the animal is a horse, the second MMO is a siallylated MMO and the third MMO is a siallylated MMO, the aforementioned ratio is preferably from 1.1 to 15.0, more preferably from 1.1 to 12.5, even more preferably from 1.1 to 10.0, even more preferably from 1.5 to 10.0, even more preferably from 2.5 to 10, even more preferably from 5.0 to 10.0, even more preferably from 7.5 to 10.0, most preferably from 8.0 to 10.0. When the animal is a pig, the second MMO is a sialylated MMO and the third MMO is a sialylated MMO, the aforementioned ratio is preferably from 7.5 to 40.0, more preferably from 7.5 to 35.0, even more preferably from 10.0 to 35.0, even more preferably from 15.0 to 35.0, even more preferably from 20.0 to 35.0, and even more preferably from 25.0 to 35.0.When the animal is a goat, the second MMO is a silylated MMO and the third MMO is a silylated MMO, the said ratio is preferably from 0.25 to 5.0, more preferably from 0.25 to 3.0, even more preferably from 0.25 to 2.0, even more preferably from 0.25 to 1.5, and even more preferably from 0.5 to 1.5. Furthermore, it is a more preferred embodiment that the amount of the second MMO in the composition is greater than the amount of the third MMO, and preferably the amount of the second MMO is from 1.1 to 40.0, more preferably from 1.1 to 35.0, most preferably from 1.5 to 35.0 times the amount of the third MMO in the composition.Furthermore, it is an even more preferred embodiment that the amount of the second MMO, when the second MMO is a sialylated MMO, in the composition is greater than the amount of the third MMO, when the third MMO is a sialylated MMO, preferably the amount of the second MMO is from 1.1 to 6.0, more preferably from 1.1 to 5.0, even more preferably from 1.25 to 4.0, even more preferably from 1.25 to 4.0. Petition 870250100655, dated 03 / 11 / 2025, pp. 148 / 226 57 / 128 3.0, even more preferably 1.5 to 2.5 times greater than the amount of the third MMO in the composition.

[127] In a more preferred embodiment, said composition further comprises a second mammalian milk oligosaccharide (MMO), which is a sialylated MMO selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialillactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB), monofucosylmonosialyl-lacto-N-octaose (sialyl Lewis a), 3'-sialillactosamine (3'SLacNAc), 6'-sialyl-lactosamine (6'SLacNAc) and sialyl Lewis x. More preferably, the second MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x. Even more preferably, the second MMO is selected from the list consisting of 3'SL, 6'SL, 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc.More preferably, the second MMO is 3'-sialyl-lactose (3'SL) or 6'-sialyl-lactose (6'SL).

[128] In a more preferred further embodiment, said composition further comprises a third mammalian milk oligosaccharide (MMO), which is a sialylated MMO selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialillactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB), monofucosylmonosialyl-lacto-N-octaose (sialyl Lewis a), 3'-sialillactosamine (3'SLacNAc), 6'-sialyl-lactosamine (6'SLacNAc) and sialyl Lewis x. More preferably, the third MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x. Even more preferably, the third MMO is selected from the list consisting of 3'SL, 6'SL, Petition 870250100655, dated 03 / 11 / 2025, pp. 149 / 226 58 / 128 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc. More preferably, the third MMO is 6'-sialyl-lactose (6'SL) or 3'-sialyl-lactose (3'SL).

[129] In the context of the present invention, the second mammalian milk oligosaccharide and the third mammalian milk oligosaccharide preferably do not contain N-acetyl-lactosamine.

[130] The inventors have surprisingly discovered that a fucosylated MMO according to the invention, preferably a composition comprising a fucosylated MMO according to the invention, is sufficient to obtain an effective medicament for preventing and / or treating shipping fever, as described in the present invention. The presence of other (oligo)saccharides is not necessary to obtain said therapeutic effect. Although the composition according to the invention may include additional (oligo)saccharides, the present invention relates to the fact that only the fucosylated MMO according to the invention is necessary to achieve an efficient therapeutic effect, as described in the present invention.

[131] It is a preferred embodiment that the said composition according to the invention does not comprise lacto-N-tetraose (LNT).

[132] In a further and / or alternative preferred embodiment, said composition according to the invention does not comprise lacto-N-neotetraose (LNnT).

[133] In a further and / or alternative preferred embodiment, said composition according to the invention does not comprise N-acetyl-lactosamine.

[134] In a further and / or preferred alternative embodiment, said composition according to the invention does not comprise an oligosaccharide containing N-acetyl-lactosamine, preferably does not comprise a saccharide containing N-acetyl-lactosamine. Petition 870250100655, dated 03 / 11 / 2025, pp. 150 / 226 59 / 128

[135] In a further and / or alternative preferred embodiment, said composition according to the invention does not comprise 3'sialyl-lactose.

[136] In a further and / or alternative preferred embodiment, said composition according to the invention does not comprise 6'sialyl-lactose.

[137] More preferably, the said composition according to the invention does not comprise a sialylated mammalian milk oligosaccharide, even more preferably does not comprise a sialylated oligosaccharide, most preferably does not comprise a sialylated saccharide.

[138] In a further and / or alternative preferred embodiment, said composition according to the invention does not comprise a fructooligosaccharide (FOS).

[139] In a further and / or alternative preferred embodiment, said composition according to the invention does not comprise a galacto-oligosaccharide (GOS).

[140] In a further and / or alternative preferred embodiment, said composition according to the invention does not comprise an isomalto-oligosaccharide.

[141] In a more preferred embodiment, said composition according to the invention comprises said fucosylated MMO as described in the present invention, optionally a second MMO as described in the present invention and optionally a third MMO as described in the present invention, and no additional MMO (preferably, no additional oligosaccharide, more preferably, no additional saccharide).

[142] In a further preferred embodiment, the said composition according to the invention comprises said MMO Petition 870250100655, dated 03 / 11 / 2025, pp. 151 / 226 60 / 128 fucosylated as described in the present invention, and no additional MMO (preferably, no additional oligosaccharide, more preferably, no additional saccharin).

[143] In a further preferred embodiment, said composition according to the invention does not comprise a non-fucosylated neutral MMO.

[144] In a further preferred embodiment, said composition according to the invention comprises only one mammalian milk oligosaccharide, namely said fucosylated MMO as described in the present invention.

[145] In a preferred embodiment, the composition said according to the invention is not breast milk.

[146] In a further and / or alternative preferred embodiment, the said composition according to the invention is a synthetic composition.

[147] In the context of the present invention, a “synthetic composition” or “synthetic nutritional composition” refers to an artificially prepared composition and, preferably, to a composition comprising at least one component produced ex vivo, chemically and / or biologically, for example, by means of chemical reaction, enzymatic reaction or recombinant process, or purified by humans. Preferably, a synthetic composition of the invention is not identical to a natural composition.

[148] In this context, it is preferable that the fucosylated MMO, as described in the present invention, has been isolated from a microbial culture or fermentation, cell culture, enzymatic reaction or chemical reaction. Or it has been isolated from a natural source (see the section “Oligosaccharide”). It is more preferable that the fucosylated MMO, as described in the present invention, has been produced in vitro and / or ex vivo by Petition 870250100655, dated 03 / 11 / 2025, pp. 152 / 226 61 / 128 a cell (see the section “Oligosaccharide”).

[149] In a further and / or preferred alternative embodiment, said composition according to the invention further comprises a microbial strain that does not use, preferably is not able to use, said fucosylated MMO as a carbon source.

[150] In a preferred alternative embodiment, the said composition, according to the invention, does not comprise a microbial strain. Examples of such a strain are Bifidobacterium, Lactobacillus and Saccharomyces boulardii.

[151] In a preferred embodiment, the said composition according to the invention is a pharmaceutical composition, optionally further comprising a vehicle, filler, preservative, solubilizer, diluent, excipient, salt, adjuvant and / or pharmaceutically acceptable solvent.

[152] In a further and / or alternative preferred embodiment, said composition is a nutritional composition, optionally further comprising a food ingredient and / or a food ingredient, wherein said food ingredient / food ingredient is preferably chosen from the list consisting of: - a lipid, preferably one or more selected from the list consisting of an oil, fat, ester, monoglyceride, diglyceride, triglyceride and free fatty acid; - a vitamin, preferably one or more selected from the list consisting of vitamin A, vitamin B, vitamin C, vitamin D, vitamin E and vitamin H, or a derivative thereof; - an amino acid compound; - a trace element; - a mineral, preferably one or more selected from Petition 870250100655, dated 03 / 11 / 2025, pp. 153 / 226 62 / 128 from the list consisting of calcium, phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, selenium and chloride; - an antioxidant; - a prebiotic agent, preferably one or more selected from the list consisting of GOS (galacto-oligosaccharide), FOS (fructo-oligosaccharide), inulin and resistant starch; - a carbohydrate; - an antimicrobial agent; and / or - a protein.

[153] Generally, any protein source can be used, provided it is suitable for nutritional compositions and compatible with any other ingredients or characteristics selected in the nutritional composition. Non-limiting examples of suitable proteins (and their sources) for use in the nutritional composition according to the invention include, among others, intact, hydrolyzed or partially hydrolyzed proteins, which can be derived from any known or suitable source, such as milk (e.g., casein, whey protein), animal (e.g., meat, fish), cereal (e.g., rice, corn, wheat), vegetable (e.g., soy, pea, potato, bean) and combinations thereof. The protein may also include a mixture of amino acids (often described as free amino acids) known for use in nutritional products or a combination of these amino acids with the intact, hydrolyzed or partially hydrolyzed proteins described herein.Amino acids can be natural or synthetic. More specific examples of suitable proteins (or sources thereof) used in a nutritional composition according to the invention include, but are not limited to, whole cow's milk, partially or fully skimmed milk, milk protein concentrates, milk protein isolates, skimmed milk powder, and condensed milk. Petition 870250100655, dated 03 / 11 / 2025, pp. 154 / 226 63 / 128 skimmed milk, whey protein concentrates, whey protein isolates, acid caseins, sodium caseinates, calcium caseinates, potassium caseinates, legume protein, soy protein concentrates, soy protein isolates, pea protein concentrates, pea protein isolates, collagen proteins, potato proteins, rice proteins, wheat proteins, canola proteins, quinoa, insect proteins, earthworm proteins, fungal proteins (e.g., mushrooms), hydrolyzed yeast, gelatin, bovine colostrum, human colostrum, glycol macropeptides, mycoproteins, proteins expressed by microorganisms (e.g., bacteria and algae) and combinations thereof. A nutritional composition according to the invention may include any single protein source or combination of the various protein sources listed above.Furthermore, the proteins for use herein may also include, or be wholly or partially replaced by, free amino acids known for use in nutritional products, examples of which are not limited to, including L-tryptophan, L-glutamine, L-tyrosine, L-methionine, L-cysteine, taurine, L-arginine, L-carnitine, and combinations thereof.

[154] The carbohydrate or carbohydrate source suitable for use in a nutritional composition according to the invention may be simple, complex, or variations or combinations thereof. In general, the carbohydrate may include any carbohydrate or carbohydrate source that is suitable for use in nutritional compositions and that is compatible with any other ingredients or features selected in the nutritional composition. Non-limiting examples of carbohydrates suitable for use in the nutritional composition according to the invention include, but are not limited to, polydextrose, maltodextrin; starch or hydrolyzed or modified corn starch; glucose polymers; corn syrup; corn syrup solids; sucrose; glucose; fructose; lactose; high-fructose corn syrup; honey; sugar alcohols (for Petition 870250100655, dated 03 / 11 / 2025, pages 155 / 226 64 / 128 example, maltitol, erythritol, sorbitol); isomaltulose; sucromaltose; pullulan; potato starch; and other slowly digested carbohydrates; Dietary fibers, including but not limited to fructooligosaccharides (FOS), galactooligosaccharides (GOS), oat fiber, soy fiber, gum arabic, sodium carboxymethylcellulose, methylcellulose, guar gum, gellan gum, locust bean gum, konjac flour, hydroxypropylmethylcellulose, tragacanth gum, karaya gum, acacia gum, chitosan, arabinogalactans, glucomannan, xanthan gum, alginate, pectin, low-methoxy pectin, high-methoxy pectin, cereal beta-glucans (e.g., oat beta-glucan, barley beta-glucan), carrageenan and psyllium, soluble and insoluble fibers derived from fruits or vegetables; other resistant starches; and combinations thereof.A nutritional composition according to the invention may include any single carbohydrate source or a combination of the various carbohydrate sources listed above.

[155] The fat or fat source suitable for use in a nutritional composition according to the invention may be derived from various sources, including, but not limited to, plants, animals and combinations thereof. In general, the fat may include any fat or fat source suitable for use in a nutritional composition according to the invention and which is compatible with any other ingredients or characteristics selected in the nutritional composition.Non-limiting examples of suitable fat (or sources thereof) for use in a nutritional composition according to the invention include coconut oil, fractionated coconut oil, soybean oil, high oleic soybean oil, corn oil, olive oil, safflower oil, high oleic safflower oil, medium-chain triglyceride oil (MCT oil), high gamma-linolenic acid (GLA) safflower oil, sunflower oil, high oleic sunflower oil, palm oil, palm kernel oil, palm olein, canola oil, high oleic canola oil. Petition 870250100655, dated 03 / 11 / 2025, pages 156 / 226 65 / 128 marine oils, fish oils, algae oils, borage oil, cottonseed oil, fungal oils, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (ARA), conjugated linoleic acid (CLA), alpha-linolenic acid, rice bran oil, wheat bran oil, interesterified oils, transesterified oils, structured lipids and combinations thereof. Generally, the fats used in a nutritional composition for the formulation of infant and pediatric formulas provide fatty acids necessary both as a source of energy and for the healthy development of the baby, toddler or child. These fats typically comprise triglycerides, although they may also comprise diglycerides, monoglycerides and free fatty acids.The fatty acids provided by the fats in the nutritional composition include, among others, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, ARA, EPA, and DHA. The nutritional composition may include any single fat source or a combination of the various fat sources listed above. Preferably, the fat is a mixture of vegetable fat and milk fat, such as that obtained from the milk of a mammal like a cow, sheep, goat, mare, or camel. More preferably, the milk fat is bovine milk fat. Mixtures of different types of fat are preferred because they help provide different fatty acids and more closely resemble the type of bond between the glycerol fraction and the fatty acid fraction in the fat, when compared to breast milk.

[156] When one or more prebiotics are present, it is preferable that the weight ratio between the oligosaccharide according to the invention and said prebiotic(s) be in the range of 0.5:10 to 10:0.5.

[157] Preferably, the said pharmaceutical or nutritional composition, according to the invention, comprises one or more probiotics Petition 870250100655, dated 03 / 11 / 2025, pp. 157 / 226 66 / 128 for its beneficial effect on the subject's gut microbiome. Examples of probiotics include Bifidobacterium, Lactobacillus, and Saccharomyces boulardii.

[158] In a more preferred embodiment, the said nutritional composition is a synthetic nutritional composition.

[159] In a more preferred further and / or alternative embodiment, said nutritional composition is selected from a list consisting of a milk replacer, starter feed, pre-weaning diet, starter diet, pre-weaning feed, weaning feed and post-weaning feed, preferably selected from the list consisting of a milk replacer, starter feed, starter feed and post-weaning feed, more preferably said nutritional composition is a milk replacer or starter feed, more preferably a milk replacer.

[160] In the context of the invention, the term creep feed refers to a nutritional composition used to supplement a pre-weaned animal with a solid diet while the animal is nursing. For example, a piglet receives creep feed to facilitate the transition from sow's milk to solid starter feed for pigs. Creep feed stimulates the piglet's digestive system to produce, for example, amylase, which digests the carbohydrates in dry feed. If a piglet is better able to digest dry feed, it can start eating rapidly after weaning for better performance.

[161] In the context of the invention, the term “milk substitute” refers to a nutritional composition that serves as a substitute for breast milk. A milk substitute comprises milk proteins, fat, carbohydrates, vitamins and minerals. Preferably, a milk substitute comprises 10% to 28% by dry weight of at least one protein, 13% to 28% by dry weight (preferably 20% to 25% by dry weight) of at least one fat and lactose < 55% by dry weight. More specifically, a Petition 870250100655, dated 03 / 11 / 2025, pp. 158 / 226 67 / 128 milk substitute comprises 18% to 24% by dry weight of at least one protein, 15% to 28% by dry weight (preferably 20% to 25% by dry weight) of at least one fat, and < 50% by dry weight lactose. In this context, “% by dry weight” refers to the ratio between the weight of the component mentioned (e.g., 2'FL) and the dry weight of the milk substitute (% w / v). Throughout this application and claims, a milk substitute is preferably a milk substitute for calves. Method for Preventing and / or Treating Shipping Fever

[162] In a second aspect, the invention provides a method for preventing and / or treating shipping fever in an animal, preferably wherein said animal is a farm animal or a domestic animal, more preferably a farm animal. The method comprises administering a fucosylated mammalian milk oligosaccharide (MMO), preferably a composition comprising a fucosylated mammalian milk oligosaccharide (MMO). Said fucosylated MMO and said composition are as described in the first aspect of the invention.

[163] In the context of the present invention, the aforementioned “method for preventing and / or treating”, “shipping fever”, “animal”, “composition” and “fucosylated mammalian milk oligosaccharide”, as described throughout the second aspect of the present invention and claims, are as described in the first aspect of the invention. USE

[164] In a third aspect, the invention provides the use of a fucosylated mammalian milk oligosaccharide (MMO), preferably the use of a composition comprising a fucosylated mammalian milk oligosaccharide (MMO) (composition as described in the first aspect of the invention), for the manufacture of a medicament to prevent and / or treat shipping fever in an animal, preferably wherein the Petition 870250100655, dated 03 / 11 / 2025, pp. 159 / 226 68 / 128 The animal in question is a farm animal or a domesticated animal, more preferably a farm animal.

[165] In the context of the present invention, the aforementioned “method for preventing and / or treating”, “shipping fever”, “animal”, “composition” and “fucosylated mammalian milk oligosaccharide”, as described throughout the third aspect of the present invention and claims, are as described in the first aspect of the invention. Method for Preventing and / or Treating Mycoplasma bovis Infection

[166] In a fourth aspect, the invention provides a method for preventing and / or treating Mycoplasma bovis infection in an animal, preferably wherein said animal is a farm animal or a domestic animal, more preferably a farm animal. The method comprises administering a fucosylated mammalian milk oligosaccharide (MMO), preferably a composition comprising a fucosylated mammalian milk oligosaccharide (MMO). Said fucosylated MMO and said composition are as described in the first aspect of the invention.

[167] In the context of the present invention, the aforementioned “method for preventing and / or treating”, “animal”, “composition” and “fucosylated mammalian milk oligosaccharide”, as described throughout the fourth aspect of the present invention and claims, are as described in the first aspect of the invention. Method for Preventing and / or Treating Adenovirus type 3 Infection

[168] In a fifth aspect, the invention provides a method for preventing and / or treating adenovirus type 3 infection in an animal, preferably said animal being a farm animal or a domesticated animal, more preferably a farm animal. The method comprises administering a mammalian milk oligosaccharide Petition 870250100655, dated 03 / 11 / 2025, pp. 160 / 226 69 / 128 (MMO) fucosylated, preferably a composition comprising a fucosylated mammalian milk oligosaccharide (MMO). Said fucosylated MMO and said composition are as described in the first aspect of the invention.

[169] In the context of the present invention, the aforementioned “method for preventing and / or treating”, “animal”, “composition” and “fucosylated mammalian milk oligosaccharide”, as described throughout the fifth aspect of the present invention and claims, are as described in the first aspect of the invention. Specific Achievement Examples

[170] The present invention relates preferably to the following specific embodiments: 1. A fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and / or treating shipping fever in an animal, preferably in a farmed or domesticated animal, more preferably in a farmed animal; 2. A fucosylated MMO for use, according to embodiment 1, wherein the method is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia; 3. A fucosylated MMO for use, according to embodiment 2, where the pneumonia is acute pneumonia; 4. A fucosylated MMO for use, according to any one of the embodiments 1 to 3, wherein said animal, preferably said farm animal or domesticated animal, is selected from the list consisting of bovine, swine, ovine, caprine, equine, camelid (preferably llama or alpaca), dog, cat, rabbit and birds; more Petition 870250100655, dated 03 / 11 / 2025, pp. 161 / 226 70 / 128 preferably selected from the list consisting of bovine, swine, ovine, caprine, equine, camelid (preferably llama or alpaca) and poultry; even more preferably selected from the list consisting of bovine, ovine, caprine, equine, camelid (preferably llama or alpaca) and poultry; even more preferably selected from the list consisting of bovine, equine and poultry; even more preferably the said animal is bovine or a horse; most preferably the said animal is bovine; 5. A fucosylated MMO for use, according to any of the embodiments 1 to 4, wherein the animal in question is a non-adult animal; 6. A fucosylated MMO for use, according to embodiment 5, wherein said animal, preferably said farm animal or domesticated animal, is selected from the list consisting of a calf, piglet, lamb, kid, foal, fledgling, puppy, kitten, rabbit and a chick; more preferably selected from the list consisting of a calf, piglet, lamb, kid, foal, fledgling and chick; even more preferably selected from the list consisting of a calf, lamb, kid, foal, fledgling and a chick; even more preferably selected from the list consisting of a calf, foal and chick; even more preferably said animal is a calf or foal; most preferably said animal is a calf; 7. A fucosylated MMO for use, according to any of the embodiments 1 to 6, wherein the fucosylated MMO consists of 3 to 8, preferably 3 to 7, more preferably 3 to 6, and even more preferably 3 to 5, monosaccharides; 8. A fucosylated MMO for use, according to any of the embodiments 1 to 7, wherein the fucosylated MMO is a neutral oligosaccharide; Petition 870250100655, dated 03 / 11 / 2025, pp. 162 / 226 71 / 128 9. A fucosylated MMO for use, according to any of the embodiments 1 to 8, wherein the fucosylated MMO comprises a fucose that is linked to a monosaccharide in an alpha-1,2, alpha-1,3 or alpha-1,4 linkage, preferably an alpha-1,2 or alpha-1,3 linkage, more preferably an alpha-1,2 linkage, and wherein the monosaccharide is preferably selected from glucose, N-acetylglucosamine and galactose, most preferably the monosaccharide is glucose or galactose, even more preferably the monosaccharide is galactose; 10. A fucosylated MMO for use, according to any of the embodiments 1 to 9, wherein the fucosylated MMO comprises lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, preferably the fucosylated oligosaccharide comprises lactose or LacNAc at its reducing end, more preferably the fucosylated oligosaccharide comprises lactose at its reducing end; 11. A fucosylated MMO for use, according to any one of embodiments 1 to 10, wherein said fucosylated MMO is selected from the list consisting of 2'-fucosyllactose (2'FL), 3-fucosyllactose (3-FL), difucosyllactose (diFL), 2'-fucosyl-N-acetyllactosamine (2'FlacNAc), difucosyl-N-acetyllactosamine (diFLacNAc), 3-fucosyl-N-acetylactosamine (3FlacNAc), 2'-fucosyl-lacto-N-biose (2'FLNB), 4-fucosyl-lacto-N-biose (4FLNB), difucosyl-lacto-N-biose (diFLNB), lacto-N-fucopentaose I (LNFP I), blood group A antigen type 1 hexaose (GalNAc-LNFP I), hexaose blood group B antigen type 1 (Gal-LNFP I), lacto-Nfucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-Nfucopentaose V (LNFP V), lacto-N-difucohexaose I (LNDFH I), lacto-Ndifucohexaose II (LNDFH II), lewis b-lewis x, monofucosylate-N-hexaose III (MFLNH III), difucosylate-N-hexaose(a) (DFLNH(a)), difucosylate-N-hexaose Petition 870250100655, dated 03 / 11 / 2025, pp. 163 / 226 72 / 128 (DFLNH), trifucosylacto-N-hexaose (TFLNH), lacto-N-neofucopentaose I (LNnFP I), lacto-N-neofucopentaose V (LNnFP V, LNFP VI) and lacto-N-neodifucohexaose (LNnDFH); more preferably selected from the list consisting of 2'FL, diFL, LNFP I, GalNAc-LNFP I, Gal-LNFP I, LNDFH I, lewis b-lewis x, DFLNH (a), TFLNH, LNnFP I, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; even more preferably selected from the list consisting of 2'FL, diFL, LNFP I, LNnFP I, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; even more preferably selected from the list consisting of 2'FL, diFL, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; even more preferably selected from the list consisting of 2'FL, 2'FLNB and 2'FlacNAc; and even more preferably the fucosylated MMO is 2'FL or diFL, most preferably the fucosylated MMO is 2'FL; 12. A fucosylated MMO for use, according to any of the embodiments 1 to 11, wherein the fucosylated MMO is selected from the list consisting of 2'FL, diFL, LNFP I, LNnFP I, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; 13. A fucosylated MMO for use, according to any of the embodiments 1 to 12, wherein said fucosylated MMO is 2'fucosylactose (2'FL); 14. A fucosylated MMO for use, according to any of the embodiments 1 to 13, wherein said fucosylated MMO is part of a composition; 15. A fucosylated MMO for use, according to embodiment 14, wherein the fucosylated MMO is present in a concentration of 0.001 to 1.000% by weight, preferably 0.001 to 0.750% by weight, more preferably 0.001 to 0.500% by weight, even more preferably 0.001 to 0.400% by weight, even more preferably 0.005 to 0.400% by weight, even more preferably Petition 870250100655, dated 03 / 11 / 2025, pp. 164 / 226 73 / 128 from 0.005 to 0.300% by weight, even more preferably from 0.005 to 0.250% by weight, more preferably from 0.005 to 0.100% by weight, in relation to the total weight of the composition; 16. A fucosylated MMO for use, according to any of the embodiments 14 or 15, wherein said fucosylated MMO is present in a concentration of 0.001 to 0.250% by weight, preferably 0.001 to 0.200% by weight, more preferably 0.001 to 0.100% by weight, even more preferably 0.001 to 0.020% by weight, even more preferably 0.001 to 0.010% by weight, even more preferably 0.002 to 0.010% by weight, even more preferably 0.003 to 0.010% by weight, even more preferably 0.003 to 0.0075% by weight, most preferably 0.003 to 0.006% by weight, relative to the total weight of the composition; wherein, preferably, the said animal is a bovine or a horse, more preferably a calf or a foal, even more preferably a calf; 17. A fucosylated MMO for use, according to any of the embodiments 14 or 15, wherein said fucosylated MMO is present in a concentration of 0.010 to 1.000% by weight, preferably 0.010 to 0.750% by weight, more preferably 0.010 to 0.500% by weight, even more preferably 0.010 to 0.400% by weight, even more preferably 0.050 to 0.400% by weight, even more preferably 0.100 to 0.400% by weight, most preferably 0.100 to 0.300% by weight, relative to the total weight of the composition; wherein the animal is preferably a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein the animal is more preferably a piglet, a lamb, a kid or a young animal, wherein the animal is even more preferably a piglet, a lamb or a kid, wherein the animal is most preferably a piglet; Petition 870250100655, dated 03 / 11 / 2025, pp. 165 / 226 74 / 128 18. A fucosylated MMO for use, according to any of the embodiments 1 to 17, wherein the method comprises administering an effective quantity of the fucosylated MMO; 19. A fucosylated MMO for use, according to any of the embodiments 1 to 18, wherein said fucosylated MMO is administered to said animal at least once, preferably at least twice, between birth (0 weeks) and 5 weeks of age, preferably between birth and 4 weeks of age, more preferably between birth and 3 weeks of age; 20. A fucosylated MMO for use, according to any of the embodiments 1 to 19, wherein said fucosylated MMO is administered to said animal at least once, preferably at least twice, most preferably daily: - in the three weeks, preferably two weeks, more preferably one week, prior to the day of transport of the animal in question; and / or - on the day of transport of the animal in question; and / or - within three weeks, preferably two weeks, more preferably one week, after the day the animal was transported; 21. A fucosylated MMO for use, according to any of the embodiments 1 to 20, wherein the fucosylated MMO is administered to the animal for at least 1 week, preferably for at least 2 weeks, more preferably for at least 3 weeks, even more preferably for at least 4 weeks, most preferably for at least 6 weeks; 22. A fucosylated MMO for use, according to any of the embodiments 1 to 21, wherein the fucosylated MMO is administered to the animal for < 32 weeks, preferably for < 28 weeks, plus Petition 870250100655, dated 03 / 11 / 2025, pp. 166 / 226 75 / 128 preferably for < 24 weeks, even more preferably for < 20 weeks, even more preferably for < 16 weeks, even more preferably for < 12 weeks, most preferably for < 6 weeks; 23. A fucosylated MMO for use, according to any of the embodiments from 1 to 22, wherein the fucosylated MMO is administered to the animal for a period of 1 to 36, preferably 1 to 30, even more preferably 1 to 28, even more preferably 1 to 24, even more preferably 1 to 18, even more preferably 1 to 12, even more preferably 1 to 8, even more preferably 1 to 6, even more preferably 1 to 4, most preferably 2 to 4 consecutive weeks; 24. A fucosylated MMO for use, according to any of the embodiments 1 to 23, wherein the fucosylated MMO is administered to the animal: - if the subject is bovine: for a period of 1 to 36, preferably 1 to 32, more preferably 1 to 30, even more preferably 1 to 28, even more preferably 1 to 24, even more preferably 1 to 18, even more preferably 1 to 12, even more preferably 2 to 12, most preferably 3 to 12, consecutive weeks; - if the subject is a pig: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a sheep: for a period of 1 to 36, preferably from 1 to 32, more preferably from 1 to 30, even more preferably from 1 to 28, even more preferably from 1 to 24, even more preferably from 1 to 18, even more preferably from 1 to 12, Petition 870250100655, dated 03 / 11 / 2025, pp. 167 / 226 76 / 128 even more preferably from 1 to 8, even more preferably from 1 to 6, even more preferably from 1 to 4, most preferably from 2 to 4 consecutive weeks; - if the subject is a goat: for a period of 1 to 36, preferably from 1 to 32, more preferably from 1 to 30, even more preferably from 1 to 28, even more preferably from 1 to 24, even more preferably from 1 to 18, even more preferably from 1 to 12, even more preferably from 1 to 8, even more preferably from 1 to 6, even more preferably from 1 to 4, most preferably from 2 to 4 consecutive weeks; - if the subject is a horse: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a camelid: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a rabbit: for a period of 1 to 12 weeks, preferably 1 to 8 weeks, more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a puppy: for a period of 1 to 12 weeks, preferably 1 to 8 weeks, more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a cat: for a period of 1 to 12, preferably 1 to 8, more preferably 1 to 6, even more Petition 870250100655, dated 03 / 11 / 2025, pp. 168 / 226 77 / 128 preferably 1 to 4, more preferably 2 to 4 consecutive weeks; - if the subject is a bird: for a period of 1 to 8 weeks, preferably 1 to 6 weeks, more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; 25. A fucosylated MMO for use, according to any of the embodiments 1 to 24, wherein the fucosylated MMO is administered at least once a week, preferably at least once every 3 days, more preferably at least once every 2 days, most preferably it is administered at least once a day; 26. A fucosylated MMO for use, according to any of the embodiments from 1 to 25, wherein the fucosylated MMO is administered in a daily dose of 0.0001 to 15.0 g, preferably 0.0001 to 10.0 g, more preferably 0.0001 to 5.0 g, even more preferably 0.0001 to 2.0 g, even more preferably 0.0001 to 1.0 g, even more preferably 0.0005 to 1.0 g, and most preferably 0.0010 to 1.0 g; 27. A fucosylated MMO for use, according to any of the embodiments 1 to 25, wherein the fucosylated MMO is administered in a daily dose of 0.01 to 15.0 g, preferably 0.01 to 10.0 g, more preferably 0.01 to 5.0 g, even more preferably 0.01 to 2.0 g, even more preferably 0.01 to 1.0 g, even more preferably 0.015 to 1.0 g, most preferably 0.02 to 1.0 g; 28. A fucosylated MMO for use, according to any of the embodiments 1 to 25, wherein said fucosylated MMO is administered at a daily dose of 0.01 to 1.0 g, preferably 0.01 to 0.75 g, more preferably 0.01 to 0.65 g, even more preferably 0.01 to 0.60 g, even more preferably 0.01 to 0.50 g, even more Petition 870250100655, dated 03 / 11 / 2025, pp. 169 / 226 78 / 128 preferably from 0.015 to 0.50 g, even more preferably from 0.015 to 0.40 g, even more preferably from 0.015 to 0.30 g, even more preferably from 0.015 to 0.20 g, most preferably from 0.015 to 0.10 g; wherein, preferably, the said animal is a bovine or a horse, wherein, more preferably, it is a calf or a foal, and even more preferably it is a calf; 29. A fucosylated MMO for use, according to any of the embodiments 1 to 25, wherein said fucosylated MMO is administered in a daily dose of 0.01 to 5.0 g, preferably 0.1 to 2.5 g, more preferably 0.1 to 1.5 g, even more preferably 0.1 to 1.2 g, even more preferably 0.2 to 1.2 g, even more preferably 0.3 to 1.2 g, even more preferably 0.4 to 1.2 g, most preferably 0.5 to 1.2 g; wherein, preferably, the said animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein, more preferably, the said animal is a piglet, a lamb, a kid or a young animal, wherein, even more preferably, the said animal is a piglet, a lamb or a kid, wherein, more preferably, the said animal is a piglet; 30. A fucosylated MMO for use, according to any of the embodiments from 1 to 29, wherein the fucosylated MMO is administered at a daily dose of 0.01 to 150.0 mg, preferably 0.01 to 125.0 mg, more preferably 0.01 to 100.0 mg, even more preferably 0.05 to 100.0 mg, even more preferably 0.1 to 100.0 mg, most preferably 0.1 to 80.0 mg, per kg of body weight of said animal; 31. A fucosylated MMO for use, according to any of the embodiments 1 to 29, wherein said fucosylated MMO is administered at a daily dose of 0.1 to 50.0 mg, preferably 0.1 to Petition 870250100655, dated 03 / 11 / 2025, pp. 170 / 226 79 / 128 30.0 mg, more preferably from 0.1 to 25.0 mg, even more preferably from 0.1 to 20.0 mg, even more preferably from 0.1 to 15.0 mg, even more preferably from 0.1 to 10.0 mg, even more preferably from 0.25 to 10.0 mg, most preferably from 0.5 to 10.0 mg, per kg of body weight of said animal; wherein, preferably, said animal is a bovine or a horse, more preferably a calf or foal, even more preferably a calf; 32. A fucosylated MMO for use, according to any of the embodiments from 1 to 29, wherein the fucosylated MMO is administered at a daily dose of 0.1 to 150.0 mg, preferably 0.1 to 125.0 mg, more preferably 1.0 to 125.0 mg, even more preferably 5.0 to 125.0 mg, even more preferably 5.0 to 100.0 mg, even more preferably 5.0 to 80.0 mg, most preferably 10.0 to 80.0 mg, per kg of body weight of said animal; wherein, preferably, the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein, more preferably, the animal is a piglet, a lamb, a kid or a young animal, wherein, even more preferably, the animal is a piglet, a lamb or a kid, wherein, most preferably, the animal is a piglet; 33. A fucosylated MMO for use, according to any of the embodiments 1 to 32, wherein the method further comprises the administration of a second mammalian milk oligosaccharide (MMO), preferably wherein the second mammalian milk oligosaccharide is a sialylated MMO, more preferably wherein the second mammalian milk oligosaccharide is a sialylated MMO comprising lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, even more preferably the sialylated MMO comprises lactose or LacNAc at its reducing end, most preferably the sialylated MMO Petition 870250100655, dated 03 / 11 / 2025, pp. 171 / 226 80 / 128 comprises lactose at its reducing end; 34. A fucosylated MMO for use, according to embodiment example 33, wherein the second MMO is selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyl-lacto-N-biose (6'SLNB), sialyl Lewis a, 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialyllactosamine (6'SLacNAc) and sialyl Lewis x; preferably, the second MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x; more preferably, the second MMO is selected from the list consisting of 3'SL, 6'SL, 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc; most preferably, the second MMO is 3'-sialyl-lactose (3'SL) or 6'-sialyl-lactose (6'SL); 35. A fucosylated MMO for use, according to either of the embodiments 33 or 34, wherein the second MMO is 3'-sialillactose (3'SL) or 6'-sialyl-lactose (6'SL); 36. A fucosylated MMO for use, according to any of the embodiments 33 to 35, wherein the fucosylated MMO and the second MMO are part of a composition; 37. A fucosylated MMO for use, according to any of the embodiments 33 to 36, wherein the amount of said fucosylated MMO administered to said animal is less than the amount of said second MMO administered to said animal, and preferably said amount of said fucosylated MMO is 1.1 to 15.0 times less, more preferably 1.5 to 15.0, even more preferably 2.5 to 15.0, even more preferably 5.0 to 15.0, even more preferably 5.0 to 12.5, most preferably 5.0 to 10.0 times less than the amount Petition 870250100655, dated 03 / 11 / 2025, pp. 172 / 226 81 / 128 of the aforementioned second MMO administered to the aforementioned animal; 38. A fucosylated MMO for use, according to any of the embodiments 33 to 36, wherein the amount of said fucosylated MMO administered to said animal is less than the amount of said second MMO administered to said animal, and preferably said amount of said fucosylated MMO is 1.1 to 10.0, preferably 1.5 to 7.5, more preferably 2.5 to 7.5, most preferably 4.0 to 7.0 times less than the amount of said second MMO administered to said animal; 39. A fucosylated MMO for use, according to any of the embodiments 33 to 36, wherein the amount of the second MMO administered to the animal is 0.1 to 30.0, preferably 0.1 to 25.0, more preferably 0.1 to 20.0, even more preferably 0.1 to 15.0, even more preferably 0.2 to 15.0, even more preferably 0.3 to 15.0, even more preferably 0.4 to 15.0, most preferably 0.5 to 15.0 times the amount of fucosylated MMO administered to the animal; 40. A fucosylated MMO for use, according to any of the embodiments from 1 to 39, wherein the method further comprises the administration of a third mammalian milk oligosaccharide (MMO), preferably wherein the third mammalian milk oligosaccharide is a sialylated MMO, more preferably wherein the third mammalian milk oligosaccharide is a sialylated MMO comprising lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, even more preferably the sialylated MMO comprises lactose or LacNAc at its reducing end, most preferably the sialylated MMO comprises lactose at its reducing end; 41. A fucosylated MMO for use, according to embodiment example 40, wherein the third MMO is selected from the list that Petition 870250100655, dated 03 / 11 / 2025, pp. 173 / 226 82 / 128 consists of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialyllacto-Nbiose (6'SLNB), sialyl Lewis a, 3'-sialyl-lactosamine (3'SLacNAc), 6'-sialyllactosamine (6'SLacNAc) and sialyl Lewis x; Preferably, the third MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x; more preferably, the third MMO is selected from the list consisting of 3'SL, 6'SL, 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc; most preferably, the third MMO is 6'-sialyl-lactose (6'SL) or 3'-sialyl-lactose (3'SL); 42. A fucosylated MMO for use, according to either of the embodiments 40 or 41, wherein the third MMO is 6'-sialyl-lactose (6'SL) or 3'-sialyl-lactose (3'SL); 43. A fucosylated MMO for use, according to any of the embodiments 40 to 42, wherein the fucosylated MMO, the second MMO and the third MMO are part of a composition; 44. A fucosylated MMO for use, according to any of the embodiments 40 to 43, wherein the quantity of said fucosylated MMO administered to said animal is less than the quantity of said third MMO administered to said animal, and preferably said quantity of said fucosylated MMO is 1.1 to 15.0 times less, more preferably 1.5 to 15.0, even more preferably 2.5 to 15.0, even more preferably 5.0 to 15.0, even more preferably 5.0 to 12.5, most preferably 5.0 to 10.0 times less than the quantity of said third MMO administered to said animal; 45. A fucosylated MMO for use, according to any of the embodiments 40 to 43, wherein the quantity of said MMO Petition 870250100655, dated 03 / 11 / 2025, pp. 174 / 226 The amount of fucosylated 83 / 128 administered to the animal in question is less than the amount of the third MMO administered to the animal in question, and preferably the amount of fucosylated MMO is 1.1 to 10.0, preferably 1.5 to 7.5, more preferably 1.5 to 5.0, most preferably 2.5 to 5.0 times less than the amount of the third MMO administered to the animal in question; 46. ​​A fucosylated MMO for use, according to any of the embodiments 40 to 43, wherein the amount of the third MMO administered to the animal is an amount of 0.1 to 30.0, preferably 0.1 to 25.0, more preferably 0.1 to 20.0, even more preferably 0.1 to 15.0, even more preferably 0.2 to 15.0, even more preferably 0.3 to 15.0, even more preferably 0.4 to 15.0, most preferably 0.5 to 15.0 times the amount of fucosylated MMO administered to the animal; 47. A fucosylated MMO for use, according to any of the embodiments 40 to 46, wherein the ratio between the amount of the second MMO and the amount of the third MMO administered to the animal is similar to the ratio found in the maternal milk of the same species; 48. A fucosylated MMO for use, according to any of the embodiments 40 to 47, wherein the amount of the second MMO administered to the animal is greater than the amount of the third MMO administered to the animal, and preferably the amount of the second MMO is 1.1 to 40.0, more preferably 1.1 to 35.0, most preferably 1.5 to 35.0 times the amount of the third MMO administered to the animal; 49. A fucosylated MMO for use, according to any of the embodiments 40 to 47, wherein the amount of the second MMO administered to the animal is greater than the amount of the third MMO administered to the animal, and preferably, the amount of the second MMO is Petition 870250100655, dated 03 / 11 / 2025, pages 175 / 226 84 / 128 from 1.1 to 6.0, more preferably from 1.1 to 5.0, even more preferably from 1.25 to 4.0, even more preferably from 1.25 to 3.0, even more preferably from 1.5 to 3.0, most preferably 1.5 to 2.5 times greater than the amount of the third MMO administered to the animal; 50. A fucosylated MMO for use, according to any of the embodiments 1 to 49, wherein the method does not comprise the administration of lacto-N-tetraose (LNT); 51. A fucosylated MMO for use, according to any of the embodiments 1 to 50, wherein the method does not comprise the administration of lacto-N-neotetraose (LNnT); 52. A fucosylated MMO for use, according to any of the embodiments 1 to 51, wherein the method does not comprise the administration of N-acetyl-lactosamine; 53. A fucosylated MMO for use, according to any of the embodiments 1 to 52, wherein the method does not comprise the administration of an oligosaccharide containing N-acetyl-lactosamine, and preferably does not comprise the administration of a saccharide containing N-acetyl-lactosamine; 54. A fucosylated MMO for use, according to any of the embodiments 1 to 53, wherein the method does not comprise the administration of a fructooligosaccharide (FOS); 55. A fucosylated MMO for use, according to any of the embodiments 1 to 54, wherein the method does not comprise the administration of a galacto-oligosaccharide (GOS); 56. A fucosylated MMO for use, according to any of the embodiments 1 to 55, wherein the method does not comprise the administration of an isomalto-oligosaccharide; 57. A fucosylated MMO for use, according to anyone Petition 870250100655, dated 03 / 11 / 2025, pp. 176 / 226 85 / 128 of embodiment examples 1 to 56, in which the method does not involve the administration of a neutral, non-fucosylated MMO; 58. A fucosylated MMO for use, according to any of the embodiments 1 to 32 and 50 to 57, wherein the method does not comprise the administration of an additional mammalian milk oligosaccharide; 59. A fucosylated MMO for use, according to any of the embodiments 1 to 58, wherein the method further comprises administering a microbial strain that does not use, or preferably is unable to use, the fucosylated MMO as a carbon source; 60. A fucosylated MMO for use, according to any of the embodiments 1 to 58, wherein the method does not comprise the administration of a microbial strain; 61. A fucosylated MMO composition for use, according to any of the embodiments 14 to 17, 36 and 43, wherein said composition is not breast milk; 62. A fucosylated MMO for use, according to any of the embodiments 14 to 17, 36, 43 and 61, wherein said composition is a synthetic composition; 63. A fucosylated MMO for use, according to any of the embodiments 1 to 62, wherein the fucosylated MMO was produced in vitro and / or ex vivo by a cell, preferably a single cell, wherein the cell is preferably chosen from the list consisting of a microorganism, a plant cell, an animal cell and a protozoan cell; 64. A fucosylated MMO for use, according to any of the embodiments 1 to 63, wherein the fucosylated MMO is linked, preferably chemically linked, to a carrier / vehicle for Petition 870250100655, dated 03 / 11 / 2025, pp. 177 / 226 86 / 128 administration of fucosylated MMO; 65. A fucosylated MMO for use, according to embodiment 64, wherein said linker is a ceramide-based carrier or a polypeptide-based carrier, preferably a ceramide-based carrier; 66. A fucosylated MMO for use, according to embodiment 65, wherein said ceramide-based vehicle is selected from a list consisting of d18:1 / 16:0, t18:0 to 16:0, t18:0-h16:0, t18:0-h22:0 and t18:0-h24:0; 67. A fucosylated MMO for use, according to any of the embodiments 1 to 66, wherein the fucosylated MMO is encapsulated; 68. A method for preventing and / or treating shipping fever in an animal, preferably a farm animal or a domesticated animal, more preferably a farm animal, wherein the method comprises administering a fucosylated MMO as defined in any of the embodiments 1 to 67; 69. A method, according to embodiment 68, wherein the method is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia; 70. A method, according to embodiment 69, in which the pneumonia is acute pneumonia; 71. A method, according to any one of the embodiment examples 68 to 70, in which the said animal is as defined in any one of the embodiment examples 4 to 6; 72. A method, according to any of the embodiments 68 to 71, wherein said method comprises administering an effective quantity of said fucosylated MMO to the animal, wherein, Petition 870250100655, dated 03 / 11 / 2025, pp. 178 / 226 87 / 128 preferably, the aforementioned fucosylated MMO is administered as defined in any of the embodiments 19 to 32; 73. Use of a fucosylated MMO, as defined in any of the embodiments 1 to 67, characterized in that it is for the manufacture of a medicament to prevent and / or treat shipping fever in an animal, preferably wherein the animal is a farm animal or a domesticated animal, wherein, more preferably, the animal is a farm animal; 74. Use, as per embodiment 73, where the medication is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia; 75. Use, according to embodiment 74, where pneumonia is acute pneumonia; 76. Use, according to any of the embodiment examples 73 to 75, wherein the animal is as defined in any of the embodiment examples 4 to 6; 77. Use, according to any of the embodiments 73 to 76, wherein the said method comprises administering an effective amount of the said fucosylated MMO to the animal, wherein, preferably, the said fucosylated MMO is administered as defined in any of the embodiments 19 to 32.

[171] In addition, the present invention relates preferably to the following specific embodiments: 1. A composition comprising a fucosylated mammalian milk oligosaccharide (MMO), wherein said composition is for use in a method for preventing and / or treating shipping fever in an animal, preferably in a farmed or domesticated animal, more Petition 870250100655, dated 03 / 11 / 2025, pp. 179 / 226 88 / 128 preferably in a farm animal; 2. A composition for use, according to embodiment 1, wherein the method is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia; 3. A composition for use, according to embodiment 2, where the pneumonia is acute pneumonia; 4. A composition for use, according to any one of the embodiments 1 to 3, wherein the said animal, preferably the said farm animal or domesticated animal, is selected from the list consisting of bovine, swine, ovine, caprine, equine, camelid (preferably llama or alpaca), dog, cat, rabbit and poultry; more preferably selected from the list consisting of bovine, swine, ovine, caprine, equine, camelid (preferably llama or alpaca) and poultry; even more preferably selected from the list consisting of bovine, ovine, caprine, equine, camelid (preferably llama or alpaca) and poultry; even more preferably selected from the list consisting of cattle, horses and poultry; even more preferably the said animal is bovine or a horse; most preferably the said animal is bovine; 5. A composition for use, according to any of the embodiments 1 to 4, wherein the animal is a non-adult animal; 6. A composition for use, according to embodiment 5, wherein the said animal, preferably the said farm animal or domesticated animal, is selected from the list consisting of a calf, piglet, lamb, kid, foal, fledgling, puppy, kitten, rabbit and a chick; more preferably selected from the list consisting of a calf, piglet, lamb, kid, foal, fledgling and chick; furthermore Petition 870250100655, dated 03 / 11 / 2025, pp. 180 / 226 89 / 128 preferably selected from the list consisting of a calf, lamb, kid, foal, cub and a chick; even more preferably selected from the list consisting of a calf, foal and chick; even more preferably the said animal is a calf or foal; most preferably the said animal is a calf; 7. A composition for use, according to any one of the embodiments 1 to 6, wherein said fucosylated MMO consists of 3 to 8, preferably 3 to 7, more preferably 3 to 6, even more preferably 3 to 5, monosaccharides; 8. A composition for use, according to any of the embodiments 1 to 7, wherein the said fucosylated MMO is a neutral oligosaccharide; 9. A composition for use, according to any one of the embodiments 1 to 8, wherein said fucosylated MMO comprises a fucose that is linked to a monosaccharide in an alpha-1,2, alpha-1,3 or alpha-1,4 linkage, preferably an alpha-1,2 or alpha-1,3 linkage, more preferably an alpha-1,2 linkage, and wherein the monosaccharide is preferably selected from glucose, N-acetylglucosamine and galactose, more preferably the monosaccharide is glucose or galactose, even more preferably the monosaccharide is galactose; 10. A composition for use, according to any of the embodiments 1 to 9, wherein said fucosylated MMO comprises lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, preferably said fucosylated oligosaccharide comprises lactose or LacNAc at its reducing end, more preferably said fucosylated oligosaccharide comprises lactose at its reducing end; Petition 870250100655, dated 03 / 11 / 2025, pp. 181 / 226 90 / 128 11. A composition for use, according to any one of the embodiments 1 to 10, wherein said fucosylated MMO is selected from the list consisting of 2'-fucosyllactose (2'FL), 3-fucosyllactose (3-FL), difucosyllactose (diFL), 2'-fucosyl-N-acetyllactosamine (2'FlacNAc), difucosyl-N-acetyllactosamine (diFLacNAc), 3-fucosyl-N-acetylactosamine (3FlacNAc), 2'-fucosyl-lacto-N-biose (2'FLNB), 4-fucosyl-lacto-N-biose (4FLNB), difucosyl-lacto-N-biose (diFLNB), lacto-N-fucopentaose I (LNFP I), blood group A antigen type 1 hexaose (GalNAc-LNFP I), blood group A antigen type 1 hexaose blood group B (Gal-LNFP I), lacto-Nfucopentaose II (LNFP II), lacto-N-fucopentaose III (LNFP III), lacto-Nfucopentaose V (LNFP V), lacto-N-difucohexaose I (LNDFH I), lacto-Ndifucohexaose II (LNDFH II), lewis b-lewis x, monofucosylate-N-hexaose III (MFLNH III), difucosylate-N-hexaose (a) (DFLNH (a)), difucosylate-N-hexaose (DFLNH), trifucosylate-N-hexaose (TFLNH),lacto-N-neofucopentaose I (LNnFP I), lacto-N-neofucopentaose V (LNnFP V, LNFP VI) and lacto-N-neodifucohexaose (LNnDFH); more preferably selected from the list consisting of 2'FL, diFL, LNFP I, GalNAc-LNFP I, Gal-LNFP I, LNDFH I, lewis b-lewis x, DFLNH (a), TFLNH, LNnFP I, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; even more preferably selected from the list consisting of 2'FL, diFL, LNFP I, LNnFP I, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; even more preferably selected from the list consisting of 2'FL, diFL, 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; even more preferably selected from the list consisting of 2'FL, 2'FLNB and 2'FlacNAc; and even more preferably the fucosylated MMO is 2'FL or diFL, most preferably the fucosylated MMO is 2'FL; 12. A composition for use, according to any of the embodiments 1 to 11, wherein the said fucosylated MMO is selected from the list consisting of 2'FL, diFL, LNFP I, LNnFP I, Petition 870250100655, dated 03 / 11 / 2025, pp. 182 / 226 91 / 128 2'FLNB, diFLNB, 2'FlacNAc and diFLacNAc; 13. A composition for use, according to any of the embodiments 1 to 12, wherein the said fucosylated MMO is 2'fucosylactose (2'FL); 14. A composition for use, according to any of the embodiments 1 to 13, wherein said fucosylated MMO is present in a concentration of 0.001 to 1.000% by weight, preferably 0.001 to 0.750% by weight, more preferably 0.001 to 0.500% by weight, even more preferably 0.001 to 0.400% by weight, even more preferably 0.005 to 0.400% by weight, even more preferably 0.005 to 0.300% by weight, even more preferably 0.005 to 0.250% by weight, most preferably 0.005 to 0.100% by weight, relative to the total weight of the composition; 15. A composition for use, according to any of the embodiments 1 to 14, wherein said fucosylated MMO is present in a concentration of 0.001 to 0.250% by weight, preferably 0.001 to 0.200% by weight, more preferably 0.001 to 0.100% by weight, even more preferably 0.001 to 0.020% by weight, even more preferably 0.001 to 0.010% by weight, even more preferably 0.002 to 0.010% by weight, even more preferably 0.003 to 0.010% by weight, even more preferably 0.003 to 0.0075% by weight, most preferably 0.003 to 0.006% by weight, relative to the total weight of the composition; wherein, preferably, the said animal is a bovine or a horse, more preferably a calf or a foal, even more preferably a calf; 16. A composition for use, according to any of the embodiments 1 to 14, in which said fucosylated MMO is present in a concentration of 0.010 to 1.000% by weight, preferably Petition 870250100655, dated 03 / 11 / 2025, pp. 183 / 226 92 / 128 from 0.010 to 0.750% by weight, more preferably from 0.010 to 0.500% by weight, even more preferably from 0.010 to 0.400% by weight, even more preferably from 0.050 to 0.400% by weight, even more preferably from 0.100 to 0.400% by weight, more preferably from 0.100 to 0.300% by weight, in relation to the total weight of the composition; wherein, preferably, the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein, more preferably, the animal is a piglet, a lamb, a kid or a young animal, wherein, even more preferably, the animal is a piglet, a lamb or a kid, and most preferably the animal is a piglet; 17. A composition for use, according to any of the embodiments 1 to 16, wherein the said method comprises administering an effective quantity of the said fucosylated MMO; 18. A composition for use, according to any of the embodiments 1 to 17, wherein said fucosylated MMO is administered to said animal at least once, preferably at least twice, between birth (0 weeks) and 5 weeks of age, preferably between birth and 4 weeks of age, more preferably between birth and 3 weeks of age; 19. A composition for use, according to any of the embodiments 1 to 18, in which the said fucosylated MMO is administered to the animal at least once, preferably at least twice, more preferably daily: - in the three weeks, preferably two weeks, more preferably one week, prior to the day of transport of the animal in question; and / or - on the day of transport of the animal in question; and / or - in the three weeks, preferably two weeks, more Petition 870250100655, dated 03 / 11 / 2025, pp. 184 / 226 93 / 128 preferably one week after the day of transport of the said animal; 20. A composition for use, according to any of the embodiments 1 to 19, wherein said fucosylated MMO is administered to said animal for at least 1 week, preferably for at least 2 weeks, more preferably for at least 3 weeks, even more preferably for at least 4 weeks, most preferably for at least 6 weeks; 21. A composition for use, according to any of the embodiments 1 to 20, wherein said fucosylated MMO is administered to the animal for < 32 weeks, preferably for < 28 weeks, more preferably for < 24 weeks, even more preferably for < 20 weeks, even more preferably for < 16 weeks, even more preferably for < 12 weeks, most preferably for < 6 weeks; 22. A composition for use, according to any one of the embodiments 1 to 21, wherein said fucosylated MMO is administered to said animal for 1 to 36, preferably 1 to 30, even more preferably 1 to 28, even more preferably 1 to 24, even more preferably 1 to 18, even more preferably 1 to 12, even more preferably 1 to 8, even more preferably 1 to 6, even more preferably 1 to 4, most preferably 2 to 4 consecutive weeks; 23. A composition for use, according to any of the embodiments 1 to 22, in which the said fucosylated MMO is administered to the said animal: - if the subject is bovine: for a period of 1 to 36, preferably from 1 to 32, more preferably from 1 to 30, even more preferably from 1 to 28, even more preferably from 1 to 24, still Petition 870250100655, dated 03 / 11 / 2025, pp. 185 / 226 94 / 128 more preferably from 1 to 18, even more preferably from 1 to 12, even more preferably from 2 to 12, most preferably from 3 to 12, consecutive weeks; - if the subject is a pig: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a sheep: for a period of 1 to 36, preferably 1 to 32, more preferably 1 to 30, even more preferably 1 to 28, even more preferably 1 to 24, even more preferably 1 to 18, even more preferably 1 to 12, even more preferably 1 to 8, even more preferably 1 to 6, even more preferably 1 to 4, most preferably 2 to 4 consecutive weeks; - if the subject is a goat: for a period of 1 to 36, preferably from 1 to 32, more preferably from 1 to 30, even more preferably from 1 to 28, even more preferably from 1 to 24, even more preferably from 1 to 18, even more preferably from 1 to 12, even more preferably from 1 to 8, even more preferably from 1 to 6, even more preferably from 1 to 4, most preferably from 2 to 4 consecutive weeks; - if the subject is a horse: for a period of 1 to 18 weeks, preferably 1 to 12 weeks, more preferably 1 to 8 weeks, even more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a camelid: for a period of 1 to 18, preferably 1 to 12, more preferably 1 to 8, even more preferably 1 to 6, even more preferably 1 to 4, more Petition 870250100655, dated 03 / 11 / 2025, pp. 186 / 226 95 / 128 preferably for 2 to 4 consecutive weeks; - if the subject is a rabbit: for a period of 1 to 12 weeks, preferably 1 to 8 weeks, more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a puppy: for a period of 1 to 12 weeks, preferably 1 to 8 weeks, more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a cat: for a period of 1 to 12 weeks, preferably 1 to 8 weeks, more preferably 1 to 6 weeks, even more preferably 1 to 4 weeks, most preferably 2 to 4 consecutive weeks; - if the subject is a bird: for a period of 1 to 8 weeks, preferably 1 to 6 weeks, more preferably 1 to 4 weeks, more preferably 2 to 4 consecutive weeks; 24. A composition for use, according to any of the embodiments 1 to 23, wherein said fucosylated MMO is administered at least once a week, preferably at least once every 3 days, more preferably at least once every 2 days, most preferably it is administered at least once a day; 25. A composition for use, according to any of the embodiments from 1 to 24, wherein said fucosylated MMO is administered in a daily dose of 0.0001 to 15.0 g, preferably 0.0001 to 10.0 g, more preferably 0.0001 to 5.0 g, even more preferably 0.0001 to 2.0 g, even more preferably 0.0001 to 1.0 g, even more preferably 0.0005 to 1.0 g, and most preferably 0.0010 to 1.0 g; Petition 870250100655, dated 03 / 11 / 2025, pp. 187 / 226 96 / 128 26. A composition for use, according to any of the embodiments from 1 to 24, wherein said fucosylated MMO is administered in a daily dose of 0.01 to 15.0 g, preferably 0.01 to 10.0 g, more preferably 0.01 to 5.0 g, even more preferably 0.01 to 2.0 g, even more preferably 0.01 to 1.0 g, even more preferably 0.015 to 1.0 g, most preferably 0.02 to 1.0 g; 27. A composition for use, according to any of the embodiments from 1 to 24, wherein said fucosylated MMO is administered in a daily dose of 0.01 to 1.0 g, preferably 0.01 to 0.75 g, more preferably 0.01 to 0.65 g, even more preferably 0.01 to 0.60 g, even more preferably 0.01 to 0.50 g, even more preferably 0.015 to 0.50 g, even more preferably 0.015 to 0.40 g, even more preferably 0.015 to 0.30 g, even more preferably 0.015 to 0.20 g, most preferably 0.015 to 0.10 g; where, preferably, the animal is a bovine or a horse, more preferably a calf or a foal, even more preferably a calf; 28. A composition for use, according to any of the embodiments from 1 to 24, wherein said fucosylated MMO is administered in a daily dose of 0.01 to 5.0 g, preferably 0.1 to 2.5 g, more preferably 0.1 to 1.5 g, even more preferably 0.1 to 1.2 g, even more preferably 0.2 to 1.2 g, even more preferably 0.3 to 1.2 g, even more preferably 0.4 to 1.2 g, most preferably 0.5 to 1.2 g; wherein, preferably, the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein, more preferably, the animal is a piglet, a lamb, a kid or a young animal, wherein, even more preferably, the animal is a piglet, a lamb or a kid; and more preferably the animal is a piglet; Petition 870250100655, dated 03 / 11 / 2025, pp. 188 / 226 97 / 128 29. A composition for use, according to any of the embodiments 1 to 28, wherein said fucosylated MMO is administered at a daily dose of 0.01 to 150.0 mg, preferably 0.01 to 125.0 mg, more preferably 0.01 to 100.0 mg, even more preferably 0.05 to 100.0 mg, even more preferably 0.1 to 100.0 mg, most preferably 0.1 to 80.0 mg, per kg of body weight of said animal; 30. A composition for use, according to any one of the embodiments from 1 to 28, wherein said fucosylated MMO is administered at a daily dose of 0.1 to 50.0 mg, preferably 0.1 to 30.0 mg, more preferably 0.1 to 25.0 mg, even more preferably 0.1 to 20.0 mg, even more preferably 0.1 to 15.0 mg, even more preferably 0.1 to 10.0 mg, even more preferably 0.25 to 10.0 mg, most preferably 0.5 to 10.0 mg, per kg of body weight of said animal; wherein, preferably, the animal is a bovine or a horse, more preferably a calf or a foal, even more preferably a calf; 31. A composition for use, according to any of the embodiments from 1 to 28, wherein said fucosylated MMO is administered at a daily dose of 0.1 to 150.0 mg, preferably 0.1 to 125.0 mg, more preferably 1.0 to 125.0 mg, even more preferably 5.0 to 125.0 mg, even more preferably 5.0 to 100.0 mg, even more preferably 5.0 to 80.0 mg, most preferably 10.0 to 80.0 mg, per kg of body weight of said animal; wherein, preferably, the animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein, more preferably, the animal is a piglet, a lamb, a kid or a young animal, wherein, even more preferably, the animal is a piglet, a lamb or a young animal. Petition 870250100655, dated 03 / 11 / 2025, pp. 189 / 226 98 / 128 kid goat, and more preferably the animal is a piglet; 32. A composition for use, according to any of the embodiments 1 to 31, wherein said composition further comprises a second mammalian milk oligosaccharide (MMO), wherein said second mammalian milk oligosaccharide is preferably a silylated MMO, more preferably said second mammalian milk oligosaccharide is a silylated MMO comprising lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, and even more preferably said silylated MMO comprises lactose or LacNAc at its reducing end, most preferably said silylated MMO comprises lactose at its reducing end; 33. A composition for use, according to embodiment 32, wherein the said second MMO is selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialillacto-N-biose (6'SLNB), sialyl Lewis a, 3'-sialyl-lactosamine (3'SLacNAc), 6'sialyl-lactosamine (6'SLacNAc) and sialyl Lewis x; preferably, the second MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x; More preferably, the second MMO is selected from the list consisting of 3'SL, 6'SL, 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc; more preferably, the said second MMO is 3'-sialyl-lactose (3'SL) or 6'sialyl-lactose (6'SL); 34. A composition for use, according to either of the embodiments 32 or 33, wherein the said second MMO is 3'-sialyl-lactose (3'SL) or 6'-sialyl-lactose (6'SL); Petition 870250100655, dated 03 / 11 / 2025, pp. 190 / 226 99 / 128 35. A composition for use, according to any of the embodiments 32 to 34, wherein the quantity of said fucosylated MMO in said composition is less than the quantity of said second MMO, and preferably said quantity of said fucosylated MMO is 1.1 to 15.0, more preferably 1.5 to 15.0, even more preferably 2.5 to 15.0, even more preferably 5.0 to 15.0, even more preferably 5.0 to 12.5, most preferably 5.0 to 10.0 times less than the quantity of said second MMO in said composition; 36. A composition for use, according to any of the embodiments 33 to 34, wherein the quantity of said fucosylated MMO in said composition is less than the quantity of said second MMO, and preferably said quantity of said fucosylated MMO is 1.1 to 10.0, preferably 1.5 to 7.5, more preferably 2.5 to 7.5, most preferably 4.0 to 7.0 times less than the quantity of said second MMO in said composition; 37. A composition for use, according to any of the embodiments 33 to 34, wherein the quantity of said second MMO in the composition is from 0.1 to 30.0, preferably from 0.1 to 25.0, more preferably from 0.1 to 20.0, even more preferably from 0.1 to 15.0, even more preferably from 0.2 to 15.0, even more preferably from 0.3 to 15.0, even more preferably from 0.4 to 15.0, most preferably from 0.5 to 15.0 times the quantity of said fucosylated MMO in said composition; 38. A composition for use, according to any of the embodiments 1 to 37, wherein said composition further comprises a third mammalian milk oligosaccharide (MMO), wherein said third mammalian milk oligosaccharide is preferably Petition 870250100655, dated 03 / 11 / 2025, pp. 191 / 226 100 / 128 a sialylated MMO, more preferably wherein said third mammalian milk oligosaccharide is a sialylated MMO comprising lactose, lacto-N-biose (LNB) or N-acetyl-lactosamine (LacNAc) at its reducing end, and even more preferably said sialylated MMO comprises lactose or LacNAc at its reducing end, more preferably said sialylated MMO comprises lactose at its reducing end; 39. A composition for use, according to embodiment 38, wherein said third MMO is selected from the list consisting of 3'-sialyl-lactose (3'SL), 6'-sialyl-lactose (6'SL), 3,6-disialyl-lactose, 6,6'-disialyl-lactose, 8,3-disialyl-lactose, 3'S-2'FL, 6'S-2'FL, 3'S-3-FL, 6'S-3-FL, LST a, LST b, LST c, LST d, 3'-sialyl-lacto-N-biose (3'SLNB), 6'-sialillacto-N-biose (6'SLNB), sialyl Lewis a, 3'-sialyl-lactosamine (3'SLacNAc), 6'sialyl-lactosamine (6'SLacNAc) and sialyl Lewis x; preferably, the aforementioned third MMO is selected from the list consisting of 3'SL, 6'SL, LST a, LST b, LST c, LST d, 3'SLNB, 6'SLNB, sialyl Lewis a, 3'SLacNAc, 6'SLacNAc and sialyl Lewis x; More preferably, the third MMO is selected from the list consisting of 3'SL, 6'SL, 3'SLNB, 6'SLNB, 3'SLacNAc and 6'SLacNAc; more preferably, the third MMO is 6'-sialyl-lactose (6'SL) or 3'-sialyl-lactose (3'SL); 40. A composition for use, according to either of the embodiments 38 or 39, wherein the said third MMO is 6'-sialyl-lactose (6'SL) or 3'-sialyl-lactose (3'SL); 41. A composition for use, according to any of the embodiments 38 to 40, wherein the amount of said fucosylated MMO in said composition is less than the amount of said third MMO, and preferably said amount of said fucosylated MMO is from 1.1 to 15.0, more preferably from 1.5 to 15.0, even more Petition 870250100655, dated 03 / 11 / 2025, pp. 192 / 226 101 / 128 preferably from 2.5 to 15.0, even more preferably from 5.0 to 15.0, even more preferably from 5.0 to 12.5, most preferably from 5.0 to 10.0 times smaller than the quantity of the aforementioned third MMO in the aforementioned composition; 42. A composition for use, according to any of the embodiments 39 to 40, wherein the quantity of said fucosylated MMO in said composition is less than the quantity of said third MMO, preferably said quantity of said fucosylated MMO is 1.1 to 10.0, preferably 1.5 to 7.5, more preferably 1.5 to 5.0, most preferably 2.5 to 5.0 times less than the quantity of said third MMO in said composition; 43. A composition for use, according to any of the embodiments 39 to 40, wherein the quantity of said third MMO in said composition is from 0.1 to 30.0, preferably from 0.1 to 25.0, more preferably from 0.1 to 20.0, even more preferably from 0.1 to 15.0, even more preferably from 0.2 to 15.0, even more preferably from 0.3 to 15.0, even more preferably from 0.4 to 15.0, most preferably from 0.5 to 15.0 times the quantity of said fucosylated MMO in said composition; 44. A composition for use, according to any of the embodiments 38 to 43, in which the ratio between the amount of said second MMO and the amount of said third MMO in said composition is similar to the ratio found in breast milk of the same species; 45. A composition for use, according to any of the embodiments 38 to 44, wherein the quantity of said second MMO in said composition is greater than the quantity of said third MMO, and preferably the quantity of said second MMO is from 1.1 to Petition 870250100655, dated 03 / 11 / 2025, pp. 193 / 226 102 / 128 40.0, more preferably from 1.1 to 35.0, more preferably from 1.5 to 35.0 times the quantity of the aforementioned third MMO in the aforementioned composition; 46. ​​A composition for use, according to any of the embodiments 39 to 44, wherein the quantity of said second MMO in said composition is greater than the quantity of said third MMO, preferably the quantity of said second MMO is from 1.1 to 6.0, more preferably from 1.1 to 5.0, even more preferably from 1.25 to 4.0, even more preferably from 1.25 to 3.0, even more preferably from 1.5 to 3.0, most preferably from 1.5 to 2.5 times greater than the quantity of said third MMO in said composition; 47. A composition for use, according to any of the embodiments 1 to 46, wherein the said method does not comprise the administration of lacto-N-tetraose (LNT); 48. A composition for use, according to any of the embodiments 1 to 47, wherein said composition does not comprise lacto-N-neotetraose (LNnT); 49. A composition for use, according to any of the embodiments 1 to 48, wherein said composition does not comprise N-acetyllactosamine; 50. A composition for use, according to any of the embodiments 1 to 49, wherein said composition does not comprise an oligosaccharide containing N-acetyllactosamine, preferably does not comprise a saccharide containing N-acetyllactosamine; 51. A composition for use, according to any of the embodiments 1 to 50, wherein said composition does not comprise a fructooligosaccharide (FOS); 52. A composition for use, according to anyone Petition 870250100655, dated 03 / 11 / 2025, pp. 194 / 226 103 / 128 of embodiments 1 to 51, in which the said composition does not comprise a galacto-oligosaccharide (GOS); 53. A composition for use, according to any of the embodiments 1 to 52, wherein said composition does not comprise an isomalto-oligosaccharide; 54. A composition for use, according to any of the embodiments 1 to 53, wherein said composition does not comprise a non-fucosylated neutral MMO; 55. A composition for use, according to any of the embodiments 1 to 31 and 47 to 54, wherein said composition does not comprise an additional mammalian milk oligosaccharide; 56. A composition for use, according to any of the embodiments 1 to 55, wherein said composition further comprises a microbial strain that does not use, or preferably is not able to use, said fucosylated MMO as a carbon source; 57. A composition for use, according to any of the embodiments 1 to 55, wherein said composition does not comprise a microbial strain; 58. A composition for use, according to any of the embodiments 1 to 57, wherein the said composition is not breast milk; 59. A composition for use, according to any of the embodiments 1 to 58, wherein the said composition is a synthetic composition; 60. A composition for use, according to any of the embodiments 1 to 59, wherein said fucosylated MMO was produced in vitro and / or ex vivo by a cell, preferably a single cell, wherein said cell is preferably chosen from the list Petition 870250100655, dated 03 / 11 / 2025, pp. 195 / 226 104 / 128 which consists of a microorganism, a plant cell, an animal cell and a protozoan cell; 61. A composition for use, according to any of the embodiments 1 to 60, wherein said fucosylated MMO is linked, preferably chemically linked, to a vehicle for administration of said fucosylated MMO; 62. A composition for use, according to embodiment 61, wherein the said binder is a ceramide-based vehicle or a polypeptide-based vehicle, preferably a ceramide-based vehicle; 63. A composition for use, according to embodiment 62, wherein the ceramide-based vehicle is selected from a list consisting of d18:1 / 16:0, t18:0 to 16:0, t18:0-h16:0, t18:0-h22:0 and t18:0-h24:0; 64. A composition for use, according to any of the embodiments 1 to 63, in which said fucosylated MMO is encapsulated; 65. A composition for use, according to any of the embodiments 1 to 64, wherein said composition is a pharmaceutical composition, optionally further comprising a pharmaceutically acceptable vehicle, filler, preservative, solubilizer, diluent, excipient, salt, adjuvant and / or solvent; 66. A composition for use, according to any of the embodiments 1 to 65, wherein said composition is a nutritional composition, optionally further comprising a feed ingredient and / or a food ingredient, wherein said feed / food ingredient is preferably chosen from the group consisting of: - a lipid, preferably one or more selected from Petition 870250100655, dated 03 / 11 / 2025, pp. 196 / 226 105 / 128 list consisting of an oil, fat, ester, monoglyceride, diglyceride, triglyceride and free fatty acid; - a vitamin, preferably one or more selected from the list consisting of vitamin A, vitamin B, vitamin C, vitamin D, vitamin E and vitamin H, or a derivative thereof; - an amino acid compound; - a trace element; - a mineral, preferably one or more selected from the list consisting of calcium, phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, selenium and chloride; - an antioxidant; - a prebiotic agent, preferably one or more selected from the list consisting of GOS (galacto-oligosaccharide), FOS (fructo-oligosaccharide), inulin and resistant starch; - a carbohydrate; - an antimicrobial agent; and / or - a protein; 67. A composition for use, according to embodiment 66, wherein said nutritional composition is selected from a list consisting of a milk replacer, creep feed, pre-starter diet, starter diet, pre-weaning feed, weaning feed and post-weaning feed, preferably selected from the list consisting of a milk replacer, starter diet, creep feed and post-weaning feed, more preferably said nutritional composition is a milk replacer or starter diet, more preferably a milk replacer; 68. A method for preventing and / or treating shipping fever in an animal, preferably a farm animal or a domesticated animal, more preferably a farm animal, wherein the method Petition 870250100655, dated 03 / 11 / 2025, pp. 197 / 226 106 / 128 comprises managing a composition, as defined in any of the embodiment examples 1 to 67; 69. A method, according to embodiment 68, wherein the method is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia; 70. A method, according to embodiment 69, in which the pneumonia is acute pneumonia; 71. A method, according to any one of the embodiment examples 68 to 70, in which the said animal is as defined in any one of the embodiment examples 4 to 6; 72. A method, according to any one of the embodiments 68 to 71, wherein said method comprises administering an effective quantity of said fucosylated MMO to the animal, wherein said fucosylated MMO is preferably administered as defined in any one of the embodiments 18 to 31; 73. Use of a composition, as defined in any of the embodiments 1 to 67, characterized in that it is for the manufacture of a medicament for preventing and / or treating shipping fever in an animal, preferably wherein the animal is a farm animal or a domesticated animal, wherein, more preferably, the animal is a farm animal; 74. Use, as per embodiment 73, where the medication is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia; 75. Use, according to embodiment 74, where pneumonia is acute pneumonia; Petition 870250100655, dated 03 / 11 / 2025, pp. 198 / 226 107 / 128 76. Use, according to any of the embodiment examples 73 to 75, wherein the animal is as defined in any of the embodiment examples 4 to 6; 77. Use, according to any of the embodiments 73 to 76, wherein said method comprises administering an effective amount of said fucosylated MMO to the animal, wherein said fucosylated MMO is preferably administered as defined in any of the embodiments 18 to 31.

[172] The present invention relates more preferably to the following specific embodiments: 1. A fucosylated mammalian milk oligosaccharide (MMO) for use in a method for preventing and / or treating shipping fever in an animal, preferably in a farmed or domesticated animal, more preferably a farmed animal; 2. A fucosylated MMO for use, according to embodiment 1, wherein the method is a method for preventing and / or treating shipping fever in an animal by increasing T-lymphocyte-mediated immunity in said animal; 3. A fucosylated MMO for use, according to either embodiment 1 or 2, wherein said method is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia; 4. A fucosylated MMO for use, according to embodiment 3, where the pneumonia is acute pneumonia; 5. A fucosylated MMO for use, according to any of the embodiments 1 to 4, wherein the said animal is selected from the list consisting of bovine, swine, ovine, caprine, equine, donkey, mule, Petition 870250100655, dated 03 / 11 / 2025, pp. 199 / 226 108 / 128 bardot, camelid, dog, cat, rabbit and birds; 6. A fucosylated MMO for use, according to any of the embodiments 1 to 5, wherein the animal in question is a non-adult animal; 7. A fucosylated MMO for use, according to any of the embodiments 1 to 6, wherein said fucosylated MMO comprises a fucose that is linked to a monosaccharide in an alpha-1,2 linkage, and wherein said monosaccharide is galactose; 8. A fucosylated MMO for use, according to any of the embodiments 1 to 7, wherein said fucosylated MMO is 2'fucosylactose (2'FL); 9. A fucosylated MMO for use, according to any of the embodiments 1 to 8, wherein said method does not comprise the administration of lacto-N-tetraose (LNT) or lacto-N-neotetraose (LNnT); 10. A fucosylated MMO for use, according to any of the embodiments 1 to 9, wherein said method does not comprise the administration of an additional MMO; 11. A fucosylated MMO for use, according to any of the embodiments 1 to 10, wherein said fucosylated MMO is administered to said animal at least once, preferably at least twice, between birth (0 weeks) and 5 weeks of age, preferably between birth and 4 weeks of age, more preferably between birth and 3 weeks of age; 12. A fucosylated MMO for use, according to any of the embodiments 1 to 11, wherein said fucosylated MMO is administered to said animal at least once, preferably at least twice, most preferably daily: - in the three weeks, preferably two weeks, more Petition 870250100655, dated 03 / 11 / 2025, pp. 200 / 226 109 / 128 preferably one week prior to the day of transport of the animal in question; and / or - on the day of transport of the animal in question; and / or - within three weeks, preferably two weeks, more preferably one week, after the day the animal was transported; 13. A fucosylated MMO for use, according to any of the embodiments 1 to 12, wherein said fucosylated MMO is administered in a daily dose of 0.01 to 1.0 g, preferably 0.01 to 0.75 g, more preferably 0.01 to 0.65 g, even more preferably 0.01 to 0.60 g, even more preferably 0.01 to 0.50 g, even more preferably 0.015 to 0.50 g, even more preferably 0.015 to 0.40 g, even more preferably 0.015 to 0.30 g, even more preferably 0.015 to 0.20 g, most preferably 0.015 to 0.10 g; wherein, preferably, the animal in question is a bovine or a horse, wherein, more preferably, it is a calf or a foal, and even more preferably it is a calf; 14. A fucosylated MMO for use, according to any of the embodiments 1 to 12, wherein said fucosylated MMO is administered in a daily dose of 0.01 to 5.0 g, preferably 0.1 to 2.5 g, more preferably 0.1 to 1.5 g, even more preferably 0.1 to 1.2 g, even more preferably 0.2 to 1.2 g, even more preferably 0.3 to 1.2 g, even more preferably 0.4 to 1.2 g, most preferably 0.5 to 1.2 g; wherein, preferably, the said animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein, more preferably, the said animal is a piglet, a lamb, a kid or a young animal, wherein, even more preferably, the said animal is a piglet, a lamb or a kid, wherein, more preferably, the said animal is a piglet; Petition 870250100655, dated 03 / 11 / 2025, pp. 201 / 226 110 / 128 15. A fucosylated MMO for use, according to any of the embodiments from 1 to 14, wherein the fucosylated MMO is administered at a daily dose of 0.01 to 150.0 mg, preferably 0.01 to 125.0 mg, more preferably 0.01 to 100.0 mg, even more preferably 0.05 to 100.0 mg, even more preferably 0.1 to 100.0 mg, most preferably 0.1 to 80.0 mg, per kg of body weight of said animal; 16. A fucosylated MMO for use, according to any of the embodiments 1 to 14, wherein said fucosylated MMO is part of a composition; 17. A fucosylated MMO for use, according to embodiment 16, wherein the said composition is not breast milk; 18. A fucosylated MMO for use, according to any of the embodiments 16 or 17, wherein said composition is a pharmaceutical composition, optionally further comprising a pharmaceutically acceptable vehicle, filler, preservative, solubilizer, diluent, excipient, salt, adjuvant and / or solvent; 19. A fucosylated MMO for use, according to any of the embodiments 16 to 18, wherein said composition is a nutritional composition and selected from a list consisting of a milk replacer, creep feed, pre-starter diet, starter diet, pre-weaning feed, weaning feed and post-weaning feed, preferably selected from the list consisting of a milk replacer, starter diet, creep feed and post-weaning feed, most preferably said nutritional composition is a milk replacer or starter diet, most preferably a milk replacer. Definitions

[173] The words used in this descriptive report to describe the invention and its various embodiments should be Petition 870250100655, dated 03 / 11 / 2025, pages 202 / 226 111 / 128 understood not only in the sense of their commonly defined meanings, but also as including, by specific definition in this descriptive report, structure, material or acts that go beyond the scope of the commonly defined meanings. Thus, if an element can be understood in the context of this descriptive report as including more than one meaning, then its use in a claim should be understood as being generic for all possible meanings supported by the descriptive report and by the word itself.

[174] The various aspects and embodiments of the invention disclosed herein should be understood not only in the order and context specifically described in this descriptive report, but also including any order and any combination thereof. Each embodiment, as identified in the present invention, may be combined unless otherwise indicated. All publications, patents and patent applications cited in this descriptive report are incorporated in their entirety into this application by reference, to the same extent as if each individual publication, patent or patent application were specifically and individually indicated to be incorporated by reference in its entirety. Unless specifically indicated otherwise, all words used in the singular should be considered as including the plural and vice versa.Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning commonly understood by a person skilled in the art to which the present invention pertains. In general, the nomenclature used herein and the laboratory procedures for cell culture, molecular genetics, organic chemistry, nucleic acid chemistry, and hybridization described below are well known and commonly used in the state of the art. Standard techniques are used for the synthesis of nucleic acids and peptides. Generally, the enzymatic reactions and steps of... Petition 870250100655, dated 03 / 11 / 2025, pages 203 / 226 112 / 128 purification processes are carried out according to the manufacturer's specifications.

[175] Examples of embodiments of the invention have been disclosed in the figures and descriptive report, and although specific terms are used, the terms are used only in a descriptive sense and not for the purpose of limitation, the scope of the invention being defined in the following claims. It should be understood that the illustrated embodiments are presented for illustrative purposes only and should not be considered as limiting the scope of the invention. It will be evident to those skilled in the art that alterations, other embodiments, improvements, details and applications can be made in a manner consistent with the letter and spirit of the present invention, being within the scope thereof, which is limited only by the claims, interpreted in accordance with patent law, including the doctrine of equivalents.In the following claims, the reference characters used to designate the steps of the claim are provided only for convenience of description and are not intended to imply any specific order for performing the steps (unless specifically indicated otherwise).

[176] In this document and its claims, the verbs “comprise”, “have”, “possess” and “contain”, and their conjugations, are used in their non-limiting sense, meaning that items following the word are included, but items not specifically mentioned are not excluded. The verb “consist essentially of” means that, for example, a composition as defined in the present invention may comprise additional component(s) beyond those specifically identified, without said additional component(s) altering the unique characteristic of the invention. Throughout the document and the claims, unless specifically indicated otherwise, the verbs “comprise”, “have”, “possess” and “contain”, and their conjugations, may preferably be Petition 870250100655, dated 03 / 11 / 2025, pages 204 / 226 113 / 128 replaced by “consist” (and its conjugations) or “consist essentially in” (and its conjugations) and vice versa. Furthermore, the reference to an element by the indefinite article “a” does not exclude the possibility that more than one element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article “the” generally means “at least one”. The word “about” or “approximately” or “around”, when used in association with a numerical value (e.g., about 10), preferably means that the value may be the given value (10), plus or minus 10%, preferably 5%, and most preferably 1% of the value.

[177] Throughout the description and claims, unless specifically stated otherwise, the expression “of xay”, where xey represent numerical values, refers to a range of numerical values ​​where xey are included, with x representing the smallest value and yo the largest. Therefore, xey are included in the range.

[178] The terms “LNT II”, “LNT-II”, “LN3”, “lacto-N-triose II”, “lacto-N-triose II”, “lacto-N-triose”, “lacto-N-triose” and “GlcNAc-β1,3-Gal-β1,4-Glc” are used interchangeably.

[179] The terms “LNT”, “lacto-N-tetraose”, “lacto-N-tetraose” and “Gal-β1,3-GlcNAc-β1,3-Gal-β1,4Glc” are used interchangeably.

[180] The terms “LNnT”, “lacto-N-neotetraose”, “lacto-N-neotetraose”, “neo-LNT” and “Galβ1-4GlcNAcβ1-3Galβ1-4Glc” are used interchangeably.

[181] The terms “2' fucosyllactose”, “2'-fucosyllactose”, “alpha-1,2fucosyllactose”, “alpha 1,2 fucosyllactose”, “α-1,2-fucosyllactose”, “α 1,2 fucosyllactose”, “Fuc-α1,2-Gal-β1,4-Glc”, 2FL” and “2'FL” are used interchangeably.

[182] The terms “3-fucosyllactose”, “alpha-1,3-fucosyllactose”, “alpha Petition 870250100655, dated 03 / 11 / 2025, pages 205 / 226 114 / 128 1,3 fucosyllactose”, “a-1,3-fucosyllactose”, “α 1,3 fucosyllactose”, “Gal-e1,4-(Fucα1,3-)Glc”, “3FL” and “3-FL” are used interchangeably.

[183] ​​The terms “diffucosyllactose”, “di-fucosyllactose”, “lactodifucotetraose”, “2',3-diffucosyllactose”, “2',3 difucosyllactose”, “α-2',3fucosyllactose”, “α 2',3 fucosyllactose”, “Fuc-α1,2-Gal-β1,4-(Fuc-α1,3-)Glc”, “DFLac”, 2',3 diFL”, “DFL”, “DiFL” and “diFL” are used interchangeably.

[184] The terms “LNFP-I”, “lacto-N-fucopentaose I”, “LNFP I”, “LNF I OH type I determinant”, “LNF I”, “LNF1”, “LNF 1”, “pentaose type 1 of blood group H antigen” and “Fuc-α1,2-Gal-β1,3-GlcNAc-β1,3-Gal-β1,4Glc” are used interchangeably.

[185] The terms “GalNAc-LNFP-I”, “hexaose type 1 of blood group A antigen” and “GalNAc-α1,3-(Fuc-α1,2)-Gal-β1,3-GlcNAc-β1,3-Galβ1,4-Glc” are used interchangeably.

[186] The terms “Gal-LNFP-I”, “hexaose type I of blood group B antigen” and “Gal-α1,3-(Fuc-α1,2)-Gal-β1,3-GlcNAc-β1,3-Gal-β1,4Glc” are used interchangeably.

[187] The terms “LNFP-II”, “lacto-N-fucopentaose II” and “Gal-β1,3(Fuc-α1,4)-GlcNAc-β1,3-Gal-β1,4-Glc” are used interchangeably.

[188] The terms “LNFP-III”, “lacto-N-fucopentaose III” and “Galβ1,4-(Fuc-α1,3)-GlcNAc-β1,3-Gal-β1,4-Glc” are used interchangeably.

[189] The terms “LNFP-V”, “lacto-N-fucopentaose V” and “Gal-β1,3-GlcNAc-β1,3-Gal-β1,4-(Fuc-α1,3)-Glc” are used interchangeably.

[190] The terms “LNDFH I”, “Lacto-N-difucohexaose I”, “LNDFHI”, “LDFH I”, “Leb-lactose”, “Lewis-b hexasaccharide” and “Fuc-α1,2-Gal-β1,3-[Fucα1,4]-GlcNAc-β1,3-Gal-β1,4-Glc” are used interchangeably.

[191] The terms “LNDFH II”, “Lacto-N-difucohexaose II”, “Lewis a-Lewis x”, “LDFH II” and “Fuc-a1,4-(Gal-e1,3)-GlcNAc-e1,3-Gal-e1,4-(Fuc-a1,3)- Petition 870250100655, dated 03 / 11 / 2025, pp. 206 / 226 115 / 128 "Glc" are used interchangeably.

[192] The terms “lewis b-lewis x” and “Fucal ,4-[Fuc-a1,2-Gaiei ,3]GlcNAc-ei,3-Gal-ei,4-[Fuc-a1,3]-Glc are used interchangeably.

[193] The terms “MFLNH III”, “monofucosylacto-N-hexaose-III” and “Gαl-β1,4-[Fuc-α1J3]-GlcNAc-β1)6-[Gal-β1,3-GlcNAc-β1)3]-Gal-β1,4-Glc” are used interchangeably.

[194] The terms “DFLNH (a)”, “difucosylacto-N-hexaose (a)” and “Gαl-β1,4-[Fuc-α1,3]-GlcNAc-β1,6-[Fuc-α1,2-Gal-β1,3-GlcNAc-β1,3]-Gal-β1,4Glc” are used interchangeably.

[195] The terms “DFLNH”, “difucosylacto-N-hexaose” and “Gαl-β1,4[Fuc-α1,3]-GlcNAc-β1,6-[Fuc-α1,4-[Gal-β1,3]-GlcNAc-β1,3]-Gal-β1,4-Glc” are used interchangeably.

[196] The terms “TFLNH”, “trifucosylacto-N-hexaose” and “Gal-β1,4[Fuc-α1,3]-GlcNAc-β1,6-[Fuc-α1,4-[Fuc-α1,2-Gal-β1,3]-GlcNAc-β1,3]-Gal-β1,4Glc” are used interchangeably.

[197] The terms “LNnFP I”, “Lacto-N-neofucopentaose I” and “Fucα1,2-Gal-β1,4-GlcNAc-β1,3-Gal-β1,4-Glc” are used interchangeably.

[198] The terms “LNFP-VI”, “LNnFP V”, “lacto-N- neofucopentaose V” and “Gal-β1,4 -GlcNAc-β1,3-Gal-β1,4-(Fuc-α1,3)-Glc” are used interchangeably.

[199] The terms “LNnDFH”, “Lacto-N-neoDiFucohexaose”, “hexaose Lewis x”, “Gal-β1,4-(Fuc-α1,3)-GlcNAc-β1,3-Gal-β1,4-(Fuc-α1,3)-Glc” are used interchangeably.

[200] The terms “2'-fucosylacto-N-biose”, “2'FLNB” and “Fuc-α1,2Gal-β1,3-GlcNAc” are used interchangeably.

[201] The terms “4-fucosylact-N-biose”, “4FLNB” and “Fuc-α1,4- [Gal-β1,3-]GlcNAc” are used interchangeably.

[202] The terms “difucosylacto-N-biose”, “diFLNB” and “Fuc-α1,4 Petition 870250100655, dated 03 / 11 / 2025, pp. 207 / 226 116 / 128 [Fuc-αΐ ,2-Gal-β1 ,3-]GlcNAc” are used interchangeably.

[203] The terms “2'-fucosyl-N-acetyl-lactosamine”, “2'FlacNAc” and “Fuc-α1,2-Gal-ei,4-GlcNAc” are used interchangeably.

[204] The terms “3-fucosyl-N-acetylactosamine”, “3FlacNAc” and “Gal-β1,4-(Fuc-α1,3-)GlcNAc” are used interchangeably.

[205] The terms “difucosyl-N-acetylactosamine”, “diFlacNAc” and “Fuc-α1,2-Gal-β1,4-[Fuc-α1,3-]GlcNAc” are used interchangeably.

[206] The terms “3'-sialyl-lactose”, “3'-sialyl-lactose”, “alpha-2,3sialyl-lactose”, “alpha 2,3 sialyl-lactose”, “α-2,3-sialyl-lactose”, “α 2,3 sialyl-lactose”, “3SL”, “Sia-α2,3-Gal-β1,4-Glc” and “3'SL” are used interchangeably.

[207] The terms “6'-sialyl-lactose”, “6'-sialyl-lactose”, “alpha-2,6sialyl-lactose”, “alpha 2,6 sialyl-lactose”, “α-2,6-sialyl-lactose”, “α 2,6 sialyl-lactose”, “6SL”, “Sia-α2,6-Gal-β1,4-Glc” and “6'SL” are used interchangeably.

[208] The terms “3,6-disialyl-lactose” and “Neu5Ac-α2,3-Neu5Acα2,6-Gal-β1,4-Glc” are used interchangeably.

[209] The terms “6,6'-disialyl-lactose” and “Neu5Ac-α2,6-Neu5Ac- α2,6-Gal-β1,4-Glc” are used interchangeably.

[210] The terms “8,3-disialyl-lactose” and “Neu5Ac-α2,8-Neu5Ac- α2,3-Gal-β1,4-Glc” are used interchangeably.

[211] The terms “3'S-2'FL” and “Neu5Ac-α2,3-[Fuc-α1,2-]Gal-β1,4Glc” are used interchangeably.

[212] The terms “6'S-2'FL” and “Neu5Ac-α2,6-[Fuc-α1,2-]Gal-β1,4Glc” are used interchangeably.

[213] The terms “3'S-3-FL” and “Neu5Ac-α2,3-Gal-β1,4-[Fuc- α1,3]Glc” are used interchangeably.

[214] The terms “6'S-3-FL” and “Neu5Ac-α2,6-Gal-β1,4-[Fuc- α1,3]Glc” are used interchangeably.

[215] The terms “LSTa”, “LS-Tetrasaccharide a”, “Sialyl-lacto-N Petition 870250100655, dated 03 / 11 / 2025, pp. 208 / 226 117 / 128 tetraose a”, “sialilacto-N-tetraose a” and “Neu5Ac-a2,3-Gal-b1,3-GlcNAc-b1,3-Galb1,4-Glc” are used interchangeably.

[216] The terms “LSTb”, “LS-Tetrasaccharide b”, “Sialyl-lacto-N-tetraose b”, “sialylacto-N-tetraose b” and “Gal-b1,3-(Neu5Ac-a2,6)-GlcNAc-b1,3Gal-b1,4-Glc” are used interchangeably.

[217] The terms “LSTc”, “LS-Tetrasaccharide c”, “Sialyl-lacto-N-tetraose c”, “sialylacto-N-tetraose c”, “sialylacto-N-neotetraose c” and “Neu5Aca2,6-Gal-b1,4-GlcNAc-b1,3-Gal-b1,4-Glc” are used interchangeably.

[218] The terms “LSTd”, “LS-Tetrasaccharide d”, “Sialyl-lacto-N-tetraose d”, “sialylacto-N-tetraose d”, “sialylacto-N-neotetraose d” and “Neu5Aca2,3-Gal-b1,4-GlcNAc-b1,3-Gal-b1,4-Glc” are used interchangeably.

[219] The terms “3'-sialylacto-N-biose”, “3'SLNB” and “Neu5Ac-a2,3Gal-b1,3-GlcNAc” are used interchangeably.

[220] The terms “6'-sialylacto-N-biose”, “6'SLNB” and “Neu5Ac-a2,6Gal-b1,3-GlcNAc” are used interchangeably.

[221] The terms “monofucosyl-monosialylacto-N-octaose”, “sialyl Lewis a”, “sialyl Lea”, “5-acetylneuraminyl-(2-3)-galactosyl-(1-3)-(fucopyranosyl-(14))-N-acetylglucosamine” and “Neu5Ac-α2,3-Gal-β1,3-[Fuc-α1,4]-GlcNAc” are used interchangeably.

[222] The terms “3'-sialyl-lactosamine”, “3'SLacNAc” and “Neu5Aca2,3-Gal-b1,4-GlcNAc” are used interchangeably.

[223] The terms “6'-sialyl-lactosamine”, “6'SLacNAc” and “Neu5Aca2,6-Gal-b1,4-GlcNAc” are used interchangeably.

[224] The terms “sialyl Lewis x”, “sialyl Lex”, “5-acetylneuraminyl-(23)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine” and “Neu5Ac-α2,3Gal-β1,4-[Fuc-α1,3-]GlcNAc” are used interchangeably.

[225] The term “culture” refers to the culture medium in which the cell is grown or fermented, to the cell itself and to the saccharide(s) that Petition 870250100655, dated 03 / 11 / 2025, pp. 209 / 226 118 / 128 is / are produced by the cell in the whole broth, that is, both inside (intracellularly) and outside (extracellularly) the cell.

[226] The term “clarification” refers to the act of treating an aqueous solution to remove suspended particles and contaminants from the production process, such as cells, cell components, insoluble metabolites and debris, which may interfere with the final purification of the oligosaccharide(s) of interest. Such treatment may be carried out conventionally by centrifugation, flocculation, flocculation with optional ultrasonic treatment, gravity filtration, microfiltration, foam separation or vacuum filtration (for example, through a ceramic filter which may include a Celite® filtration aid). Brief Description of the Figures

[227] The following figures are intended to illustrate and clarify the present invention and should not, under any circumstances, be interpreted as limiting it.

[228] Figure 1 - Probability of incidence of first pneumonia over time in control animals (placebo) and animals treated with 2'-fucosyllactose (2'FL) from the first trial (calves destined for veal).

[229] Figure 2 - Probability of incidence of first pneumonia over time in control animals (placebo) and animals treated with 2'-fucosyllactose (2'FL) from the second trial (rearing calves). Examples

[230] The invention will be described in more detail in the examples. The following examples will serve as further illustration and clarification of the present invention and are not intended to be limiting in any way. Example 1 2'FL

[231] 2'-fucosylactose (2'FL) was recombinantly produced in E. coli and purified as described in Examples 10, 13 and Petition 870250100655, dated 03 / 11 / 2025, pages 210 / 226 119 / 128 of WO 2022 / 034079, and subsequently spray-dried as described in Example 21 of WO 2022 / 034079 to obtain 2” FL powder (89.6% purity). Example 2 Animal Calf Trials and Diets

[232] Holstein-Friesian calves (2 to 3 weeks old, 95% male) were transported from different farms to the experimental unit in Denkavit (Voorthuizen, Netherlands), where the animals were raised. The experiment was carried out in two rounds of testing. Round 1: Veal

[233] The calves were randomly and equally divided by gender into two groups based on the experimental calf milk replacer: group A (placebo - standard calf milk replacer (CMR) powder from the farm) and group B (standard CMR powder supplemented with 0.005% dry weight of 2'-fucosyllactose (2'FL, see Example 1). The calf milk replacer was administered as a liquid to the calves (water was added to the CMR powder to obtain 150 grams of CMR powder per liter of liquid CMR). Each group involved 290 calves, distributed in 12 rows. Each row contained 4 pens, where six calves lived in one pen.

[234] 2'-fucosylactose was provided to calves via CMR (the main components are presented in Table 1) throughout the experiment, which lasted 6 months. The initial CMR was administered from arrival until week 6, then replaced by CMR Gold Alfa until day 136. For the remainder of the period, the calves were fed CMR Omega. Solid feed (concentrate) was gradually introduced from arrival, starting with Avance Alfa until day 126, then replaced. Petition 870250100655, dated 03 / 11 / 2025, pages 211 / 226 120 / 128 by Avance Omega until the end of the experiment. The feed was provided ad libitum to the calves twice a day (morning and evening) and consumption was recorded daily based on consumption by rows (concentrates, straw, corn silage) or groups (CMR). Table 1 Main Components of Standard Calf Diets in the Trial of Round 1 Diet Protein (% dry weight) Fat (% dry weight) Carbohydrate (% dry weight) Ash (% dry weight) Calf Milk Replacer (CMR) starter 24.1 20.8 44 8.3 CMR Gold Alpha 18.0 18.7 54 7.4 CMR Gold Omega 13.7 19.2 58 6.8 Advance Alpha 16.7 4.4 57.7 Advance Omega 14.6 4.4 59.5 Round 2: Calves in Rearing

[235] Calves were randomly and equally divided by gender into two groups based on the experimental calf milk replacer (CMR): group A (placebo - standard farm CMR powder), group B (standard CMR powder supplemented with 0.005% dry weight of 2'FL). The calf milk replacer was administered as a liquid to the calves (water was added to the CMR powder to obtain 150 grams of CMR powder per liter of liquid CMR). Each group involved 100 calves, distributed in four rows (25 calves per row) of two-compartment blocks. Each row contained five pens, where four to six calves lived in one pen.

[236] From the day of arrival, calves received standard calf milk replacer (CMR) for a period of 9 weeks. Group A received only CMR, while the CMR provided to groups B was supplemented with 2'FL at 0.005% dry weight. Creep feed (concentrate) and straw were gradually introduced from day 6 until the end of the experiment (12 weeks), while calves had access to silage. Petition 870250100655, dated 03 / 11 / 2025, pages 212 / 226 121 / 128 corn in weeks 11 and 12. The rations were provided ad libitum to the calves twice a day (morning and evening) and consumption was recorded daily based on consumption by rows (concentrates, straw, corn silage) or groups (CMR). The main components of the standard CMR and starter diets are presented in Table 2. Table 2 Main Components of Standard Calf Diets in the Trial of Round 2 Diet Protein (% dry weight) Fat (% dry weight) Carbohydrate (% dry weight) Crude fiber (% dry weight) Ash (% dry weight) Milk replacer for calves 22 18 49 Whey protein powder, vegetable oils (palm, coconut, rapeseed), hydrolyzed wheat gluten, dextrose, premix Starter for calves 17.5 2.2 5.8 6.9 Corn, soybean meal, beet pulp, barley, wheat, whey powder, sugar, calcium carbonate, lignocellulose, premix Health, Safety and Performance Observation

[237] Calves were monitored by the farm staff from arrival until the end of the experiment. Fecal consistency on a scale of 1 to 4 (Larson et al., 1977, J. Dairy Science, 60(6): p. 989 to 991) was recorded daily during the first ten days after arrival. The number of mortalities and signs of adverse effects were recorded daily. Animals were treated prophylactically or metaphylactically (herd treatment) with 1 g of 100% oxytetracycline (on day 4), 0.5 g of 50% WSP doxylamine and 0.8 g of 2% bromhexine (on day 13), and 3.1 mL of 250 mg / mL tilmicosol (on day 24) to prevent and / or treat acute pulmonary inflammation. Individual treatments were monitored by observations from the farm staff and diagnoses from farm veterinarians. Disease incidences and medicinal use based on individual treatments were recorded for comparison between treatment groups.The live weight of the animals was monitored at arrival (d1), two weeks (S2), six weeks (S6), ten. Petition 870250100655, dated 03 / 11 / 2025, pages 213 / 226 122 / 128 weeks (S10), 12 weeks (S12), and 17 weeks (S17) since arrival. The feed conversion ratio (FCR) for each period was calculated based on daily weight gain and daily feed intake. Pneumonia Assessment

[238] Acute pneumonia is reported by the farm staff and assessed by the farm veterinarians based on some or all of the following symptoms (Wolfger et al., 2015, Veterinary Clinics of North America Food Animal 31, 351-365): depression; anorexia; nasal discharge; eye discharge; cough; increased respiratory rate; increased breath sounds on chest auscultation; and pyrexia (fever). Serodiagnosis of Respiratory Pathogens in Calves with Acute Pneumonia

[239] Blood was collected from the jugular vein of 11 sick calves in S2 and S10. One mL of blood was aliquoted and kept at room temperature for 1 h for coagulation. The coagulated blood was transported to the laboratory under cold conditions (6-10 °C). Upon arrival at the laboratory, the blood was centrifuged at 2500 rpm for 5 min, then the supernatant collected earlier was heat-treated at 56 °C for 30 min and stored at -80 °C. Serum samples were applied to the AbELISA multiscreen test kit to detect antibodies to bovine respiratory syncytial virus (BRSV), parainfluenza virus 3 (BPI3), Mycoplasma bovis, Mannheimia haemolytica, adenovirus type 3 (ADENO 3), and to Ab-ELISA monoscreen test kits to detect antibodies to BoHV1 (bovine rhinotracheitis) or BVDV (bovine viral diarrhea) (BioX Diagnostics, Rochefort, Belgium) according to the manufacturer's instructions. Jejunal Sampling, RNA Extraction and RNaseq (Transcriptomics)

[240] A healthy, average-weight calf from one pen per group was selected for euthanasia at the slaughterhouse on day 71 (S11) (8 Petition 870250100655, dated 03 / 11 / 2025, pages 214 / 226 (123 / 128 calves in total, 4 per group). A 20 cm segment of the jejunum without Peyer's patch was excised and washed three times with physiological saline using a 30 mL syringe. A small segment (2 to 3 mm) was subsequently excised and stored in 2 mL of RNA tissue protection reagent (Qiagen) containing RNA preservation buffer for transport at room temperature before long-term storage at -80 °C.

[241] Jejunal samples stored in RNA tissue protection reagent were excised to transfer 50 mg of tissue to 2 mL tubes. The tissues were broken up and homogenized using a 5 mm stainless steel sphere in 900 pL of QIAzol lysis reagent (QIAgen) in combination with a Fastprep® 24 device. The homogenates were handled according to the manufacturer's instructions for the RNeasy plus universal tissue mini-kit (QIAgen). The purified total RNA was eluted in 40 pL and the concentration and quality were rapidly checked with Nanodrop (Implen Nanophotometer®) before storage at -80 °C.

[242] Total RNA was sent to Azenta (Genewiz, Germany) for RNA sequencing. Total RNA was again checked for quality and concentration using Qubit and fragment analyzer before mRNA selection for polyA library preparation and sequencing using the Illumina® Novaseq 2x150 bp technology platform, ensuring 20 million pair reads per sample (40 million reads).

[243] RNA sequencing reads were quality checked with fastqc (https: / / www.bioinformatics.babraham.ac.uk / projects / fastqc / ) and trimmed with Trimmomatic (Bolger et al., 2014, Bioinformatics 30(15): p. 2114-2120). Reads were aligned to the cow reference sequence (Bos_taurus_UMD_3.1.1) using the STAR genome alignment method (Dobin et al., 2013, Bioinformatics 29(1): p. 15-21); Gene expression Petition 870250100655, dated 03 / 11 / 2025, pp. 215 / 226 124 / 128 was quantified by featureCounts (Liao et al., 2014, Bioinformatics 30(7): p. 923-930) and differential expression analysis was performed using DEseq2 (Love et al., 2014, Genome Biol. 15(2): 550). Differential expression enrichment analysis was performed in clusterProfiler (Wu et al., 2021, Innovation 2(3): 100-141) based on Gene Ontology. Statistical Analysis

[244] The odds and hazard ratios of pneumonia and diarrhea incidence were assessed using the epitools R statistical package using the Wald test (https: / / cran.r-project.org / web / packages / epitools / epitools.pdf). The incidence of pneumonia in two rounds of trials was compared between the different treatment groups using the Mantel-Haenszel chi-square test with trial correction using the epitools R package. Incidence plots were created using the survival R package (https: / / cran.rproject.org / web / packages / survival / index.html). Differences in mortality were assessed using the Kaplan-Meier test in the survival package. Results

[245] In terms of safety, there were no adverse effects of mammalian milk oligosaccharide, as recorded by the farm team, and it is therefore considered safe for the current target animals. In the first round, 21 calves died during the 6-month trial, of which 12 (4.14%) were from group A and 9 (3.1%) from group B. This proportion is normally observed on most farms (<5%). There is no significant difference in mortality between the experimental groups. In the second round, during the 12-week trial, 7 / 400 calves died with no significant difference in mortality between the different groups.

[246] Due to transportation from different farms and the mixing of animals upon arrival at the breeding facilities, the calves may become Petition 870250100655, dated 03 / 11 / 2025, pages 216 / 226 125 / 128 stressed and susceptible to disease, especially shipping fever. Two main health problems associated with shipping fever were monitored in the trials: acute pneumonia and diarrhea. The calves became ill mainly due to airway involvement, specifically acute pneumonia (Table 5).

[247] In the first round, the number of diagnostic cases of acute pneumonia in the 2'FL-treated group (B; 96 cases in 290 calves) was lower compared to the placebo group (A; 111 cases in 290 calves). The relative risk of acute pneumonia in group B compared to the placebo group is 0.86. Figure 1 illustrates the probability of incidence of the first pneumonia in both groups of the trial with calves. Diagnostic assays performed on sera from calves with symptoms of acute pneumonia identified multiple causative respiratory pathogens (Table 3), such as Mycoplasma bovis and adenovirus type 3 (ADENO 3) based on frank seroconversion from at least + to +++ or from ++ to ++++, less potentially by bovine respiratory syncytial virus (BRSV), parainfluenza virus 3 (BPI3) or Mannheimia haemolytica, but not by BoHV1 (bovine rhinotracheitis) or BVDV (bovine viral diarrhea). Table 3 SORODIAGNOSIS OF RESPIRATORY PATHOGENS FOR BLEEDING SORES OF Calves Suffering from Transport Fever at Week 2 (S2) and Week 10 (S10) on Arrival at the Trial Facilities Calf Point in time BRSV BPI3 M BOVIS MANNHEIIA ADENO 3 1 BoHV1 BVDV 1 S2 ++ ++ 0 0 + 0 0 S10 ++ + + 0 ++++ Petition 870250100655, of 03 / 11 / 2025, p. 217 / 226 126 / 128 Calf Point in time BRSV BPI3 M BOVIS MANNHEIIA ADENO 3 BoHV1 BVDV 3 S2 ++ ++ 0 + ++ 0 0 S10 ++ + +++ 0 + 0 0 4 S2 + + 0 + +++ 0 0 S10 0 + + + + + 5 + 0 + 0 + 0 + 0 + 0 0 S10 ++ ++ + 0 ++ 0 0 6 S2 +++ +++ 0 + +++ 0 0 S10 ++ + ++ 0 ++++ 0 0 7 S2 +++ +++ + + +++ 0 ++ S10 0 + + + 0 +++ 0 0 8 S2 + + + + + + 1 + + + S +++++ 0 0 9 S2 +++ +++ 0 0 ++ 0 0 S10 ++ 0 ++ 0 +++ 0 0 10 S2 ++ +++ 0 + ++++ 0 0 S10 ++ 0 ++ 0 +++++ 0 0 0 11 S2 +++ +0 +0 + + + + + + + 0 + 0 ++++ 0 0

[248] In the second round, acute pneumonia affected most of the sick calves, with 27 cases in the placebo group (group A; 27%) and 17 cases in the group treated with 2'FL (B; 17%). The relative risk of acute pneumonia in group B compared to the placebo group is 0.63. Figure 2 shows the probability of incidence of the first pneumonia in both groups of the trial with rearing calves.

[249] After differential expression analysis, enrichment analysis of differentially expressed genes (DEGs) and ranked genes was performed. Compared to placebo, the group treated with 2'FL improved immune responses in several ways (T cell activation, cell differentiation, cell-cell adhesion, adaptive immune response) (Table 4). This immune modulation favored the animals' fight against pathogens, explaining the less acute pneumonia in the group. Petition 870250100655, dated 03 / 11 / 2025, pages 218 / 226 127 / 128 treated with 2'FL, especially in the context of shipping fever, where animals typically exhibit lower immunity due to transport-related stress and are therefore more prone to pathogenic infections (which is further accentuated by the close proximity between animals). Table 4 Top 20 Biological Processes of Genetic Ontology Positively Regulated in the Jejunum of Calves Supplemented with 2'FL (Group B) Compared to Placebo (Group A) Description of the adjustment of p ADAPTIVE_IMMUNE_RESPONSE 4.15E-06 T-CELL_ACTIVATION 9.06E-06 MONONUCLEAR_CELL_DIFFERENTIATION 0.000274 T-CELL_RECEPTOR_COMPLEX 0.000274 T-CELL_DIFFERENTIATION 0.000662 OUTSIDE_OF_THE_PLASMA_MEMBRANE 0.000673 NEGATIVE_REGULATION_OF_THE_IMMUNE_SYSTEM_PROCESS 0.001169 T-CELL_PROLIFERATION 0.002368 NEGATIVE_REGULATION_OF_THE_ADAPTIVE_IMMUNE_RESPONSE 0.002368 Negative regulation of leukocyte-mediated immunity 0.002368 Regulation of the adaptive immune response 0.003206 Selection of positive T cells 0.003206 Leukocyte differentiation 0.003462 Heterotypic cell adhesion 0.003478 Lymphocyte-mediated immunity 0.003478 Regulation of leukocyte-mediated immunity 0.003478 Regulation of T cell activation 0.003668 NEGATIVE_REGULATION_OF_LYMPHOCYTE_MEDIATED_IMMUNITY 0.00552 POSITIVE_SELECTION_OF_THYMIC_T_CELLS 0,00573 ADAPTIVE_IMMUNE_RESPONSE_BASED_ON_SOMATIC_RECOMBINATION_OF_IMMUNE_RECEPTORS_CONSTRUCTED_FROM_IMMUNOGLOBULIN_SUPERFAMILY_DOMAINS 0.00573

[250] When two-round trials were integrated to assess the effectiveness of 2'FL supplementation on the incidence of pneumonia, the common odds ratio was calculated to be 1.35 (P-value = 0.064). This means that calves that received standard CMR developed acute pneumonia 1.35 times more often than calves that Petition 870250100655, dated 03 / 11 / 2025, pages 219 / 226 128 / 128 received CMR supplemented with 2'FL. This strongly indicates that calves treated with 2'FL had a lower risk of developing acute pneumonia compared to the control group. Table 5 Cases of Acute Pneumonia in Trials Placebo Trial (A) 2'FL (B) Relative Risk Common Odds Ratio p-value Round 1 (veal calves) 111 96 0.86 1.35 0.064 Round 2 (rearing calves) 27 17 0.63

[251] Diarrhea occurred mainly during the first month after the calves arrived (Table 6). In the first round (round 1), again the number of diarrhea cases in the 2'FL treated group (B; 36 of 290 calves) was lower than in the placebo group (group A; 51 of 290 calves). The relative risk of having diarrhea in group B versus placebo is 0.71. Unlike round 1, there were rarely any cases of diarrhea in round 2. Only one case was recorded in the placebo group for the entire trial. Therefore, the relative risk and odds ratio associated with diarrhea were calculated without taking round 2 into account. The odds ratio associated with diarrhea based on the round 1 trial was calculated with a value of 1.51 (P-value = 0.081). This means that calves receiving standard CMR have diarrhea 1.51 times more frequently than calves receiving CMR supplemented with 2'FL.This strongly suggests that calves treated with 2'FL had a lower risk of developing diarrhea compared to the control group. Table 6 Cases of Diarrhea in Trials Placebo Trial (A) 2'FL (B) Relative Risk Odds Ratio p-value Round 1 (veal calves) 51 36 0.71 1.51 0.081 Round 2 (rearing calves) 1 0 Not available Not available Petition 870250100655, dated 03 / 11 / 2025, pages 220 / 226

Claims

1 / 4 Claims 1. FUCOSYLATED MAMMALIAN MILK OLIGOSACCHARIDE (MMO), characterized by being for use in a method to prevent and / or treat shipping fever in an animal, preferably in a farmed or domesticated animal, more preferably a farmed animal.

2. FUCOSYLATED MMO FOR USE, according to claim 1, characterized in that the method is a method for preventing and / or treating shipping fever in an animal by increasing T-lymphocyte-mediated immunity in said animal.

3. FUCOSYLATED MMO FOR USE, according to any of claims 1 or 2, characterized in that said method is for preventing and / or treating transport fever-associated pneumonia and / or transport fever-associated diarrhea, preferably for preventing and / or treating transport fever-associated pneumonia.

4. FUCOSYLATED MMO FOR USE, according to claim 3, characterized by the pneumonia being acute pneumonia.

5. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 4, characterized in that said animal is selected from a list consisting of bovine, swine, ovine, caprine, equine, donkey, mule, hinny, camelid, dog, cat, rabbit and poultry.

6. MMO FUCOSILADO PARA USO, according to any one of claims 1 to 5, characterized in that said animal is a non-adult animal.

7. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 6, characterized in that said fucosylated MMO comprises a fucose that is linked to a monosaccharide in an alpha-1,2 linkage, and in that said monosaccharide is galactose. Petition 870250100655, dated 03 / 11 / 2025, pp. 221 / 226 2 / 4 8. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 7, characterized in that said fucosylated MMO is 2'-fucosyllactose (2'FL).

9. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 8, characterized in that said method does not comprise the administration of lacto-N-tetraose (LNT) or lacto-N-neotetraose (LNnT).

10. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 9, characterized in that said method does not comprise the administration of an additional MMO.

11. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 10, characterized in that said fucosylated MMO is administered to said animal at least once, preferably at least twice, between birth (0 weeks) and 5 weeks of age, preferably between birth and 4 weeks of age, more preferably between birth and 3 weeks of age.

12. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 11, characterized in that said fucosylated MMO is administered to said animal at least once, preferably at least twice, more preferably daily: - in the three weeks, preferably two weeks, more preferably one week, prior to the day of transport of said animal; and / or - on the day of transport of said animal; and / or - in the three weeks, preferably two weeks, more preferably one week, after the day of transport of said animal.

13. FUCOSYLATED MMO FOR USE, according to any of claims 1 to 12, characterized in that said fucosylated MMO is Petition 870250100655, dated 03 / 11 / 2025, p. 222 / 226 3 / 4 administered in a daily dose of 0.01 to 1.0 g, preferably 0.01 to 0.75 g, more preferably 0.01 to 0.65 g, even more preferably 0.01 to 0.60 g, even more preferably 0.01 to 0.50 g, even more preferably 0.015 to 0.50 g, even more preferably 0.015 to 0.40 g, even more preferably 0.015 to 0.30 g, even more preferably 0.015 to 0.20 g, most preferably 0.015 to 0.10 g; wherein, preferably, the said animal is a bovine or a horse, wherein, more preferably, it is a calf or a foal, and even more preferably it is a calf.

14. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 12, characterized in that said fucosylated MMO is administered in a daily dose of 0.01 to 5.0 g, preferably 0.1 to 2.5 g, more preferably 0.1 to 1.5 g, even more preferably 0.1 to 1.2 g, even more preferably 0.2 to 1.2 g, even more preferably 0.3 to 1.2 g, even more preferably 0.4 to 1.2 g, most preferably 0.5 to 1.2 g; wherein, preferably, the said animal is a pig, a sheep, a goat or a camelid (preferably a llama or alpaca), wherein, more preferably, the said animal is a piglet, a lamb, a kid or a young animal, wherein, even more preferably, the said animal is a piglet, a lamb or a kid, wherein, most preferably, the said animal is a piglet.

15. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 14, characterized in that the fucosylated MMO is administered at a daily dose of 0.01 to 150.0 mg, preferably 0.01 to 125.0 mg, more preferably 0.01 to 100.0 mg, even more preferably 0.05 to 100.0 mg, even more preferably 0.1 to 100.0 mg, most preferably 0.1 to 80.0 mg, per kg of body weight of said animal. Petition 870250100655, dated 03 / 11 / 2025, pp. 223 / 226 4 / 4 16. FUCOSYLATED MMO FOR USE, according to any one of claims 1 to 15, characterized in that said fucosylated MMO is part of a composition.

17. FUCOSYLATED MMO FOR USE, according to claim 16, characterized in that said composition is not breast milk.

18. FUCOSYLATED MMO FOR USE, according to any of claims 16 or 17, characterized in that said composition is a pharmaceutical composition, optionally further comprising a pharmaceutically acceptable vehicle, filler, preservative, solubilizer, diluent, excipient, salt, adjuvant and / or solvent.

19. FUCOSYLATED MMO FOR USE, according to any of claims 16 to 18, characterized in that said composition is a nutritional composition selected from a list consisting of a milk replacer, creep feed, pre-starter diet, starter diet, pre-weaning feed, weaning feed and post-weaning feed, preferably selected from the list consisting of a milk replacer, starter diet, creep feed and post-weaning feed, more preferably said nutritional composition is a milk replacer or starter diet, more preferably a milk replacer. Petition 870250100655, dated 03 / 11 / 2025, pp. 224 / 226